#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Psychosis subgroups differ in intrinsic neural activity but not task-specific processing
#Text=Individuals with psychosis often show high levels of intrinsic, or nonspecific, neural activity, but attenuated stimulus-specific activity. proposed that one subgroup of psychosis cases has accentuated intrinsic activity (Biotype-2’s) and a different subgroup (Biotype-1’s) has diminished intrinsic activity, with both groups exhibiting varying degrees of cognitive deficits.
1-1	0-9	Psychosis	_
1-2	10-19	subgroups	_
1-3	20-26	differ	_
1-4	27-29	in	_
1-5	30-39	intrinsic	_
1-6	40-46	neural	_
1-7	47-55	activity	_
1-8	56-59	but	_
1-9	60-63	not	_
1-10	64-77	task-specific	_
1-11	78-88	processing	_
1-12	89-100	Individuals	_
1-13	101-105	with	_
1-14	106-115	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
1-15	116-121	often	_
1-16	122-126	show	_
1-17	127-131	high	_
1-18	132-138	levels	_
1-19	139-141	of	_
1-20	142-151	intrinsic	_
1-21	151-152	,	_
1-22	153-155	or	_
1-23	156-167	nonspecific	_
1-24	167-168	,	_
1-25	169-175	neural	_
1-26	176-184	activity	_
1-27	184-185	,	_
1-28	186-189	but	_
1-29	190-200	attenuated	_
1-30	201-218	stimulus-specific	_
1-31	219-227	activity	_
1-32	227-228	.	_
1-33	229-237	proposed	_
1-34	238-242	that	_
1-35	243-246	one	_
1-36	247-255	subgroup	_
1-37	256-258	of	_
1-38	259-268	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
1-39	269-274	cases	_
1-40	275-278	has	_
1-41	279-290	accentuated	_
1-42	291-300	intrinsic	_
1-43	301-309	activity	_
1-44	310-311	(	_
1-45	311-318	Biotype	_
1-46	318-319	-	_
1-47	319-320	2	_
1-48	320-321	’	_
1-49	321-322	s	_
1-50	322-323	)	_
1-51	324-327	and	_
1-52	328-329	a	_
1-53	330-339	different	_
1-54	340-348	subgroup	_
1-55	349-350	(	_
1-56	350-357	Biotype	_
1-57	357-358	-	_
1-58	358-359	1	_
1-59	359-360	’	_
1-60	360-361	s	_
1-61	361-362	)	_
1-62	363-366	has	_
1-63	367-377	diminished	_
1-64	378-387	intrinsic	_
1-65	388-396	activity	_
1-66	396-397	,	_
1-67	398-402	with	_
1-68	403-407	both	_
1-69	408-414	groups	_
1-70	415-425	exhibiting	_
1-71	426-433	varying	_
1-72	434-441	degrees	_
1-73	442-444	of	_
1-74	445-454	cognitive	_
1-75	455-463	deficits	_
1-76	463-464	.	_

#Text=This model was studied by assessing neural activity in psychosis probands (N=105) during baseline and a 5sec period in preparation for a pro-/anti-saccade task.
2-1	465-469	This	_
2-2	470-475	model	_
2-3	476-479	was	_
2-4	480-487	studied	_
2-5	488-490	by	_
2-6	491-500	assessing	_
2-7	501-507	neural	_
2-8	508-516	activity	_
2-9	517-519	in	_
2-10	520-529	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
2-11	530-538	probands	_
2-12	539-540	(	_
2-13	540-541	N	_
2-14	541-542	=	_
2-15	542-545	105	_
2-16	545-546	)	_
2-17	547-553	during	_
2-18	554-562	baseline	_
2-19	563-566	and	_
2-20	567-568	a	_
2-21	569-573	5sec	_
2-22	574-580	period	_
2-23	581-583	in	_
2-24	584-595	preparation	_
2-25	596-599	for	_
2-26	600-601	a	_
2-27	602-605	pro	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]
2-28	605-606	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]
2-29	606-607	/	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]
2-30	607-619	anti-saccade	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]
2-31	620-624	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]
2-32	624-625	.	_

#Text=Steady-state stimuli allowed real-time assessment of modulation of visuocortical investment to different target locations.
3-1	626-638	Steady-state	_
3-2	639-646	stimuli	_
3-3	647-654	allowed	_
3-4	655-664	real-time	_
3-5	665-675	assessment	_
3-6	676-678	of	_
3-7	679-689	modulation	_
3-8	690-692	of	_
3-9	693-706	visuocortical	_
3-10	707-717	investment	_
3-11	718-720	to	_
3-12	721-730	different	_
3-13	731-737	target	_
3-14	738-747	locations	_
3-15	747-748	.	_

#Text=Psychosis probands as a whole showed poor antisaccade performance.
4-1	749-758	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
4-2	759-767	probands	_
4-3	768-770	as	_
4-4	771-772	a	_
4-5	773-778	whole	_
4-6	779-785	showed	_
4-7	786-790	poor	_
4-8	791-802	antisaccade	_
4-9	803-814	performance	_
4-10	814-815	.	_

#Text=As expected, Biotype-1 showed diminished intrinsic neural activity and the worst behavior, and Biotype-2 showed accentuated intrinsic activity and less deviant behavior.
5-1	816-818	As	_
5-2	819-827	expected	_
5-3	827-828	,	_
5-4	829-836	Biotype	_
5-5	836-837	-	_
5-6	837-838	1	_
5-7	839-845	showed	_
5-8	846-856	diminished	_
5-9	857-866	intrinsic	_
5-10	867-873	neural	_
5-11	874-882	activity	_
5-12	883-886	and	_
5-13	887-890	the	_
5-14	891-896	worst	_
5-15	897-905	behavior	_
5-16	905-906	,	_
5-17	907-910	and	_
5-18	911-918	Biotype	_
5-19	918-919	-	_
5-20	919-920	2	_
5-21	921-927	showed	_
5-22	928-939	accentuated	_
5-23	940-949	intrinsic	_
5-24	950-958	activity	_
5-25	959-962	and	_
5-26	963-967	less	_
5-27	968-975	deviant	_
5-28	976-984	behavior	_
5-29	984-985	.	_

#Text=Both of these groups also exhibited less dynamic oscillatory phase synchrony.
6-1	986-990	Both	_
6-2	991-993	of	_
6-3	994-999	these	_
6-4	1000-1006	groups	_
6-5	1007-1011	also	_
6-6	1012-1021	exhibited	_
6-7	1022-1026	less	_
6-8	1027-1034	dynamic	_
6-9	1035-1046	oscillatory	_
6-10	1047-1052	phase	_
6-11	1053-1062	synchrony	_
6-12	1062-1063	.	_

#Text=Biotype-3 showed no neurophysiological differences from healthy individuals, despite a history of psychosis.
7-1	1064-1071	Biotype	_
7-2	1071-1072	-	_
7-3	1072-1073	3	_
7-4	1074-1080	showed	_
7-5	1081-1083	no	_
7-6	1084-1102	neurophysiological	_
7-7	1103-1114	differences	_
7-8	1115-1119	from	_
7-9	1120-1127	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]
7-10	1128-1139	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]
7-11	1139-1140	,	_
7-12	1141-1148	despite	_
7-13	1149-1150	a	_
7-14	1151-1158	history	_
7-15	1159-1161	of	_
7-16	1162-1171	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
7-17	1171-1172	.	_

#Text=Interestingly, all psychosis subgroups showed normal (i.e., not different from healthy) preparatory modulation of visuocortical investment as a function of cognitive demands, despite varying levels of task performance.
8-1	1173-1186	Interestingly	_
8-2	1186-1187	,	_
8-3	1188-1191	all	_
8-4	1192-1201	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
8-5	1202-1211	subgroups	_
8-6	1212-1218	showed	_
8-7	1219-1225	normal	_
8-8	1226-1227	(	_
8-9	1227-1230	i.e	_
8-10	1230-1231	.	_
8-11	1231-1232	,	_
8-12	1233-1236	not	_
8-13	1237-1246	different	_
8-14	1247-1251	from	_
8-15	1252-1259	healthy	_
8-16	1259-1260	)	_
8-17	1261-1272	preparatory	_
8-18	1273-1283	modulation	_
8-19	1284-1286	of	_
8-20	1287-1300	visuocortical	_
8-21	1301-1311	investment	_
8-22	1312-1314	as	_
8-23	1315-1316	a	_
8-24	1317-1325	function	_
8-25	1326-1328	of	_
8-26	1329-1338	cognitive	_
8-27	1339-1346	demands	_
8-28	1346-1347	,	_
8-29	1348-1355	despite	_
8-30	1356-1363	varying	_
8-31	1364-1370	levels	_
8-32	1371-1373	of	_
8-33	1374-1378	task	_
8-34	1379-1390	performance	_
8-35	1390-1391	.	_

#Text=Similar analyses conducted subgrouping cases by psychotic symptomatology revealed fewer and less consistent differences, including no intrinsic activity differences between any clinical subgroup and healthy individuals.
9-1	1392-1399	Similar	_
9-2	1400-1408	analyses	_
9-3	1409-1418	conducted	_
9-4	1419-1430	subgrouping	_
9-5	1431-1436	cases	_
9-6	1437-1439	by	_
9-7	1440-1449	psychotic	_
9-8	1450-1464	symptomatology	_
9-9	1465-1473	revealed	_
9-10	1474-1479	fewer	_
9-11	1480-1483	and	_
9-12	1484-1488	less	_
9-13	1489-1499	consistent	_
9-14	1500-1511	differences	_
9-15	1511-1512	,	_
9-16	1513-1522	including	_
9-17	1523-1525	no	_
9-18	1526-1535	intrinsic	_
9-19	1536-1544	activity	_
9-20	1545-1556	differences	_
9-21	1557-1564	between	_
9-22	1565-1568	any	_
9-23	1569-1577	clinical	_
9-24	1578-1586	subgroup	_
9-25	1587-1590	and	_
9-26	1591-1598	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
9-27	1599-1610	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
9-28	1610-1611	.	_

#Text=This study illustrates that (i) differences in intrinsic neural activity may be a fundamental characteristic of psychosis and need to be evaluated separately from stimulus-specific responses, and (ii) grouping patients based on multidimensional classification using neurobiological data may have advantages for resolving heterogeneity and clarifying illness mechanisms relative to traditional psychiatric diagnoses.
#Text=1.
10-1	1612-1616	This	_
10-2	1617-1622	study	_
10-3	1623-1634	illustrates	_
10-4	1635-1639	that	_
10-5	1640-1641	(	_
10-6	1641-1642	i	_
10-7	1642-1643	)	_
10-8	1644-1655	differences	_
10-9	1656-1658	in	_
10-10	1659-1668	intrinsic	_
10-11	1669-1675	neural	_
10-12	1676-1684	activity	_
10-13	1685-1688	may	_
10-14	1689-1691	be	_
10-15	1692-1693	a	_
10-16	1694-1705	fundamental	_
10-17	1706-1720	characteristic	_
10-18	1721-1723	of	_
10-19	1724-1733	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
10-20	1734-1737	and	_
10-21	1738-1742	need	_
10-22	1743-1745	to	_
10-23	1746-1748	be	_
10-24	1749-1758	evaluated	_
10-25	1759-1769	separately	_
10-26	1770-1774	from	_
10-27	1775-1792	stimulus-specific	_
10-28	1793-1802	responses	_
10-29	1802-1803	,	_
10-30	1804-1807	and	_
10-31	1808-1809	(	_
10-32	1809-1811	ii	_
10-33	1811-1812	)	_
10-34	1813-1821	grouping	_
10-35	1822-1830	patients	_
10-36	1831-1836	based	_
10-37	1837-1839	on	_
10-38	1840-1856	multidimensional	_
10-39	1857-1871	classification	_
10-40	1872-1877	using	_
10-41	1878-1893	neurobiological	_
10-42	1894-1898	data	_
10-43	1899-1902	may	_
10-44	1903-1907	have	_
10-45	1908-1918	advantages	_
10-46	1919-1922	for	_
10-47	1923-1932	resolving	_
10-48	1933-1946	heterogeneity	_
10-49	1947-1950	and	_
10-50	1951-1961	clarifying	_
10-51	1962-1969	illness	_
10-52	1970-1980	mechanisms	_
10-53	1981-1989	relative	_
10-54	1990-1992	to	_
10-55	1993-2004	traditional	_
10-56	2005-2016	psychiatric	_
10-57	2017-2026	diagnoses	_
10-58	2026-2027	.	_
10-59	2028-2029	1	_
10-60	2029-2030	.	_

#Text=Introduction
#Text=Intrinsic, or nonspecific, neural activity is not directly linked to stimulus processing, though it can be correlated with sensory cortical responses (e.g.,).
11-1	2031-2043	Introduction	_
11-2	2044-2053	Intrinsic	_
11-3	2053-2054	,	_
11-4	2055-2057	or	_
11-5	2058-2069	nonspecific	_
11-6	2069-2070	,	_
11-7	2071-2077	neural	_
11-8	2078-2086	activity	_
11-9	2087-2089	is	_
11-10	2090-2093	not	_
11-11	2094-2102	directly	_
11-12	2103-2109	linked	_
11-13	2110-2112	to	_
11-14	2113-2121	stimulus	_
11-15	2122-2132	processing	_
11-16	2132-2133	,	_
11-17	2134-2140	though	_
11-18	2141-2143	it	_
11-19	2144-2147	can	_
11-20	2148-2150	be	_
11-21	2151-2161	correlated	_
11-22	2162-2166	with	_
11-23	2167-2174	sensory	_
11-24	2175-2183	cortical	_
11-25	2184-2193	responses	_
11-26	2194-2195	(	_
11-27	2195-2198	e.g	_
11-28	2198-2199	.	_
11-29	2199-2200	,	_
11-30	2200-2201	)	_
11-31	2201-2202	.	_

#Text=Individuals with psychosis often show high levels of intrinsic neural activity.
12-1	2203-2214	Individuals	_
12-2	2215-2219	with	_
12-3	2220-2229	psychosis	_
12-4	2230-2235	often	_
12-5	2236-2240	show	_
12-6	2241-2245	high	_
12-7	2246-2252	levels	_
12-8	2253-2255	of	_
12-9	2256-2265	intrinsic	_
12-10	2266-2272	neural	_
12-11	2273-2281	activity	_
12-12	2281-2282	.	_

#Text=For instance, in response to periodically flickering visual stimuli, observed augmented baseline and stimulus-related activity among psychosis patients compared to healthy persons.
13-1	2283-2286	For	_
13-2	2287-2295	instance	_
13-3	2295-2296	,	_
13-4	2297-2299	in	_
13-5	2300-2308	response	_
13-6	2309-2311	to	_
13-7	2312-2324	periodically	_
13-8	2325-2335	flickering	_
13-9	2336-2342	visual	_
13-10	2343-2350	stimuli	_
13-11	2350-2351	,	_
13-12	2352-2360	observed	_
13-13	2361-2370	augmented	_
13-14	2371-2379	baseline	_
13-15	2380-2383	and	_
13-16	2384-2400	stimulus-related	_
13-17	2401-2409	activity	_
13-18	2410-2415	among	_
13-19	2416-2425	psychosis	_
13-20	2426-2434	patients	_
13-21	2435-2443	compared	_
13-22	2444-2446	to	_
13-23	2447-2454	healthy	_
13-24	2455-2462	persons	_
13-25	2462-2463	.	_

#Text=Levels of stimulus-specific activity (brain activity to the stimulus minus baseline activity), however, were diminished in psychosis.
14-1	2464-2470	Levels	_
14-2	2471-2473	of	_
14-3	2474-2491	stimulus-specific	_
14-4	2492-2500	activity	_
14-5	2501-2502	(	_
14-6	2502-2507	brain	_
14-7	2508-2516	activity	_
14-8	2517-2519	to	_
14-9	2520-2523	the	_
14-10	2524-2532	stimulus	_
14-11	2533-2538	minus	_
14-12	2539-2547	baseline	_
14-13	2548-2556	activity	_
14-14	2556-2557	)	_
14-15	2557-2558	,	_
14-16	2559-2566	however	_
14-17	2566-2567	,	_
14-18	2568-2572	were	_
14-19	2573-2583	diminished	_
14-20	2584-2586	in	_
14-21	2587-2596	psychosis	_
14-22	2596-2597	.	_

#Text=proposed, given similarity across a range of brain-based biomarkers, that a distinct subgroup of psychosis cases will have high levels of intrinsic activity and excessive reactivity to sensory stimuli (Biotype-2) while a different subgroup will have diminished intrinsic activity and low levels of sensory reactivity (Biotype-1). found that Biotype-2 and Biotype-1 cases indeed exhibited these diametrically opposed differences in baseline and stimulus-related activity in response to centrally located flickering visual stimuli.
15-1	2599-2607	proposed	_
15-2	2607-2608	,	_
15-3	2609-2614	given	_
15-4	2615-2625	similarity	_
15-5	2626-2632	across	_
15-6	2633-2634	a	_
15-7	2635-2640	range	_
15-8	2641-2643	of	_
15-9	2644-2655	brain-based	_
15-10	2656-2666	biomarkers	_
15-11	2666-2667	,	_
15-12	2668-2672	that	_
15-13	2673-2674	a	_
15-14	2675-2683	distinct	_
15-15	2684-2692	subgroup	_
15-16	2693-2695	of	_
15-17	2696-2705	psychosis	_
15-18	2706-2711	cases	_
15-19	2712-2716	will	_
15-20	2717-2721	have	_
15-21	2722-2726	high	_
15-22	2727-2733	levels	_
15-23	2734-2736	of	_
15-24	2737-2746	intrinsic	_
15-25	2747-2755	activity	_
15-26	2756-2759	and	_
15-27	2760-2769	excessive	_
15-28	2770-2780	reactivity	_
15-29	2781-2783	to	_
15-30	2784-2791	sensory	_
15-31	2792-2799	stimuli	_
15-32	2800-2801	(	_
15-33	2801-2808	Biotype	_
15-34	2808-2809	-	_
15-35	2809-2810	2	_
15-36	2810-2811	)	_
15-37	2812-2817	while	_
15-38	2818-2819	a	_
15-39	2820-2829	different	_
15-40	2830-2838	subgroup	_
15-41	2839-2843	will	_
15-42	2844-2848	have	_
15-43	2849-2859	diminished	_
15-44	2860-2869	intrinsic	_
15-45	2870-2878	activity	_
15-46	2879-2882	and	_
15-47	2883-2886	low	_
15-48	2887-2893	levels	_
15-49	2894-2896	of	_
15-50	2897-2904	sensory	_
15-51	2905-2915	reactivity	_
15-52	2916-2917	(	_
15-53	2917-2924	Biotype	_
15-54	2924-2925	-	_
15-55	2925-2926	1	_
15-56	2926-2927	)	_
15-57	2927-2928	.	_
15-58	2929-2934	found	_
15-59	2935-2939	that	_
15-60	2940-2947	Biotype	_
15-61	2947-2948	-	_
15-62	2948-2949	2	_
15-63	2950-2953	and	_
15-64	2954-2961	Biotype	_
15-65	2961-2962	-	_
15-66	2962-2963	1	_
15-67	2964-2969	cases	_
15-68	2970-2976	indeed	_
15-69	2977-2986	exhibited	_
15-70	2987-2992	these	_
15-71	2993-3006	diametrically	_
15-72	3007-3014	opposed	_
15-73	3015-3026	differences	_
15-74	3027-3029	in	_
15-75	3030-3038	baseline	_
15-76	3039-3042	and	_
15-77	3043-3059	stimulus-related	_
15-78	3060-3068	activity	_
15-79	3069-3071	in	_
15-80	3072-3080	response	_
15-81	3081-3083	to	_
15-82	3084-3093	centrally	_
15-83	3094-3101	located	_
15-84	3102-3112	flickering	_
15-85	3113-3119	visual	_
15-86	3120-3127	stimuli	_
15-87	3127-3128	.	_

#Text=It has been theorized that either abnormally high or low intrinsic activity may lead to low signal-to-noise ratios, reducing the ability to parse stimulus relevance and accurately code perceptual events.
16-1	3129-3131	It	_
16-2	3132-3135	has	_
16-3	3136-3140	been	_
16-4	3141-3150	theorized	_
16-5	3151-3155	that	_
16-6	3156-3162	either	_
16-7	3163-3173	abnormally	_
16-8	3174-3178	high	_
16-9	3179-3181	or	_
16-10	3182-3185	low	_
16-11	3186-3195	intrinsic	_
16-12	3196-3204	activity	_
16-13	3205-3208	may	_
16-14	3209-3213	lead	_
16-15	3214-3216	to	_
16-16	3217-3220	low	_
16-17	3221-3236	signal-to-noise	_
16-18	3237-3243	ratios	_
16-19	3243-3244	,	_
16-20	3245-3253	reducing	_
16-21	3254-3257	the	_
16-22	3258-3265	ability	_
16-23	3266-3268	to	_
16-24	3269-3274	parse	_
16-25	3275-3283	stimulus	_
16-26	3284-3293	relevance	_
16-27	3294-3297	and	_
16-28	3298-3308	accurately	_
16-29	3309-3313	code	_
16-30	3314-3324	perceptual	_
16-31	3325-3331	events	_
16-32	3331-3332	.	_

#Text=In the case of, either high or low levels of intrinsic activity in psychosis were associated with decreased cognitive control, suggesting that modes of facilitating context-appropriate behavior through modulation of sensory systems may differ between distinct psychosis subgroups.
17-1	3333-3335	In	_
17-2	3336-3339	the	_
17-3	3340-3344	case	_
17-4	3345-3347	of	_
17-5	3347-3348	,	_
17-6	3349-3355	either	_
17-7	3356-3360	high	_
17-8	3361-3363	or	_
17-9	3364-3367	low	_
17-10	3368-3374	levels	_
17-11	3375-3377	of	_
17-12	3378-3387	intrinsic	_
17-13	3388-3396	activity	_
17-14	3397-3399	in	_
17-15	3400-3409	psychosis	_
17-16	3410-3414	were	_
17-17	3415-3425	associated	_
17-18	3426-3430	with	_
17-19	3431-3440	decreased	_
17-20	3441-3450	cognitive	_
17-21	3451-3458	control	_
17-22	3458-3459	,	_
17-23	3460-3470	suggesting	_
17-24	3471-3475	that	_
17-25	3476-3481	modes	_
17-26	3482-3484	of	_
17-27	3485-3497	facilitating	_
17-28	3498-3517	context-appropriate	_
17-29	3518-3526	behavior	_
17-30	3527-3534	through	_
17-31	3535-3545	modulation	_
17-32	3546-3548	of	_
17-33	3549-3556	sensory	_
17-34	3557-3564	systems	_
17-35	3565-3568	may	_
17-36	3569-3575	differ	_
17-37	3576-3583	between	_
17-38	3584-3592	distinct	_
17-39	3593-3602	psychosis	_
17-40	3603-3612	subgroups	_
17-41	3612-3613	.	_

#Text=Under this hypothesis, networks characterized by hyperexcitation would likely show less extensive deficits than those characterized by hypoexcitation, consistent with less deviant behavioral performance in Biotype-2 than Biotype-1.
18-1	3614-3619	Under	_
18-2	3620-3624	this	_
18-3	3625-3635	hypothesis	_
18-4	3635-3636	,	_
18-5	3637-3645	networks	_
18-6	3646-3659	characterized	_
18-7	3660-3662	by	_
18-8	3663-3678	hyperexcitation	_
18-9	3679-3684	would	_
18-10	3685-3691	likely	_
18-11	3692-3696	show	_
18-12	3697-3701	less	_
18-13	3702-3711	extensive	_
18-14	3712-3720	deficits	_
18-15	3721-3725	than	_
18-16	3726-3731	those	_
18-17	3732-3745	characterized	_
18-18	3746-3748	by	_
18-19	3749-3763	hypoexcitation	_
18-20	3763-3764	,	_
18-21	3765-3775	consistent	_
18-22	3776-3780	with	_
18-23	3781-3785	less	_
18-24	3786-3793	deviant	_
18-25	3794-3804	behavioral	_
18-26	3805-3816	performance	_
18-27	3817-3819	in	_
18-28	3820-3827	Biotype	_
18-29	3827-3828	-	_
18-30	3828-3829	2	_
18-31	3830-3834	than	_
18-32	3835-3842	Biotype	_
18-33	3842-3843	-	_
18-34	3843-3844	1	_
18-35	3844-3845	.	_

#Text=Individuals with psychosis have difficulty inhibiting context-inappropriate behavioral responses, illustrated by high error rates on antisaccade tasks.
19-1	3846-3857	Individuals	_
19-2	3858-3862	with	_
19-3	3863-3872	psychosis	_
19-4	3873-3877	have	_
19-5	3878-3888	difficulty	_
19-6	3889-3899	inhibiting	_
19-7	3900-3921	context-inappropriate	_
19-8	3922-3932	behavioral	_
19-9	3933-3942	responses	_
19-10	3942-3943	,	_
19-11	3944-3955	illustrated	_
19-12	3956-3958	by	_
19-13	3959-3963	high	_
19-14	3964-3969	error	_
19-15	3970-3975	rates	_
19-16	3976-3978	on	_
19-17	3979-3990	antisaccade	_
19-18	3991-3996	tasks	_
19-19	3996-3997	.	_

#Text=Unlike prosaccade tasks, where a glance is made towards a peripheral cue, antisaccade tasks require inhibiting a glance to a peripheral cue and instead looking to that cue’s mirror image location.
20-1	3998-4004	Unlike	_
20-2	4005-4015	prosaccade	_
20-3	4016-4021	tasks	_
20-4	4021-4022	,	_
20-5	4023-4028	where	_
20-6	4029-4030	a	_
20-7	4031-4037	glance	_
20-8	4038-4040	is	_
20-9	4041-4045	made	_
20-10	4046-4053	towards	_
20-11	4054-4055	a	_
20-12	4056-4066	peripheral	_
20-13	4067-4070	cue	_
20-14	4070-4071	,	_
20-15	4072-4083	antisaccade	_
20-16	4084-4089	tasks	_
20-17	4090-4097	require	_
20-18	4098-4108	inhibiting	_
20-19	4109-4110	a	_
20-20	4111-4117	glance	_
20-21	4118-4120	to	_
20-22	4121-4122	a	_
20-23	4123-4133	peripheral	_
20-24	4134-4137	cue	_
20-25	4138-4141	and	_
20-26	4142-4149	instead	_
20-27	4150-4157	looking	_
20-28	4158-4160	to	_
20-29	4161-4165	that	_
20-30	4166-4169	cue	_
20-31	4169-4170	’	_
20-32	4170-4171	s	_
20-33	4172-4178	mirror	_
20-34	4179-4184	image	_
20-35	4185-4193	location	_
20-36	4193-4194	.	_

#Text=Neurophysiology studies indicate that suppression of reflexive saccades during antisaccade tasks requires preparatory modulation of neural activity in visual cortex, theoretically generated via top-down control by prefrontal cortex.
21-1	4195-4210	Neurophysiology	_
21-2	4211-4218	studies	_
21-3	4219-4227	indicate	_
21-4	4228-4232	that	_
21-5	4233-4244	suppression	_
21-6	4245-4247	of	_
21-7	4248-4257	reflexive	_
21-8	4258-4266	saccades	_
21-9	4267-4273	during	_
21-10	4274-4285	antisaccade	_
21-11	4286-4291	tasks	_
21-12	4292-4300	requires	_
21-13	4301-4312	preparatory	_
21-14	4313-4323	modulation	_
21-15	4324-4326	of	_
21-16	4327-4333	neural	_
21-17	4334-4342	activity	_
21-18	4343-4345	in	_
21-19	4346-4352	visual	_
21-20	4353-4359	cortex	_
21-21	4359-4360	,	_
21-22	4361-4374	theoretically	_
21-23	4375-4384	generated	_
21-24	4385-4388	via	_
21-25	4389-4397	top-down	_
21-26	4398-4405	control	_
21-27	4406-4408	by	_
21-28	4409-4419	prefrontal	_
21-29	4420-4426	cortex	_
21-30	4426-4427	.	_

#Text=Healthy persons and those with psychosis have been found to increase visuocortical neural investment to central stimuli (i.e., activity related to these stimuli) prior to anti- versus pro-saccade responses.
22-1	4428-4435	Healthy	_
22-2	4436-4443	persons	_
22-3	4444-4447	and	_
22-4	4448-4453	those	_
22-5	4454-4458	with	_
22-6	4459-4468	psychosis	_
22-7	4469-4473	have	_
22-8	4474-4478	been	_
22-9	4479-4484	found	_
22-10	4485-4487	to	_
22-11	4488-4496	increase	_
22-12	4497-4510	visuocortical	_
22-13	4511-4517	neural	_
22-14	4518-4528	investment	_
22-15	4529-4531	to	_
22-16	4532-4539	central	_
22-17	4540-4547	stimuli	_
22-18	4548-4549	(	_
22-19	4549-4552	i.e	_
22-20	4552-4553	.	_
22-21	4553-4554	,	_
22-22	4555-4563	activity	_
22-23	4564-4571	related	_
22-24	4572-4574	to	_
22-25	4575-4580	these	_
22-26	4581-4588	stimuli	_
22-27	4588-4589	)	_
22-28	4590-4595	prior	_
22-29	4596-4598	to	_
22-30	4599-4603	anti	_
22-31	4603-4604	-	_
22-32	4605-4611	versus	_
22-33	4612-4623	pro-saccade	_
22-34	4624-4633	responses	_
22-35	4633-4634	.	_

#Text=Although the complimentary process, decreased visuocortical investment to peripheral stimuli prior to anti- versus pro-saccades, has been found in healthy persons, this has not been investigated in individuals with psychosis.
23-1	4635-4643	Although	_
23-2	4644-4647	the	_
23-3	4648-4661	complimentary	_
23-4	4662-4669	process	_
23-5	4669-4670	,	_
23-6	4671-4680	decreased	_
23-7	4681-4694	visuocortical	_
23-8	4695-4705	investment	_
23-9	4706-4708	to	_
23-10	4709-4719	peripheral	_
23-11	4720-4727	stimuli	_
23-12	4728-4733	prior	_
23-13	4734-4736	to	_
23-14	4737-4741	anti	_
23-15	4741-4742	-	_
23-16	4743-4749	versus	_
23-17	4750-4762	pro-saccades	_
23-18	4762-4763	,	_
23-19	4764-4767	has	_
23-20	4768-4772	been	_
23-21	4773-4778	found	_
23-22	4779-4781	in	_
23-23	4782-4789	healthy	_
23-24	4790-4797	persons	_
23-25	4797-4798	,	_
23-26	4799-4803	this	_
23-27	4804-4807	has	_
23-28	4808-4811	not	_
23-29	4812-4816	been	_
23-30	4817-4829	investigated	_
23-31	4830-4832	in	_
23-32	4833-4844	individuals	_
23-33	4845-4849	with	_
23-34	4850-4859	psychosis	_
23-35	4859-4860	.	_

#Text=This is particularly relevant as found the vSSR in individuals with SZ to be deviant specifically in relation to targets, while activity related to non-targets was unaffected.
24-1	4861-4865	This	_
24-2	4866-4868	is	_
24-3	4869-4881	particularly	_
24-4	4882-4890	relevant	_
24-5	4891-4893	as	_
24-6	4894-4899	found	_
24-7	4900-4903	the	_
24-8	4904-4908	vSSR	_
24-9	4909-4911	in	_
24-10	4912-4923	individuals	_
24-11	4924-4928	with	_
24-12	4929-4931	SZ	_
24-13	4932-4934	to	_
24-14	4935-4937	be	_
24-15	4938-4945	deviant	_
24-16	4946-4958	specifically	_
24-17	4959-4961	in	_
24-18	4962-4970	relation	_
24-19	4971-4973	to	_
24-20	4974-4981	targets	_
24-21	4981-4982	,	_
24-22	4983-4988	while	_
24-23	4989-4997	activity	_
24-24	4998-5005	related	_
24-25	5006-5008	to	_
24-26	5009-5020	non-targets	_
24-27	5021-5024	was	_
24-28	5025-5035	unaffected	_
24-29	5035-5036	.	_

#Text=The present study used peripherally-located oscillating steady-state visual stimuli to assess modulation of neural activity during preparation for pro- or anti-saccades.
25-1	5037-5040	The	_
25-2	5041-5048	present	_
25-3	5049-5054	study	_
25-4	5055-5059	used	_
25-5	5060-5080	peripherally-located	_
25-6	5081-5092	oscillating	_
25-7	5093-5105	steady-state	_
25-8	5106-5112	visual	_
25-9	5113-5120	stimuli	_
25-10	5121-5123	to	_
25-11	5124-5130	assess	_
25-12	5131-5141	modulation	_
25-13	5142-5144	of	_
25-14	5145-5151	neural	_
25-15	5152-5160	activity	_
25-16	5161-5167	during	_
25-17	5168-5179	preparation	_
25-18	5180-5183	for	_
25-19	5184-5187	pro	_
25-20	5187-5188	-	_
25-21	5189-5191	or	_
25-22	5192-5205	anti-saccades	_
25-23	5205-5206	.	_

#Text=The visual steady state response (vSSR) develops in primary visual cortex in relation to stimuli flickering at a specific rate.
26-1	5207-5210	The	_
26-2	5211-5217	visual	_
26-3	5218-5224	steady	_
26-4	5225-5230	state	_
26-5	5231-5239	response	_
26-6	5240-5241	(	_
26-7	5241-5245	vSSR	_
26-8	5245-5246	)	_
26-9	5247-5255	develops	_
26-10	5256-5258	in	_
26-11	5259-5266	primary	_
26-12	5267-5273	visual	_
26-13	5274-5280	cortex	_
26-14	5281-5283	in	_
26-15	5284-5292	relation	_
26-16	5293-5295	to	_
26-17	5296-5303	stimuli	_
26-18	5304-5314	flickering	_
26-19	5315-5317	at	_
26-20	5318-5319	a	_
26-21	5320-5328	specific	_
26-22	5329-5333	rate	_
26-23	5333-5334	.	_

#Text=The resultant oscillations resonate at the stimulus flicker rate and vary in amplitude with the task relevance of the stimulus.
27-1	5335-5338	The	_
27-2	5339-5348	resultant	_
27-3	5349-5361	oscillations	_
27-4	5362-5370	resonate	_
27-5	5371-5373	at	_
27-6	5374-5377	the	_
27-7	5378-5386	stimulus	_
27-8	5387-5394	flicker	_
27-9	5395-5399	rate	_
27-10	5400-5403	and	_
27-11	5404-5408	vary	_
27-12	5409-5411	in	_
27-13	5412-5421	amplitude	_
27-14	5422-5426	with	_
27-15	5427-5430	the	_
27-16	5431-5435	task	_
27-17	5436-5445	relevance	_
27-18	5446-5448	of	_
27-19	5449-5452	the	_
27-20	5453-5461	stimulus	_
27-21	5461-5462	.	_

#Text=Given findings from, we expected that (i) both behavioral performance and brain activity measures would differentiate psychosis Biotypes; (ii) Biotype-1 would have the worst antisaccade performance and diminished intrinsic neural activity, Biotype-2 would have less deviant antisaccade performance but accentuated intrinsic activity, Biotype-3 would be most similar to healthy subjects on both performance and brain responses; and (iii) neural synchrony deviations would be found for Bioype-1 and Biotype-2, but not for Biotype-3.
#Text=2.
28-1	5463-5468	Given	_
28-2	5469-5477	findings	_
28-3	5478-5482	from	_
28-4	5482-5483	,	_
28-5	5484-5486	we	_
28-6	5487-5495	expected	_
28-7	5496-5500	that	_
28-8	5501-5502	(	_
28-9	5502-5503	i	_
28-10	5503-5504	)	_
28-11	5505-5509	both	_
28-12	5510-5520	behavioral	_
28-13	5521-5532	performance	_
28-14	5533-5536	and	_
28-15	5537-5542	brain	_
28-16	5543-5551	activity	_
28-17	5552-5560	measures	_
28-18	5561-5566	would	_
28-19	5567-5580	differentiate	_
28-20	5581-5590	psychosis	_
28-21	5591-5599	Biotypes	_
28-22	5599-5600	;	_
28-23	5601-5602	(	_
28-24	5602-5604	ii	_
28-25	5604-5605	)	_
28-26	5606-5613	Biotype	_
28-27	5613-5614	-	_
28-28	5614-5615	1	_
28-29	5616-5621	would	_
28-30	5622-5626	have	_
28-31	5627-5630	the	_
28-32	5631-5636	worst	_
28-33	5637-5648	antisaccade	_
28-34	5649-5660	performance	_
28-35	5661-5664	and	_
28-36	5665-5675	diminished	_
28-37	5676-5685	intrinsic	_
28-38	5686-5692	neural	_
28-39	5693-5701	activity	_
28-40	5701-5702	,	_
28-41	5703-5710	Biotype	_
28-42	5710-5711	-	_
28-43	5711-5712	2	_
28-44	5713-5718	would	_
28-45	5719-5723	have	_
28-46	5724-5728	less	_
28-47	5729-5736	deviant	_
28-48	5737-5748	antisaccade	_
28-49	5749-5760	performance	_
28-50	5761-5764	but	_
28-51	5765-5776	accentuated	_
28-52	5777-5786	intrinsic	_
28-53	5787-5795	activity	_
28-54	5795-5796	,	_
28-55	5797-5804	Biotype	_
28-56	5804-5805	-	_
28-57	5805-5806	3	_
28-58	5807-5812	would	_
28-59	5813-5815	be	_
28-60	5816-5820	most	_
28-61	5821-5828	similar	_
28-62	5829-5831	to	_
28-63	5832-5839	healthy	_
28-64	5840-5848	subjects	_
28-65	5849-5851	on	_
28-66	5852-5856	both	_
28-67	5857-5868	performance	_
28-68	5869-5872	and	_
28-69	5873-5878	brain	_
28-70	5879-5888	responses	_
28-71	5888-5889	;	_
28-72	5890-5893	and	_
28-73	5894-5895	(	_
28-74	5895-5898	iii	_
28-75	5898-5899	)	_
28-76	5900-5906	neural	_
28-77	5907-5916	synchrony	_
28-78	5917-5927	deviations	_
28-79	5928-5933	would	_
28-80	5934-5936	be	_
28-81	5937-5942	found	_
28-82	5943-5946	for	_
28-83	5947-5953	Bioype	_
28-84	5953-5954	-	_
28-85	5954-5955	1	_
28-86	5956-5959	and	_
28-87	5960-5967	Biotype	_
28-88	5967-5968	-	_
28-89	5968-5969	2	_
28-90	5969-5970	,	_
28-91	5971-5974	but	_
28-92	5975-5978	not	_
28-93	5979-5982	for	_
28-94	5983-5990	Biotype	_
28-95	5990-5991	-	_
28-96	5991-5992	3	_
28-97	5992-5993	.	_
28-98	5994-5995	2	_
28-99	5995-5996	.	_

#Text=Methods and Materials
#Text=2.1.
29-1	5997-6004	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]
29-2	6005-6008	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]
29-3	6009-6018	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]
29-4	6019-6022	2.1	_
29-5	6022-6023	.	_

#Text=Participants
#Text=As a part of a multisite data collection project, the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP), subjects were recruited, interviewed, and tested for the present study at the University of Illinois-Chicago site.
30-1	6024-6036	Participants	_
30-2	6037-6039	As	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-3	6040-6041	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-4	6042-6046	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-5	6047-6049	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-6	6050-6051	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-7	6052-6061	multisite	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-8	6062-6066	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-9	6067-6077	collection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-10	6078-6085	project	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-11	6085-6086	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-12	6087-6090	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-13	6091-6112	Bipolar-Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-14	6113-6120	Network	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-15	6121-6123	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-16	6124-6136	Intermediate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-17	6137-6147	Phenotypes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-18	6148-6149	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-19	6149-6155	B-SNIP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-20	6155-6156	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-21	6156-6157	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-22	6158-6166	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-23	6167-6171	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-24	6172-6181	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-25	6181-6182	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-26	6183-6194	interviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-27	6194-6195	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-28	6196-6199	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-29	6200-6206	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-30	6207-6210	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-31	6211-6214	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-32	6215-6222	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-33	6223-6228	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-34	6229-6231	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-35	6232-6235	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-36	6236-6246	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-37	6247-6249	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-38	6250-6266	Illinois-Chicago	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-39	6267-6271	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
30-40	6271-6272	.	_

#Text=Clinically stable psychosis probands (N = 105) and healthy comparison subjects (HC; N =50) were recruited via community advertisements, linked community facilities and programs, and family support groups (see Table 1 and Supplemental Table 1 and 2 for clinical and demographic information).
31-1	6273-6283	Clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-2	6284-6290	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-3	6291-6300	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[8]
31-4	6301-6309	probands	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-5	6310-6311	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-6	6311-6312	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-7	6313-6314	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-8	6315-6318	105	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-9	6318-6319	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-10	6320-6323	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-11	6324-6331	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
31-12	6332-6342	comparison	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
31-13	6343-6351	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-14	6352-6353	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-15	6353-6355	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
31-16	6355-6356	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-17	6357-6358	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-18	6359-6360	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-19	6360-6362	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-20	6362-6363	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-21	6364-6368	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-22	6369-6378	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-23	6379-6382	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-24	6383-6392	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-25	6393-6407	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-26	6407-6408	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-27	6409-6415	linked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-28	6416-6425	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-29	6426-6436	facilities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-30	6437-6440	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-31	6441-6449	programs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-32	6449-6450	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-33	6451-6454	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-34	6455-6461	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-35	6462-6469	support	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-36	6470-6476	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
31-37	6477-6478	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-38	6478-6481	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-39	6482-6487	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-40	6488-6489	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-41	6490-6493	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-42	6494-6506	Supplemental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-43	6507-6512	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-44	6513-6514	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-45	6515-6518	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-46	6519-6520	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-47	6521-6524	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-48	6525-6533	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-49	6534-6537	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-50	6538-6549	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-51	6550-6561	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-52	6561-6562	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-53	6562-6563	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=Clinical diagnosis was determined through administration of the Structured Clinical Interview for DSM-IV Diagnosis and consensus diagnostic review; see for clinical evaluation details.
32-1	6564-6572	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-2	6573-6582	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-3	6583-6586	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-4	6587-6597	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-5	6598-6605	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-6	6606-6620	administration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-7	6621-6623	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-8	6624-6627	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-9	6628-6638	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
32-10	6639-6647	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
32-11	6648-6657	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
32-12	6658-6661	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
32-13	6662-6668	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
32-14	6669-6678	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
32-15	6679-6682	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-16	6683-6692	consensus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-17	6693-6703	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-18	6704-6710	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-19	6710-6711	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-20	6712-6715	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-21	6716-6719	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-22	6720-6728	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-23	6729-6739	evaluation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-24	6740-6747	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
32-25	6747-6748	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=HC had no personal history of psychotic, bipolar, or recurrent major depressive disorder, or a family history of schizophrenia-bipolar spectrum disorders in first or second degree relatives.
33-1	6749-6751	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]
33-2	6752-6755	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-3	6756-6758	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-4	6759-6767	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-5	6768-6775	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-6	6776-6778	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-7	6779-6788	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-8	6788-6789	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-9	6790-6797	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-10	6797-6798	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-11	6799-6801	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-12	6802-6811	recurrent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-13	6812-6817	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-14	6818-6828	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-15	6829-6837	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-16	6837-6838	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-17	6839-6841	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-18	6842-6843	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-19	6844-6850	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-20	6851-6858	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-21	6859-6861	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-22	6862-6883	schizophrenia-bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-23	6884-6892	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-24	6893-6902	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-25	6903-6905	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-26	6906-6911	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-27	6912-6914	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-28	6915-6921	second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-29	6922-6928	degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-30	6929-6938	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
33-31	6938-6939	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=All subjects provided written consent before participating, and the study was approved by the University of Illinois-Chicago Institutional Review Board.
34-1	6940-6943	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-2	6944-6952	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-3	6953-6961	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-4	6962-6969	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-5	6970-6977	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-6	6978-6984	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-7	6985-6998	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-8	6998-6999	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-9	7000-7003	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-10	7004-7007	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-11	7008-7013	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-12	7014-7017	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-13	7018-7026	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-14	7027-7029	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-15	7030-7033	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-16	7034-7044	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-17	7045-7047	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-18	7048-7064	Illinois-Chicago	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-19	7065-7078	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-20	7079-7085	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-21	7086-7091	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
34-22	7091-7092	.	_

#Text=used biomarker data to classify psychosis cases into Biotypes.
35-1	7094-7098	used	_
35-2	7099-7108	biomarker	_
35-3	7109-7113	data	_
35-4	7114-7116	to	_
35-5	7117-7125	classify	_
35-6	7126-7135	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
35-7	7136-7141	cases	_
35-8	7142-7146	into	_
35-9	7147-7155	Biotypes	_
35-10	7155-7156	.	_

#Text=Biotype-1 was most reminiscent of poor-outcome, chronic, and neurobiologically impaired psychosis cases; Biotype-2 was characterized by hyper-responsiveness to sensorimotor events, while Biotype-3 was closer to HC than to the other Biotype subgroups across biomarkers (despite presence of psychosis), although they still had modest deviations on multiple biomarkers.
36-1	7157-7164	Biotype	_
36-2	7164-7165	-	_
36-3	7165-7166	1	_
36-4	7167-7170	was	_
36-5	7171-7175	most	_
36-6	7176-7187	reminiscent	_
36-7	7188-7190	of	_
36-8	7191-7203	poor-outcome	_
36-9	7203-7204	,	_
36-10	7205-7212	chronic	_
36-11	7212-7213	,	_
36-12	7214-7217	and	_
36-13	7218-7235	neurobiologically	_
36-14	7236-7244	impaired	_
36-15	7245-7254	psychosis	_
36-16	7255-7260	cases	_
36-17	7260-7261	;	_
36-18	7262-7269	Biotype	_
36-19	7269-7270	-	_
36-20	7270-7271	2	_
36-21	7272-7275	was	_
36-22	7276-7289	characterized	_
36-23	7290-7292	by	_
36-24	7293-7313	hyper-responsiveness	_
36-25	7314-7316	to	_
36-26	7317-7329	sensorimotor	_
36-27	7330-7336	events	_
36-28	7336-7337	,	_
36-29	7338-7343	while	_
36-30	7344-7351	Biotype	_
36-31	7351-7352	-	_
36-32	7352-7353	3	_
36-33	7354-7357	was	_
36-34	7358-7364	closer	_
36-35	7365-7367	to	_
36-36	7368-7370	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
36-37	7371-7375	than	_
36-38	7376-7378	to	_
36-39	7379-7382	the	_
36-40	7383-7388	other	_
36-41	7389-7396	Biotype	_
36-42	7397-7406	subgroups	_
36-43	7407-7413	across	_
36-44	7414-7424	biomarkers	_
36-45	7425-7426	(	_
36-46	7426-7433	despite	_
36-47	7434-7442	presence	_
36-48	7443-7445	of	_
36-49	7446-7455	psychosis	_
36-50	7455-7456	)	_
36-51	7456-7457	,	_
36-52	7458-7466	although	_
36-53	7467-7471	they	_
36-54	7472-7477	still	_
36-55	7478-7481	had	_
36-56	7482-7488	modest	_
36-57	7489-7499	deviations	_
36-58	7500-7502	on	_
36-59	7503-7511	multiple	_
36-60	7512-7522	biomarkers	_
36-61	7522-7523	.	_

#Text=All participants in the current study were included in, and so their current Biotype membership (Biotype-1, N=20; Biotype-2, N=30; Biotype-3, N=55) is known.
37-1	7524-7527	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-2	7528-7540	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-3	7541-7543	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-4	7544-7547	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-5	7548-7555	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-6	7556-7561	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-7	7562-7566	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-8	7567-7575	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-9	7576-7578	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-10	7578-7579	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-11	7580-7583	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-12	7584-7586	so	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-13	7587-7592	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-14	7593-7600	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-15	7601-7608	Biotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-16	7609-7619	membership	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-17	7620-7621	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-18	7621-7628	Biotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-19	7628-7629	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-20	7629-7630	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-21	7630-7631	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-22	7632-7633	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-23	7633-7634	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-24	7634-7636	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-25	7636-7637	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-26	7638-7645	Biotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-27	7645-7646	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-28	7646-7647	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-29	7647-7648	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-30	7649-7650	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-31	7650-7651	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-32	7651-7653	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-33	7653-7654	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-34	7655-7662	Biotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-35	7662-7663	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-36	7663-7664	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-37	7664-7665	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-38	7666-7667	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-39	7667-7668	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-40	7668-7670	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-41	7670-7671	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-42	7672-7674	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-43	7675-7680	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
37-44	7680-7681	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=The data used for developing Biotypes was independent, however, from tasks and measurements obtained for the present study (see Supplemental Materials).
38-1	7682-7685	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-2	7686-7690	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-3	7691-7695	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-4	7696-7699	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-5	7700-7710	developing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-6	7711-7719	Biotypes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-7	7720-7723	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-8	7724-7735	independent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-9	7735-7736	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-10	7737-7744	however	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-11	7744-7745	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-12	7746-7750	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-13	7751-7756	tasks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-14	7757-7760	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-15	7761-7773	measurements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-16	7774-7782	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-17	7783-7786	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-18	7787-7790	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-19	7791-7798	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-20	7799-7804	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-21	7805-7806	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-22	7806-7809	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-23	7810-7822	Supplemental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-24	7823-7832	Materials	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-25	7832-7833	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
38-26	7833-7834	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]

#Text=The current data were collected as part of a series of complimentary paradigms on the same sample as reported in.
39-1	7835-7838	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-2	7839-7846	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-3	7847-7851	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-4	7852-7856	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-5	7857-7866	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-6	7867-7869	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-7	7870-7874	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-8	7875-7877	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-9	7878-7879	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-10	7880-7886	series	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-11	7887-7889	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-12	7890-7903	complimentary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-13	7904-7913	paradigms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-14	7914-7916	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-15	7917-7920	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-16	7921-7925	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-17	7926-7932	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-18	7933-7935	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-19	7936-7944	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-20	7945-7947	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
39-21	7947-7948	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]

#Text=Sample size differences are due to EEG data quality.
40-1	7949-7955	Sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-2	7956-7960	size	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-3	7961-7972	differences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-4	7973-7976	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-5	7977-7980	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-6	7981-7983	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-7	7984-7987	EEG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram[20]
40-8	7988-7992	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-9	7993-8000	quality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-10	8000-8001	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=The recording and preprocessing of EEG data were identical to that in previous work (; also see Supplemental Materials), except that here the data were kept at the original sampling rate of 1000 Hz.
#Text=2.2.
41-1	8002-8005	The	_
41-2	8006-8015	recording	_
41-3	8016-8019	and	_
41-4	8020-8033	preprocessing	_
41-5	8034-8036	of	_
41-6	8037-8040	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
41-7	8041-8045	data	_
41-8	8046-8050	were	_
41-9	8051-8060	identical	_
41-10	8061-8063	to	_
41-11	8064-8068	that	_
41-12	8069-8071	in	_
41-13	8072-8080	previous	_
41-14	8081-8085	work	_
41-15	8086-8087	(	_
41-16	8087-8088	;	_
41-17	8089-8093	also	_
41-18	8094-8097	see	_
41-19	8098-8110	Supplemental	_
41-20	8111-8120	Materials	_
41-21	8120-8121	)	_
41-22	8121-8122	,	_
41-23	8123-8129	except	_
41-24	8130-8134	that	_
41-25	8135-8139	here	_
41-26	8140-8143	the	_
41-27	8144-8148	data	_
41-28	8149-8153	were	_
41-29	8154-8158	kept	_
41-30	8159-8161	at	_
41-31	8162-8165	the	_
41-32	8166-8174	original	_
41-33	8175-8183	sampling	_
41-34	8184-8188	rate	_
41-35	8189-8191	of	_
41-36	8192-8196	1000	_
41-37	8197-8199	Hz	_
41-38	8199-8200	.	_
41-39	8201-8204	2.2	_
41-40	8204-8205	.	_

#Text=Stimuli
#Text=Stimuli were presented on a 19-inch flat-surface computer monitor with a refresh rate of 60Hz.
42-1	8206-8213	Stimuli	_
42-2	8214-8221	Stimuli	_
42-3	8222-8226	were	_
42-4	8227-8236	presented	_
42-5	8237-8239	on	_
42-6	8240-8241	a	_
42-7	8242-8244	19	_
42-8	8244-8245	-	_
42-9	8245-8249	inch	_
42-10	8250-8262	flat-surface	_
42-11	8263-8271	computer	_
42-12	8272-8279	monitor	_
42-13	8280-8284	with	_
42-14	8285-8286	a	_
42-15	8287-8294	refresh	_
42-16	8295-8299	rate	_
42-17	8300-8302	of	_
42-18	8303-8307	60Hz	_
42-19	8307-8308	.	_

#Text=Stimuli consisted of three 5×5cm checkerboards (alternating colored and black squares, each 1deg square) located at central fixation and 8 deg to the left and right of central fixation (Figure 1).
43-1	8309-8316	Stimuli	_
43-2	8317-8326	consisted	_
43-3	8327-8329	of	_
43-4	8330-8335	three	_
43-5	8336-8337	5	_
43-6	8337-8338	×	_
43-7	8338-8341	5cm	_
43-8	8342-8355	checkerboards	_
43-9	8356-8357	(	_
43-10	8357-8368	alternating	_
43-11	8369-8376	colored	_
43-12	8377-8380	and	_
43-13	8381-8386	black	_
43-14	8387-8394	squares	_
43-15	8394-8395	,	_
43-16	8396-8400	each	_
43-17	8401-8405	1deg	_
43-18	8406-8412	square	_
43-19	8412-8413	)	_
43-20	8414-8421	located	_
43-21	8422-8424	at	_
43-22	8425-8432	central	_
43-23	8433-8441	fixation	_
43-24	8442-8445	and	_
43-25	8446-8447	8	_
43-26	8448-8451	deg	_
43-27	8452-8454	to	_
43-28	8455-8458	the	_
43-29	8459-8463	left	_
43-30	8464-8467	and	_
43-31	8468-8473	right	_
43-32	8474-8476	of	_
43-33	8477-8484	central	_
43-34	8485-8493	fixation	_
43-35	8494-8495	(	_
43-36	8495-8501	Figure	_
43-37	8502-8503	1	_
43-38	8503-8504	)	_
43-39	8504-8505	.	_

#Text=Checkerboards were either green (during the prosaccade block) or red (during the antisaccade block).
44-1	8506-8519	Checkerboards	_
44-2	8520-8524	were	_
44-3	8525-8531	either	_
44-4	8532-8537	green	_
44-5	8538-8539	(	_
44-6	8539-8545	during	_
44-7	8546-8549	the	_
44-8	8550-8560	prosaccade	_
44-9	8561-8566	block	_
44-10	8566-8567	)	_
44-11	8568-8570	or	_
44-12	8571-8574	red	_
44-13	8575-8576	(	_
44-14	8576-8582	during	_
44-15	8583-8586	the	_
44-16	8587-8598	antisaccade	_
44-17	8599-8604	block	_
44-18	8604-8605	)	_
44-19	8605-8606	.	_

#Text=Both colors had equal luminance (5 cd/m2).
45-1	8607-8611	Both	_
45-2	8612-8618	colors	_
45-3	8619-8622	had	_
45-4	8623-8628	equal	_
45-5	8629-8638	luminance	_
45-6	8639-8640	(	_
45-7	8640-8641	5	_
45-8	8642-8644	cd	_
45-9	8644-8645	/	_
45-10	8645-8647	m2	_
45-11	8647-8648	)	_
45-12	8648-8649	.	_

#Text=The peripheral checkerboards were luminance modulated (100% modulation depth) at two flickering frequencies (12Hz in the left visual field, 15Hz in the right visual field), with the central checkerboard not flickering.
46-1	8650-8653	The	_
46-2	8654-8664	peripheral	_
46-3	8665-8678	checkerboards	_
46-4	8679-8683	were	_
46-5	8684-8693	luminance	_
46-6	8694-8703	modulated	_
46-7	8704-8705	(	_
46-8	8705-8709	100%	_
46-9	8710-8720	modulation	_
46-10	8721-8726	depth	_
46-11	8726-8727	)	_
46-12	8728-8730	at	_
46-13	8731-8734	two	_
46-14	8735-8745	flickering	_
46-15	8746-8757	frequencies	_
46-16	8758-8759	(	_
46-17	8759-8763	12Hz	_
46-18	8764-8766	in	_
46-19	8767-8770	the	_
46-20	8771-8775	left	_
46-21	8776-8782	visual	_
46-22	8783-8788	field	_
46-23	8788-8789	,	_
46-24	8790-8794	15Hz	_
46-25	8795-8797	in	_
46-26	8798-8801	the	_
46-27	8802-8807	right	_
46-28	8808-8814	visual	_
46-29	8815-8820	field	_
46-30	8820-8821	)	_
46-31	8821-8822	,	_
46-32	8823-8827	with	_
46-33	8828-8831	the	_
46-34	8832-8839	central	_
46-35	8840-8852	checkerboard	_
46-36	8853-8856	not	_
46-37	8857-8867	flickering	_
46-38	8867-8868	.	_

#Text=Blocks consisted of 50 trials of either pro- or anti-saccades, for a total of 100 trials.
47-1	8869-8875	Blocks	_
47-2	8876-8885	consisted	_
47-3	8886-8888	of	_
47-4	8889-8891	50	_
47-5	8892-8898	trials	_
47-6	8899-8901	of	_
47-7	8902-8908	either	_
47-8	8909-8912	pro	_
47-9	8912-8913	-	_
47-10	8914-8916	or	_
47-11	8917-8930	anti-saccades	_
47-12	8930-8931	,	_
47-13	8932-8935	for	_
47-14	8936-8937	a	_
47-15	8938-8943	total	_
47-16	8944-8946	of	_
47-17	8947-8950	100	_
47-18	8951-8957	trials	_
47-19	8957-8958	.	_

#Text=Each trial was preceded by an inter-trial interval of 6sec, in which a gray central fixation square (1 deg square) was presented.
48-1	8959-8963	Each	_
48-2	8964-8969	trial	_
48-3	8970-8973	was	_
48-4	8974-8982	preceded	_
48-5	8983-8985	by	_
48-6	8986-8988	an	_
48-7	8989-9000	inter-trial	_
48-8	9001-9009	interval	_
48-9	9010-9012	of	_
48-10	9013-9017	6sec	_
48-11	9017-9018	,	_
48-12	9019-9021	in	_
48-13	9022-9027	which	_
48-14	9028-9029	a	_
48-15	9030-9034	gray	_
48-16	9035-9042	central	_
48-17	9043-9051	fixation	_
48-18	9052-9058	square	_
48-19	9059-9060	(	_
48-20	9060-9061	1	_
48-21	9062-9065	deg	_
48-22	9066-9072	square	_
48-23	9072-9073	)	_
48-24	9074-9077	was	_
48-25	9078-9087	presented	_
48-26	9087-9088	.	_

#Text=At each quarter of this Fixation Period (1.5sec), the central square decreased in size by ¼ in order to give a “countdown” to the next trial.
49-1	9089-9091	At	_
49-2	9092-9096	each	_
49-3	9097-9104	quarter	_
49-4	9105-9107	of	_
49-5	9108-9112	this	_
49-6	9113-9121	Fixation	_
49-7	9122-9128	Period	_
49-8	9129-9130	(	_
49-9	9130-9136	1.5sec	_
49-10	9136-9137	)	_
49-11	9137-9138	,	_
49-12	9139-9142	the	_
49-13	9143-9150	central	_
49-14	9151-9157	square	_
49-15	9158-9167	decreased	_
49-16	9168-9170	in	_
49-17	9171-9175	size	_
49-18	9176-9178	by	_
49-19	9179-9180	¼	_
49-20	9181-9183	in	_
49-21	9184-9189	order	_
49-22	9190-9192	to	_
49-23	9193-9197	give	_
49-24	9198-9199	a	_
49-25	9200-9201	“	_
49-26	9201-9210	countdown	_
49-27	9210-9211	”	_
49-28	9212-9214	to	_
49-29	9215-9218	the	_
49-30	9219-9223	next	_
49-31	9224-9229	trial	_
49-32	9229-9230	.	_

#Text=Trials began with the peripheral checkerboards flickering for 5 sec.
50-1	9231-9237	Trials	_
50-2	9238-9243	began	_
50-3	9244-9248	with	_
50-4	9249-9252	the	_
50-5	9253-9263	peripheral	_
50-6	9264-9277	checkerboards	_
50-7	9278-9288	flickering	_
50-8	9289-9292	for	_
50-9	9293-9294	5	_
50-10	9295-9298	sec	_
50-11	9298-9299	.	_

#Text=Participants were instructed to maintain fixation on the central checkerboard throughout this Preparatory Period.
51-1	9300-9312	Participants	_
51-2	9313-9317	were	_
51-3	9318-9328	instructed	_
51-4	9329-9331	to	_
51-5	9332-9340	maintain	_
51-6	9341-9349	fixation	_
51-7	9350-9352	on	_
51-8	9353-9356	the	_
51-9	9357-9364	central	_
51-10	9365-9377	checkerboard	_
51-11	9378-9388	throughout	_
51-12	9389-9393	this	_
51-13	9394-9405	Preparatory	_
51-14	9406-9412	Period	_
51-15	9412-9413	.	_

#Text=Similar to the Fixation Period, at 1sec intervals during the Preparatory Period the center square of the central checkerboard decreased in size by ¼ in order to give the participants information about the impending response requirement.
52-1	9414-9421	Similar	_
52-2	9422-9424	to	_
52-3	9425-9428	the	_
52-4	9429-9437	Fixation	_
52-5	9438-9444	Period	_
52-6	9444-9445	,	_
52-7	9446-9448	at	_
52-8	9449-9453	1sec	_
52-9	9454-9463	intervals	_
52-10	9464-9470	during	_
52-11	9471-9474	the	_
52-12	9475-9486	Preparatory	_
52-13	9487-9493	Period	_
52-14	9494-9497	the	_
52-15	9498-9504	center	_
52-16	9505-9511	square	_
52-17	9512-9514	of	_
52-18	9515-9518	the	_
52-19	9519-9526	central	_
52-20	9527-9539	checkerboard	_
52-21	9540-9549	decreased	_
52-22	9550-9552	in	_
52-23	9553-9557	size	_
52-24	9558-9560	by	_
52-25	9561-9562	¼	_
52-26	9563-9565	in	_
52-27	9566-9571	order	_
52-28	9572-9574	to	_
52-29	9575-9579	give	_
52-30	9580-9583	the	_
52-31	9584-9596	participants	_
52-32	9597-9608	information	_
52-33	9609-9614	about	_
52-34	9615-9618	the	_
52-35	9619-9628	impending	_
52-36	9629-9637	response	_
52-37	9638-9649	requirement	_
52-38	9649-9650	.	_

#Text=After the 5sec Preparatory Period, one of the peripheral checkerboards (pseudo-randomly determined) increased in luminance to 20 cd/m2 for 1.25sec (the saccadic Response Period), while both peripheral checkerboards continued flickering.
53-1	9651-9656	After	_
53-2	9657-9660	the	_
53-3	9661-9665	5sec	_
53-4	9666-9677	Preparatory	_
53-5	9678-9684	Period	_
53-6	9684-9685	,	_
53-7	9686-9689	one	_
53-8	9690-9692	of	_
53-9	9693-9696	the	_
53-10	9697-9707	peripheral	_
53-11	9708-9721	checkerboards	_
53-12	9722-9723	(	_
53-13	9723-9738	pseudo-randomly	_
53-14	9739-9749	determined	_
53-15	9749-9750	)	_
53-16	9751-9760	increased	_
53-17	9761-9763	in	_
53-18	9764-9773	luminance	_
53-19	9774-9776	to	_
53-20	9777-9779	20	_
53-21	9780-9782	cd	_
53-22	9782-9783	/	_
53-23	9783-9785	m2	_
53-24	9786-9789	for	_
53-25	9790-9797	1.25sec	_
53-26	9798-9799	(	_
53-27	9799-9802	the	_
53-28	9803-9811	saccadic	_
53-29	9812-9820	Response	_
53-30	9821-9827	Period	_
53-31	9827-9828	)	_
53-32	9828-9829	,	_
53-33	9830-9835	while	_
53-34	9836-9840	both	_
53-35	9841-9851	peripheral	_
53-36	9852-9865	checkerboards	_
53-37	9866-9875	continued	_
53-38	9876-9886	flickering	_
53-39	9886-9887	.	_

#Text=On prosaccade trials, participants were to look as quickly and accurately as possible toward this target; on antisaccade trials, participants were instructed to look as quickly and accurately as possible to the mirror image location (opposite checkerboard).
54-1	9888-9890	On	_
54-2	9891-9901	prosaccade	_
54-3	9902-9908	trials	_
54-4	9908-9909	,	_
54-5	9910-9922	participants	_
54-6	9923-9927	were	_
54-7	9928-9930	to	_
54-8	9931-9935	look	_
54-9	9936-9938	as	_
54-10	9939-9946	quickly	_
54-11	9947-9950	and	_
54-12	9951-9961	accurately	_
54-13	9962-9964	as	_
54-14	9965-9973	possible	_
54-15	9974-9980	toward	_
54-16	9981-9985	this	_
54-17	9986-9992	target	_
54-18	9992-9993	;	_
54-19	9994-9996	on	_
54-20	9997-10008	antisaccade	_
54-21	10009-10015	trials	_
54-22	10015-10016	,	_
54-23	10017-10029	participants	_
54-24	10030-10034	were	_
54-25	10035-10045	instructed	_
54-26	10046-10048	to	_
54-27	10049-10053	look	_
54-28	10054-10056	as	_
54-29	10057-10064	quickly	_
54-30	10065-10068	and	_
54-31	10069-10079	accurately	_
54-32	10080-10082	as	_
54-33	10083-10091	possible	_
54-34	10092-10094	to	_
54-35	10095-10098	the	_
54-36	10099-10105	mirror	_
54-37	10106-10111	image	_
54-38	10112-10120	location	_
54-39	10121-10122	(	_
54-40	10122-10130	opposite	_
54-41	10131-10143	checkerboard	_
54-42	10143-10144	)	_
54-43	10144-10145	.	_

#Text=All analyses were time-locked to the onset of the Preparatory Period, and descriptions below (e.g., pre or post stimulus onset) reflect this.
55-1	10146-10149	All	_
55-2	10150-10158	analyses	_
55-3	10159-10163	were	_
55-4	10164-10175	time-locked	_
55-5	10176-10178	to	_
55-6	10179-10182	the	_
55-7	10183-10188	onset	_
55-8	10189-10191	of	_
55-9	10192-10195	the	_
55-10	10196-10207	Preparatory	_
55-11	10208-10214	Period	_
55-12	10214-10215	,	_
55-13	10216-10219	and	_
55-14	10220-10232	descriptions	_
55-15	10233-10238	below	_
55-16	10239-10240	(	_
55-17	10240-10243	e.g	_
55-18	10243-10244	.	_
55-19	10244-10245	,	_
55-20	10246-10249	pre	_
55-21	10250-10252	or	_
55-22	10253-10257	post	_
55-23	10258-10266	stimulus	_
55-24	10267-10272	onset	_
55-25	10272-10273	)	_
55-26	10274-10281	reflect	_
55-27	10282-10286	this	_
55-28	10286-10287	.	_

#Text=As the primary interest of this study was preparatory modulation, analyses do not include any brain data from the Response Period.
#Text=2.3.
56-1	10288-10290	As	_
56-2	10291-10294	the	_
56-3	10295-10302	primary	_
56-4	10303-10311	interest	_
56-5	10312-10314	of	_
56-6	10315-10319	this	_
56-7	10320-10325	study	_
56-8	10326-10329	was	_
56-9	10330-10341	preparatory	_
56-10	10342-10352	modulation	_
56-11	10352-10353	,	_
56-12	10354-10362	analyses	_
56-13	10363-10365	do	_
56-14	10366-10369	not	_
56-15	10370-10377	include	_
56-16	10378-10381	any	_
56-17	10382-10387	brain	_
56-18	10388-10392	data	_
56-19	10393-10397	from	_
56-20	10398-10401	the	_
56-21	10402-10410	Response	_
56-22	10411-10417	Period	_
56-23	10417-10418	.	_
56-24	10419-10422	2.3	_
56-25	10422-10423	.	_

#Text=Data Analyses
#Text=Two approaches were used to quantify brain activity.
57-1	10424-10428	Data	_
57-2	10429-10437	Analyses	_
57-3	10438-10441	Two	_
57-4	10442-10452	approaches	_
57-5	10453-10457	were	_
57-6	10458-10462	used	_
57-7	10463-10465	to	_
57-8	10466-10474	quantify	_
57-9	10475-10480	brain	_
57-10	10481-10489	activity	_
57-11	10489-10490	.	_

#Text=First, evoked potentials were used to evaluate the amplitude and spatial distribution of brain activity at the onset of visual stimulation (at the beginning of the Preparatory Period, before stabilization of the steady-state response).
58-1	10491-10496	First	_
58-2	10496-10497	,	_
58-3	10498-10504	evoked	_
58-4	10505-10515	potentials	_
58-5	10516-10520	were	_
58-6	10521-10525	used	_
58-7	10526-10528	to	_
58-8	10529-10537	evaluate	_
58-9	10538-10541	the	_
58-10	10542-10551	amplitude	_
58-11	10552-10555	and	_
58-12	10556-10563	spatial	_
58-13	10564-10576	distribution	_
58-14	10577-10579	of	_
58-15	10580-10585	brain	_
58-16	10586-10594	activity	_
58-17	10595-10597	at	_
58-18	10598-10601	the	_
58-19	10602-10607	onset	_
58-20	10608-10610	of	_
58-21	10611-10617	visual	_
58-22	10618-10629	stimulation	_
58-23	10630-10631	(	_
58-24	10631-10633	at	_
58-25	10634-10637	the	_
58-26	10638-10647	beginning	_
58-27	10648-10650	of	_
58-28	10651-10654	the	_
58-29	10655-10666	Preparatory	_
58-30	10667-10673	Period	_
58-31	10673-10674	,	_
58-32	10675-10681	before	_
58-33	10682-10695	stabilization	_
58-34	10696-10698	of	_
58-35	10699-10702	the	_
58-36	10703-10715	steady-state	_
58-37	10716-10724	response	_
58-38	10724-10725	)	_
58-39	10725-10726	.	_

#Text=Second, as in, spectral measures were used to assess the power, phase stability, and spatial distribution of the vSSR over time before and during the Preparatory Period (−500ms to 5000ms in relation to stimuli onset).
59-1	10727-10733	Second	_
59-2	10733-10734	,	_
59-3	10735-10737	as	_
59-4	10738-10740	in	_
59-5	10740-10741	,	_
59-6	10742-10750	spectral	_
59-7	10751-10759	measures	_
59-8	10760-10764	were	_
59-9	10765-10769	used	_
59-10	10770-10772	to	_
59-11	10773-10779	assess	_
59-12	10780-10783	the	_
59-13	10784-10789	power	_
59-14	10789-10790	,	_
59-15	10791-10796	phase	_
59-16	10797-10806	stability	_
59-17	10806-10807	,	_
59-18	10808-10811	and	_
59-19	10812-10819	spatial	_
59-20	10820-10832	distribution	_
59-21	10833-10835	of	_
59-22	10836-10839	the	_
59-23	10840-10844	vSSR	_
59-24	10845-10849	over	_
59-25	10850-10854	time	_
59-26	10855-10861	before	_
59-27	10862-10865	and	_
59-28	10866-10872	during	_
59-29	10873-10876	the	_
59-30	10877-10888	Preparatory	_
59-31	10889-10895	Period	_
59-32	10896-10897	(	_
59-33	10897-10898	−	_
59-34	10898-10903	500ms	_
59-35	10904-10906	to	_
59-36	10907-10913	5000ms	_
59-37	10914-10916	in	_
59-38	10917-10925	relation	_
59-39	10926-10928	to	_
59-40	10929-10936	stimuli	_
59-41	10937-10942	onset	_
59-42	10942-10943	)	_
59-43	10943-10944	.	_

#Text=For all analyses, Greenhouse-Geisser correction was used when sphericity was violated.
60-1	10945-10948	For	_
60-2	10949-10952	all	_
60-3	10953-10961	analyses	_
60-4	10961-10962	,	_
60-5	10963-10981	Greenhouse-Geisser	_
60-6	10982-10992	correction	_
60-7	10993-10996	was	_
60-8	10997-11001	used	_
60-9	11002-11006	when	_
60-10	11007-11017	sphericity	_
60-11	11018-11021	was	_
60-12	11022-11030	violated	_
60-13	11030-11031	.	_

#Text=All analyses were replicated as a function of subgrouping psychosis cases by clinical symptomatology (see Supplemental Results).
#Text=2.3.1.
61-1	11032-11035	All	_
61-2	11036-11044	analyses	_
61-3	11045-11049	were	_
61-4	11050-11060	replicated	_
61-5	11061-11063	as	_
61-6	11064-11065	a	_
61-7	11066-11074	function	_
61-8	11075-11077	of	_
61-9	11078-11089	subgrouping	_
61-10	11090-11099	psychosis	_
61-11	11100-11105	cases	_
61-12	11106-11108	by	_
61-13	11109-11117	clinical	_
61-14	11118-11132	symptomatology	_
61-15	11133-11134	(	_
61-16	11134-11137	see	_
61-17	11138-11150	Supplemental	_
61-18	11151-11158	Results	_
61-19	11158-11159	)	_
61-20	11159-11160	.	_
61-21	11161-11166	2.3.1	_
61-22	11166-11167	.	_

#Text=Visual Evoked Potentials
#Text=The voltage data were used to test for differences in brain activations, at the beginning of visual processing at Preparatory Period onset, between the pro- and anti-saccade conditions and between groups (Figure 2), using methods identical to previous work (; also see Supplemental Materials).
#Text=2.4.2.
62-1	11168-11174	Visual	_
62-2	11175-11181	Evoked	_
62-3	11182-11192	Potentials	_
62-4	11193-11196	The	_
62-5	11197-11204	voltage	_
62-6	11205-11209	data	_
62-7	11210-11214	were	_
62-8	11215-11219	used	_
62-9	11220-11222	to	_
62-10	11223-11227	test	_
62-11	11228-11231	for	_
62-12	11232-11243	differences	_
62-13	11244-11246	in	_
62-14	11247-11252	brain	_
62-15	11253-11264	activations	_
62-16	11264-11265	,	_
62-17	11266-11268	at	_
62-18	11269-11272	the	_
62-19	11273-11282	beginning	_
62-20	11283-11285	of	_
62-21	11286-11292	visual	_
62-22	11293-11303	processing	_
62-23	11304-11306	at	_
62-24	11307-11318	Preparatory	_
62-25	11319-11325	Period	_
62-26	11326-11331	onset	_
62-27	11331-11332	,	_
62-28	11333-11340	between	_
62-29	11341-11344	the	_
62-30	11345-11348	pro	_
62-31	11348-11349	-	_
62-32	11350-11353	and	_
62-33	11354-11366	anti-saccade	_
62-34	11367-11377	conditions	_
62-35	11378-11381	and	_
62-36	11382-11389	between	_
62-37	11390-11396	groups	_
62-38	11397-11398	(	_
62-39	11398-11404	Figure	_
62-40	11405-11406	2	_
62-41	11406-11407	)	_
62-42	11407-11408	,	_
62-43	11409-11414	using	_
62-44	11415-11422	methods	_
62-45	11423-11432	identical	_
62-46	11433-11435	to	_
62-47	11436-11444	previous	_
62-48	11445-11449	work	_
62-49	11450-11451	(	_
62-50	11451-11452	;	_
62-51	11453-11457	also	_
62-52	11458-11461	see	_
62-53	11462-11474	Supplemental	_
62-54	11475-11484	Materials	_
62-55	11484-11485	)	_
62-56	11485-11486	.	_
62-57	11487-11492	2.4.2	_
62-58	11492-11493	.	_

#Text=Spectral measures
#Text=Similar to previous work using paradigms comparable to those used in the present study, the vSSR was quantified using inter-trial phase coherence (ITC; increased across-trial phase similarity of the EEG signals in relation to frequency of visual flickering stimuli) and single-trial power (STP).
63-1	11494-11502	Spectral	_
63-2	11503-11511	measures	_
63-3	11512-11519	Similar	_
63-4	11520-11522	to	_
63-5	11523-11531	previous	_
63-6	11532-11536	work	_
63-7	11537-11542	using	_
63-8	11543-11552	paradigms	_
63-9	11553-11563	comparable	_
63-10	11564-11566	to	_
63-11	11567-11572	those	_
63-12	11573-11577	used	_
63-13	11578-11580	in	_
63-14	11581-11584	the	_
63-15	11585-11592	present	_
63-16	11593-11598	study	_
63-17	11598-11599	,	_
63-18	11600-11603	the	_
63-19	11604-11608	vSSR	_
63-20	11609-11612	was	_
63-21	11613-11623	quantified	_
63-22	11624-11629	using	_
63-23	11630-11641	inter-trial	_
63-24	11642-11647	phase	_
63-25	11648-11657	coherence	_
63-26	11658-11659	(	_
63-27	11659-11662	ITC	_
63-28	11662-11663	;	_
63-29	11664-11673	increased	_
63-30	11674-11686	across-trial	_
63-31	11687-11692	phase	_
63-32	11693-11703	similarity	_
63-33	11704-11706	of	_
63-34	11707-11710	the	_
63-35	11711-11714	EEG	_
63-36	11715-11722	signals	_
63-37	11723-11725	in	_
63-38	11726-11734	relation	_
63-39	11735-11737	to	_
63-40	11738-11747	frequency	_
63-41	11748-11750	of	_
63-42	11751-11757	visual	_
63-43	11758-11768	flickering	_
63-44	11769-11776	stimuli	_
63-45	11776-11777	)	_
63-46	11778-11781	and	_
63-47	11782-11794	single-trial	_
63-48	11795-11800	power	_
63-49	11801-11802	(	_
63-50	11802-11805	STP	_
63-51	11805-11806	)	_
63-52	11806-11807	.	_

#Text=ITC and STP of the steady-state response across time were estimated by complex demodulation at the flickering rates (12 and 15 Hz) using published methods (; also see Supplemental Materials).
64-1	11808-11811	ITC	_
64-2	11812-11815	and	_
64-3	11816-11819	STP	_
64-4	11820-11822	of	_
64-5	11823-11826	the	_
64-6	11827-11839	steady-state	_
64-7	11840-11848	response	_
64-8	11849-11855	across	_
64-9	11856-11860	time	_
64-10	11861-11865	were	_
64-11	11866-11875	estimated	_
64-12	11876-11878	by	_
64-13	11879-11886	complex	_
64-14	11887-11899	demodulation	_
64-15	11900-11902	at	_
64-16	11903-11906	the	_
64-17	11907-11917	flickering	_
64-18	11918-11923	rates	_
64-19	11924-11925	(	_
64-20	11925-11927	12	_
64-21	11928-11931	and	_
64-22	11932-11934	15	_
64-23	11935-11937	Hz	_
64-24	11937-11938	)	_
64-25	11939-11944	using	_
64-26	11945-11954	published	_
64-27	11955-11962	methods	_
64-28	11963-11964	(	_
64-29	11964-11965	;	_
64-30	11966-11970	also	_
64-31	11971-11974	see	_
64-32	11975-11987	Supplemental	_
64-33	11988-11997	Materials	_
64-34	11997-11998	)	_
64-35	11998-11999	.	_

#Text=Spectral values for the two driving frequencies were initially analyzed individually but were later summed as frequency did not systematically interact with group, task, or time.
65-1	12000-12008	Spectral	_
65-2	12009-12015	values	_
65-3	12016-12019	for	_
65-4	12020-12023	the	_
65-5	12024-12027	two	_
65-6	12028-12035	driving	_
65-7	12036-12047	frequencies	_
65-8	12048-12052	were	_
65-9	12053-12062	initially	_
65-10	12063-12071	analyzed	_
65-11	12072-12084	individually	_
65-12	12085-12088	but	_
65-13	12089-12093	were	_
65-14	12094-12099	later	_
65-15	12100-12106	summed	_
65-16	12107-12109	as	_
65-17	12110-12119	frequency	_
65-18	12120-12123	did	_
65-19	12124-12127	not	_
65-20	12128-12142	systematically	_
65-21	12143-12151	interact	_
65-22	12152-12156	with	_
65-23	12157-12162	group	_
65-24	12162-12163	,	_
65-25	12164-12168	task	_
65-26	12168-12169	,	_
65-27	12170-12172	or	_
65-28	12173-12177	time	_
65-29	12177-12178	.	_

#Text=ITC values were averaged over 9 posterior cortex sensors capturing peak vSSR activity (Supplemental Figure 1), averaged from −500:0ms pre-stimulus and over each of the five 1sec Preparatory Period countdowns, and analyzed using mixed effects 3-way MANOVAs (Group × Saccade Type × Time Bin) with post hoc Tukey honestly significant difference tests.
66-1	12179-12182	ITC	_
66-2	12183-12189	values	_
66-3	12190-12194	were	_
66-4	12195-12203	averaged	_
66-5	12204-12208	over	_
66-6	12209-12210	9	_
66-7	12211-12220	posterior	_
66-8	12221-12227	cortex	_
66-9	12228-12235	sensors	_
66-10	12236-12245	capturing	_
66-11	12246-12250	peak	_
66-12	12251-12255	vSSR	_
66-13	12256-12264	activity	_
66-14	12265-12266	(	_
66-15	12266-12278	Supplemental	_
66-16	12279-12285	Figure	_
66-17	12286-12287	1	_
66-18	12287-12288	)	_
66-19	12288-12289	,	_
66-20	12290-12298	averaged	_
66-21	12299-12303	from	_
66-22	12304-12305	−	_
66-23	12305-12308	500	_
66-24	12308-12309	:	_
66-25	12309-12312	0ms	_
66-26	12313-12325	pre-stimulus	_
66-27	12326-12329	and	_
66-28	12330-12334	over	_
66-29	12335-12339	each	_
66-30	12340-12342	of	_
66-31	12343-12346	the	_
66-32	12347-12351	five	_
66-33	12352-12356	1sec	_
66-34	12357-12368	Preparatory	_
66-35	12369-12375	Period	_
66-36	12376-12386	countdowns	_
66-37	12386-12387	,	_
66-38	12388-12391	and	_
66-39	12392-12400	analyzed	_
66-40	12401-12406	using	_
66-41	12407-12412	mixed	_
66-42	12413-12420	effects	_
66-43	12421-12422	3	_
66-44	12422-12423	-	_
66-45	12423-12426	way	_
66-46	12427-12434	MANOVAs	_
66-47	12435-12436	(	_
66-48	12436-12441	Group	_
66-49	12442-12443	×	_
66-50	12444-12451	Saccade	_
66-51	12452-12456	Type	_
66-52	12457-12458	×	_
66-53	12459-12463	Time	_
66-54	12464-12467	Bin	_
66-55	12467-12468	)	_
66-56	12469-12473	with	_
66-57	12474-12478	post	_
66-58	12479-12482	hoc	_
66-59	12483-12488	Tukey	_
66-60	12489-12497	honestly	_
66-61	12498-12509	significant	_
66-62	12510-12520	difference	_
66-63	12521-12526	tests	_
66-64	12526-12527	.	_

#Text=To most accurately and comprehensively capture the shared variance in spatial topographies of STP across time, spatial PCA was implemented using the ERP PCA Toolkit in Matlab (Mathworks, Matick, MA).
67-1	12528-12530	To	_
67-2	12531-12535	most	_
67-3	12536-12546	accurately	_
67-4	12547-12550	and	_
67-5	12551-12566	comprehensively	_
67-6	12567-12574	capture	_
67-7	12575-12578	the	_
67-8	12579-12585	shared	_
67-9	12586-12594	variance	_
67-10	12595-12597	in	_
67-11	12598-12605	spatial	_
67-12	12606-12618	topographies	_
67-13	12619-12621	of	_
67-14	12622-12625	STP	_
67-15	12626-12632	across	_
67-16	12633-12637	time	_
67-17	12637-12638	,	_
67-18	12639-12646	spatial	_
67-19	12647-12650	PCA	_
67-20	12651-12654	was	_
67-21	12655-12666	implemented	_
67-22	12667-12672	using	_
67-23	12673-12676	the	_
67-24	12677-12680	ERP	_
67-25	12681-12684	PCA	_
67-26	12685-12692	Toolkit	_
67-27	12693-12695	in	_
67-28	12696-12702	Matlab	_
67-29	12703-12704	(	_
67-30	12704-12713	Mathworks	_
67-31	12713-12714	,	_
67-32	12715-12721	Matick	_
67-33	12721-12722	,	_
67-34	12723-12725	MA	_
67-35	12725-12726	)	_
67-36	12726-12727	.	_

#Text=For each group and task individually, power values from −500:5000ms were standardized across sensors before averaging across subjects.
68-1	12728-12731	For	_
68-2	12732-12736	each	_
68-3	12737-12742	group	_
68-4	12743-12746	and	_
68-5	12747-12751	task	_
68-6	12752-12764	individually	_
68-7	12764-12765	,	_
68-8	12766-12771	power	_
68-9	12772-12778	values	_
68-10	12779-12783	from	_
68-11	12784-12785	−	_
68-12	12785-12788	500	_
68-13	12788-12789	:	_
68-14	12789-12795	5000ms	_
68-15	12796-12800	were	_
68-16	12801-12813	standardized	_
68-17	12814-12820	across	_
68-18	12821-12828	sensors	_
68-19	12829-12835	before	_
68-20	12836-12845	averaging	_
68-21	12846-12852	across	_
68-22	12853-12861	subjects	_
68-23	12861-12862	.	_

#Text=Scree tests for each identified one component.
69-1	12863-12868	Scree	_
69-2	12869-12874	tests	_
69-3	12875-12878	for	_
69-4	12879-12883	each	_
69-5	12884-12894	identified	_
69-6	12895-12898	one	_
69-7	12899-12908	component	_
69-8	12908-12909	.	_

#Text=The spatial distribution and amount of variance accounted for were nearly identical (all correlations greater than r = .975), so the same procedure was repeated on a single grand average time course, resulting in a component accounting for 48.6% of variance (see Supplemental Figure 2).
70-1	12910-12913	The	_
70-2	12914-12921	spatial	_
70-3	12922-12934	distribution	_
70-4	12935-12938	and	_
70-5	12939-12945	amount	_
70-6	12946-12948	of	_
70-7	12949-12957	variance	_
70-8	12958-12967	accounted	_
70-9	12968-12971	for	_
70-10	12972-12976	were	_
70-11	12977-12983	nearly	_
70-12	12984-12993	identical	_
70-13	12994-12995	(	_
70-14	12995-12998	all	_
70-15	12999-13011	correlations	_
70-16	13012-13019	greater	_
70-17	13020-13024	than	_
70-18	13025-13026	r	_
70-19	13027-13028	=	_
70-20	13029-13033	.975	_
70-21	13033-13034	)	_
70-22	13034-13035	,	_
70-23	13036-13038	so	_
70-24	13039-13042	the	_
70-25	13043-13047	same	_
70-26	13048-13057	procedure	_
70-27	13058-13061	was	_
70-28	13062-13070	repeated	_
70-29	13071-13073	on	_
70-30	13074-13075	a	_
70-31	13076-13082	single	_
70-32	13083-13088	grand	_
70-33	13089-13096	average	_
70-34	13097-13101	time	_
70-35	13102-13108	course	_
70-36	13108-13109	,	_
70-37	13110-13119	resulting	_
70-38	13120-13122	in	_
70-39	13123-13124	a	_
70-40	13125-13134	component	_
70-41	13135-13145	accounting	_
70-42	13146-13149	for	_
70-43	13150-13155	48.6%	_
70-44	13156-13158	of	_
70-45	13159-13167	variance	_
70-46	13168-13169	(	_
70-47	13169-13172	see	_
70-48	13173-13185	Supplemental	_
70-49	13186-13192	Figure	_
70-50	13193-13194	2	_
70-51	13194-13195	)	_
70-52	13195-13196	.	_

#Text=Component weights were multiplied by each subject’s data, summed across sensors, and divided by the absolute square sum of the component weights, reducing STP waveforms from 64 (one for each sensor) to 1 for each participant.
71-1	13197-13206	Component	_
71-2	13207-13214	weights	_
71-3	13215-13219	were	_
71-4	13220-13230	multiplied	_
71-5	13231-13233	by	_
71-6	13234-13238	each	_
71-7	13239-13246	subject	_
71-8	13246-13247	’	_
71-9	13247-13248	s	_
71-10	13249-13253	data	_
71-11	13253-13254	,	_
71-12	13255-13261	summed	_
71-13	13262-13268	across	_
71-14	13269-13276	sensors	_
71-15	13276-13277	,	_
71-16	13278-13281	and	_
71-17	13282-13289	divided	_
71-18	13290-13292	by	_
71-19	13293-13296	the	_
71-20	13297-13305	absolute	_
71-21	13306-13312	square	_
71-22	13313-13316	sum	_
71-23	13317-13319	of	_
71-24	13320-13323	the	_
71-25	13324-13333	component	_
71-26	13334-13341	weights	_
71-27	13341-13342	,	_
71-28	13343-13351	reducing	_
71-29	13352-13355	STP	_
71-30	13356-13365	waveforms	_
71-31	13366-13370	from	_
71-32	13371-13373	64	_
71-33	13374-13375	(	_
71-34	13375-13378	one	_
71-35	13379-13382	for	_
71-36	13383-13387	each	_
71-37	13388-13394	sensor	_
71-38	13394-13395	)	_
71-39	13396-13398	to	_
71-40	13399-13400	1	_
71-41	13401-13404	for	_
71-42	13405-13409	each	_
71-43	13410-13421	participant	_
71-44	13421-13422	.	_

#Text=STP averaged over the entire 5500ms time course provided a measure of intrinsic activity and were subjected to a 2-way ANOVA (Group × Saccade Type) with post hoc Tukey honestly significant difference tests.
72-1	13423-13426	STP	_
72-2	13427-13435	averaged	_
72-3	13436-13440	over	_
72-4	13441-13444	the	_
72-5	13445-13451	entire	_
72-6	13452-13458	5500ms	_
72-7	13459-13463	time	_
72-8	13464-13470	course	_
72-9	13471-13479	provided	_
72-10	13480-13481	a	_
72-11	13482-13489	measure	_
72-12	13490-13492	of	_
72-13	13493-13502	intrinsic	_
72-14	13503-13511	activity	_
72-15	13512-13515	and	_
72-16	13516-13520	were	_
72-17	13521-13530	subjected	_
72-18	13531-13533	to	_
72-19	13534-13535	a	_
72-20	13536-13537	2	_
72-21	13537-13538	-	_
72-22	13538-13541	way	_
72-23	13542-13547	ANOVA	_
72-24	13548-13549	(	_
72-25	13549-13554	Group	_
72-26	13555-13556	×	_
72-27	13557-13564	Saccade	_
72-28	13565-13569	Type	_
72-29	13569-13570	)	_
72-30	13571-13575	with	_
72-31	13576-13580	post	_
72-32	13581-13584	hoc	_
72-33	13585-13590	Tukey	_
72-34	13591-13599	honestly	_
72-35	13600-13611	significant	_
72-36	13612-13622	difference	_
72-37	13623-13628	tests	_
72-38	13628-13629	.	_

#Text=Averaged values for each of the five 1sec Preparatory Period countdowns were baseline-subtracted and analyzed using a mixed effects 3-way MANOVAs (Group × Saccade Type × Time Bin) with post hoc Tukey honestly significant difference tests.
73-1	13630-13638	Averaged	_
73-2	13639-13645	values	_
73-3	13646-13649	for	_
73-4	13650-13654	each	_
73-5	13655-13657	of	_
73-6	13658-13661	the	_
73-7	13662-13666	five	_
73-8	13667-13671	1sec	_
73-9	13672-13683	Preparatory	_
73-10	13684-13690	Period	_
73-11	13691-13701	countdowns	_
73-12	13702-13706	were	_
73-13	13707-13726	baseline-subtracted	_
73-14	13727-13730	and	_
73-15	13731-13739	analyzed	_
73-16	13740-13745	using	_
73-17	13746-13747	a	_
73-18	13748-13753	mixed	_
73-19	13754-13761	effects	_
73-20	13762-13763	3	_
73-21	13763-13764	-	_
73-22	13764-13767	way	_
73-23	13768-13775	MANOVAs	_
73-24	13776-13777	(	_
73-25	13777-13782	Group	_
73-26	13783-13784	×	_
73-27	13785-13792	Saccade	_
73-28	13793-13797	Type	_
73-29	13798-13799	×	_
73-30	13800-13804	Time	_
73-31	13805-13808	Bin	_
73-32	13808-13809	)	_
73-33	13810-13814	with	_
73-34	13815-13819	post	_
73-35	13820-13823	hoc	_
73-36	13824-13829	Tukey	_
73-37	13830-13838	honestly	_
73-38	13839-13850	significant	_
73-39	13851-13861	difference	_
73-40	13862-13867	tests	_
73-41	13867-13868	.	_

#Text=Induced power was also examined as an alternative measure of intrinsic neural activity, with results similar to those of STP (see Supplemental Materials).
#Text=3.
74-1	13869-13876	Induced	_
74-2	13877-13882	power	_
74-3	13883-13886	was	_
74-4	13887-13891	also	_
74-5	13892-13900	examined	_
74-6	13901-13903	as	_
74-7	13904-13906	an	_
74-8	13907-13918	alternative	_
74-9	13919-13926	measure	_
74-10	13927-13929	of	_
74-11	13930-13939	intrinsic	_
74-12	13940-13946	neural	_
74-13	13947-13955	activity	_
74-14	13955-13956	,	_
74-15	13957-13961	with	_
74-16	13962-13969	results	_
74-17	13970-13977	similar	_
74-18	13978-13980	to	_
74-19	13981-13986	those	_
74-20	13987-13989	of	_
74-21	13990-13993	STP	_
74-22	13994-13995	(	_
74-23	13995-13998	see	_
74-24	13999-14011	Supplemental	_
74-25	14012-14021	Materials	_
74-26	14021-14022	)	_
74-27	14022-14023	.	_
74-28	14024-14025	3	_
74-29	14025-14026	.	_

#Text=Results
#Text=3.1.
75-1	14027-14034	Results	_
75-2	14035-14038	3.1	_
75-3	14038-14039	.	_

#Text=Behavioral Data
#Text=As expected, correct antisaccades had longer latencies than correct prosaccades, F(1,151)=134.93, p=1.09E-22 (Table 1), which is thought to represent additional computational requirements for task performance.
76-1	14040-14050	Behavioral	_
76-2	14051-14055	Data	_
76-3	14056-14058	As	_
76-4	14059-14067	expected	_
76-5	14067-14068	,	_
76-6	14069-14076	correct	_
76-7	14077-14089	antisaccades	_
76-8	14090-14093	had	_
76-9	14094-14100	longer	_
76-10	14101-14110	latencies	_
76-11	14111-14115	than	_
76-12	14116-14123	correct	_
76-13	14124-14135	prosaccades	_
76-14	14135-14136	,	_
76-15	14137-14138	F	_
76-16	14138-14139	(	_
76-17	14139-14144	1,151	_
76-18	14144-14145	)	_
76-19	14145-14146	=	_
76-20	14146-14152	134.93	_
76-21	14152-14153	,	_
76-22	14154-14155	p	_
76-23	14155-14156	=	_
76-24	14156-14161	1.09E	_
76-25	14161-14162	-	_
76-26	14162-14164	22	_
76-27	14165-14166	(	_
76-28	14166-14171	Table	_
76-29	14172-14173	1	_
76-30	14173-14174	)	_
76-31	14174-14175	,	_
76-32	14176-14181	which	_
76-33	14182-14184	is	_
76-34	14185-14192	thought	_
76-35	14193-14195	to	_
76-36	14196-14205	represent	_
76-37	14206-14216	additional	_
76-38	14217-14230	computational	_
76-39	14231-14243	requirements	_
76-40	14244-14247	for	_
76-41	14248-14252	task	_
76-42	14253-14264	performance	_
76-43	14264-14265	.	_

#Text=A Group × Task interaction for latency of correct responses, F(3,151)=2.88, p=.04, was driven by HC showing faster antisaccade responses than Biotype-1.
77-1	14266-14267	A	_
77-2	14268-14273	Group	_
77-3	14274-14275	×	_
77-4	14276-14280	Task	_
77-5	14281-14292	interaction	_
77-6	14293-14296	for	_
77-7	14297-14304	latency	_
77-8	14305-14307	of	_
77-9	14308-14315	correct	_
77-10	14316-14325	responses	_
77-11	14325-14326	,	_
77-12	14327-14328	F	_
77-13	14328-14329	(	_
77-14	14329-14334	3,151	_
77-15	14334-14335	)	_
77-16	14335-14336	=	_
77-17	14336-14340	2.88	_
77-18	14340-14341	,	_
77-19	14342-14343	p	_
77-20	14343-14344	=	_
77-21	14344-14347	.04	_
77-22	14347-14348	,	_
77-23	14349-14352	was	_
77-24	14353-14359	driven	_
77-25	14360-14362	by	_
77-26	14363-14365	HC	_
77-27	14366-14373	showing	_
77-28	14374-14380	faster	_
77-29	14381-14392	antisaccade	_
77-30	14393-14402	responses	_
77-31	14403-14407	than	_
77-32	14408-14415	Biotype	_
77-33	14415-14416	-	_
77-34	14416-14417	1	_
77-35	14417-14418	.	_

#Text=Error rate was greater for anti- than pro-saccades, F(1,151)=154.57, p=7.0E-25.
78-1	14419-14424	Error	_
78-2	14425-14429	rate	_
78-3	14430-14433	was	_
78-4	14434-14441	greater	_
78-5	14442-14445	for	_
78-6	14446-14450	anti	_
78-7	14450-14451	-	_
78-8	14452-14456	than	_
78-9	14457-14469	pro-saccades	_
78-10	14469-14470	,	_
78-11	14471-14472	F	_
78-12	14472-14473	(	_
78-13	14473-14478	1,151	_
78-14	14478-14479	)	_
78-15	14479-14480	=	_
78-16	14480-14486	154.57	_
78-17	14486-14487	,	_
78-18	14488-14489	p	_
78-19	14489-14490	=	_
78-20	14490-14494	7.0E	_
78-21	14494-14495	-	_
78-22	14495-14497	25	_
78-23	14497-14498	.	_

#Text=Group differences, F(3,151)=9.78, p=.000006, and Group × Task interactions, F(3,151)=5.89, p=.001, were driven by HC making fewer antisaccade errors than all psychosis groups, as well as Biotype-1making more antisaccade errors than all other groups.
79-1	14499-14504	Group	_
79-2	14505-14516	differences	_
79-3	14516-14517	,	_
79-4	14518-14519	F	_
79-5	14519-14520	(	_
79-6	14520-14525	3,151	_
79-7	14525-14526	)	_
79-8	14526-14527	=	_
79-9	14527-14531	9.78	_
79-10	14531-14532	,	_
79-11	14533-14534	p	_
79-12	14534-14535	=	_
79-13	14535-14542	.000006	_
79-14	14542-14543	,	_
79-15	14544-14547	and	_
79-16	14548-14553	Group	_
79-17	14554-14555	×	_
79-18	14556-14560	Task	_
79-19	14561-14573	interactions	_
79-20	14573-14574	,	_
79-21	14575-14576	F	_
79-22	14576-14577	(	_
79-23	14577-14582	3,151	_
79-24	14582-14583	)	_
79-25	14583-14584	=	_
79-26	14584-14588	5.89	_
79-27	14588-14589	,	_
79-28	14590-14591	p	_
79-29	14591-14592	=	_
79-30	14592-14596	.001	_
79-31	14596-14597	,	_
79-32	14598-14602	were	_
79-33	14603-14609	driven	_
79-34	14610-14612	by	_
79-35	14613-14615	HC	_
79-36	14616-14622	making	_
79-37	14623-14628	fewer	_
79-38	14629-14640	antisaccade	_
79-39	14641-14647	errors	_
79-40	14648-14652	than	_
79-41	14653-14656	all	_
79-42	14657-14666	psychosis	_
79-43	14667-14673	groups	_
79-44	14673-14674	,	_
79-45	14675-14677	as	_
79-46	14678-14682	well	_
79-47	14683-14685	as	_
79-48	14686-14693	Biotype	_
79-49	14693-14694	-	_
79-50	14694-14701	1making	_
79-51	14702-14706	more	_
79-52	14707-14718	antisaccade	_
79-53	14719-14725	errors	_
79-54	14726-14730	than	_
79-55	14731-14734	all	_
79-56	14735-14740	other	_
79-57	14741-14747	groups	_
79-58	14747-14748	.	_

#Text=This is consistent with the findings of using a different antisaccade testing paradigm, which found Biotype-1 to be most prototypical of the chronic, poor-outcome cases often considered to capture the essence of schizophrenia.
#Text=3.2.
80-1	14749-14753	This	_
80-2	14754-14756	is	_
80-3	14757-14767	consistent	_
80-4	14768-14772	with	_
80-5	14773-14776	the	_
80-6	14777-14785	findings	_
80-7	14786-14788	of	_
80-8	14789-14794	using	_
80-9	14795-14796	a	_
80-10	14797-14806	different	_
80-11	14807-14818	antisaccade	_
80-12	14819-14826	testing	_
80-13	14827-14835	paradigm	_
80-14	14835-14836	,	_
80-15	14837-14842	which	_
80-16	14843-14848	found	_
80-17	14849-14856	Biotype	_
80-18	14856-14857	-	_
80-19	14857-14858	1	_
80-20	14859-14861	to	_
80-21	14862-14864	be	_
80-22	14865-14869	most	_
80-23	14870-14882	prototypical	_
80-24	14883-14885	of	_
80-25	14886-14889	the	_
80-26	14890-14897	chronic	_
80-27	14897-14898	,	_
80-28	14899-14911	poor-outcome	_
80-29	14912-14917	cases	_
80-30	14918-14923	often	_
80-31	14924-14934	considered	_
80-32	14935-14937	to	_
80-33	14938-14945	capture	_
80-34	14946-14949	the	_
80-35	14950-14957	essence	_
80-36	14958-14960	of	_
80-37	14961-14974	schizophrenia	_
80-38	14974-14975	.	_
80-39	14976-14979	3.2	_
80-40	14979-14980	.	_

#Text=Evoked Potentials to Checkerboard Onset
#Text=At the onset of the checkerboard stimuli, there were four clearly identifiable peaks in global field power (GFP) prior to the onset of the vSSR (Figure 2).
81-1	14981-14987	Evoked	_
81-2	14988-14998	Potentials	_
81-3	14999-15001	to	_
81-4	15002-15014	Checkerboard	_
81-5	15015-15020	Onset	_
81-6	15021-15023	At	_
81-7	15024-15027	the	_
81-8	15028-15033	onset	_
81-9	15034-15036	of	_
81-10	15037-15040	the	_
81-11	15041-15053	checkerboard	_
81-12	15054-15061	stimuli	_
81-13	15061-15062	,	_
81-14	15063-15068	there	_
81-15	15069-15073	were	_
81-16	15074-15078	four	_
81-17	15079-15086	clearly	_
81-18	15087-15099	identifiable	_
81-19	15100-15105	peaks	_
81-20	15106-15108	in	_
81-21	15109-15115	global	_
81-22	15116-15121	field	_
81-23	15122-15127	power	_
81-24	15128-15129	(	_
81-25	15129-15132	GFP	_
81-26	15132-15133	)	_
81-27	15134-15139	prior	_
81-28	15140-15142	to	_
81-29	15143-15146	the	_
81-30	15147-15152	onset	_
81-31	15153-15155	of	_
81-32	15156-15159	the	_
81-33	15160-15164	vSSR	_
81-34	15165-15166	(	_
81-35	15166-15172	Figure	_
81-36	15173-15174	2	_
81-37	15174-15175	)	_
81-38	15175-15176	.	_

#Text=The latencies of these peaks (135ms, 175ms, 245ms, and 320ms) are consistent with studies using similar stimuli.
82-1	15177-15180	The	_
82-2	15181-15190	latencies	_
82-3	15191-15193	of	_
82-4	15194-15199	these	_
82-5	15200-15205	peaks	_
82-6	15206-15207	(	_
82-7	15207-15212	135ms	_
82-8	15212-15213	,	_
82-9	15214-15219	175ms	_
82-10	15219-15220	,	_
82-11	15221-15226	245ms	_
82-12	15226-15227	,	_
82-13	15228-15231	and	_
82-14	15232-15237	320ms	_
82-15	15237-15238	)	_
82-16	15239-15242	are	_
82-17	15243-15253	consistent	_
82-18	15254-15258	with	_
82-19	15259-15266	studies	_
82-20	15267-15272	using	_
82-21	15273-15280	similar	_
82-22	15281-15288	stimuli	_
82-23	15288-15289	.	_

#Text=Group differences in GFP were found from 150–450ms, F(3,151)=4.08, p=.014 (Figure 2A), with Biotype-2 showing greater GFP than all other groups.
83-1	15290-15295	Group	_
83-2	15296-15307	differences	_
83-3	15308-15310	in	_
83-4	15311-15314	GFP	_
83-5	15315-15319	were	_
83-6	15320-15325	found	_
83-7	15326-15330	from	_
83-8	15331-15334	150	_
83-9	15334-15335	–	_
83-10	15335-15340	450ms	_
83-11	15340-15341	,	_
83-12	15342-15343	F	_
83-13	15343-15344	(	_
83-14	15344-15349	3,151	_
83-15	15349-15350	)	_
83-16	15350-15351	=	_
83-17	15351-15355	4.08	_
83-18	15355-15356	,	_
83-19	15357-15358	p	_
83-20	15358-15359	=	_
83-21	15359-15363	.014	_
83-22	15364-15365	(	_
83-23	15365-15371	Figure	_
83-24	15372-15374	2A	_
83-25	15374-15375	)	_
83-26	15375-15376	,	_
83-27	15377-15381	with	_
83-28	15382-15389	Biotype	_
83-29	15389-15390	-	_
83-30	15390-15391	2	_
83-31	15392-15399	showing	_
83-32	15400-15407	greater	_
83-33	15408-15411	GFP	_
83-34	15412-15416	than	_
83-35	15417-15420	all	_
83-36	15421-15426	other	_
83-37	15427-15433	groups	_
83-38	15433-15434	.	_

#Text=From 150–330ms, GFP was lower in Biotype-1 than all other groups.
84-1	15435-15439	From	_
84-2	15440-15443	150	_
84-3	15443-15444	–	_
84-4	15444-15449	330ms	_
84-5	15449-15450	,	_
84-6	15451-15454	GFP	_
84-7	15455-15458	was	_
84-8	15459-15464	lower	_
84-9	15465-15467	in	_
84-10	15468-15475	Biotype	_
84-11	15475-15476	-	_
84-12	15476-15477	1	_
84-13	15478-15482	than	_
84-14	15483-15486	all	_
84-15	15487-15492	other	_
84-16	15493-15499	groups	_
84-17	15499-15500	.	_

#Text=A Group × Task interaction effect was found at 400–430ms, F(3,151)=3.88, p=.011, which was driven by Biotype-2 showing greater GFP during pro- than anti-saccade trials (Figure 2B).
85-1	15501-15502	A	_
85-2	15503-15508	Group	_
85-3	15509-15510	×	_
85-4	15511-15515	Task	_
85-5	15516-15527	interaction	_
85-6	15528-15534	effect	_
85-7	15535-15538	was	_
85-8	15539-15544	found	_
85-9	15545-15547	at	_
85-10	15548-15551	400	_
85-11	15551-15552	–	_
85-12	15552-15557	430ms	_
85-13	15557-15558	,	_
85-14	15559-15560	F	_
85-15	15560-15561	(	_
85-16	15561-15566	3,151	_
85-17	15566-15567	)	_
85-18	15567-15568	=	_
85-19	15568-15572	3.88	_
85-20	15572-15573	,	_
85-21	15574-15575	p	_
85-22	15575-15576	=	_
85-23	15576-15580	.011	_
85-24	15580-15581	,	_
85-25	15582-15587	which	_
85-26	15588-15591	was	_
85-27	15592-15598	driven	_
85-28	15599-15601	by	_
85-29	15602-15609	Biotype	_
85-30	15609-15610	-	_
85-31	15610-15611	2	_
85-32	15612-15619	showing	_
85-33	15620-15627	greater	_
85-34	15628-15631	GFP	_
85-35	15632-15638	during	_
85-36	15639-15642	pro	_
85-37	15642-15643	-	_
85-38	15644-15648	than	_
85-39	15649-15661	anti-saccade	_
85-40	15662-15668	trials	_
85-41	15669-15670	(	_
85-42	15670-15676	Figure	_
85-43	15677-15679	2B	_
85-44	15679-15680	)	_
85-45	15680-15681	.	_

#Text=These opposing deviations in visuocortical responsiveness (hypoactivity in Biotype-1 and hyperactivity in Biotype-2) are consistent with results from auditory tasks.
#Text=3.3.
86-1	15682-15687	These	_
86-2	15688-15696	opposing	_
86-3	15697-15707	deviations	_
86-4	15708-15710	in	_
86-5	15711-15724	visuocortical	_
86-6	15725-15739	responsiveness	_
86-7	15740-15741	(	_
86-8	15741-15753	hypoactivity	_
86-9	15754-15756	in	_
86-10	15757-15764	Biotype	_
86-11	15764-15765	-	_
86-12	15765-15766	1	_
86-13	15767-15770	and	_
86-14	15771-15784	hyperactivity	_
86-15	15785-15787	in	_
86-16	15788-15795	Biotype	_
86-17	15795-15796	-	_
86-18	15796-15797	2	_
86-19	15797-15798	)	_
86-20	15799-15802	are	_
86-21	15803-15813	consistent	_
86-22	15814-15818	with	_
86-23	15819-15826	results	_
86-24	15827-15831	from	_
86-25	15832-15840	auditory	_
86-26	15841-15846	tasks	_
86-27	15846-15847	.	_
86-28	15848-15851	3.3	_
86-29	15851-15852	.	_

#Text=Single-Trial Oscillatory Power
#Text=Intrinsic neural activity (STP averaged from −500ms to 5000ms in relation to onset of the Preparatory Period) showed a main effect of Task, F(1,151)=5.07, p=.026, being greater during anti- than pro-saccade blocks (Figure 3).
87-1	15853-15865	Single-Trial	_
87-2	15866-15877	Oscillatory	_
87-3	15878-15883	Power	_
87-4	15884-15893	Intrinsic	_
87-5	15894-15900	neural	_
87-6	15901-15909	activity	_
87-7	15910-15911	(	_
87-8	15911-15914	STP	_
87-9	15915-15923	averaged	_
87-10	15924-15928	from	_
87-11	15929-15930	−	_
87-12	15930-15935	500ms	_
87-13	15936-15938	to	_
87-14	15939-15945	5000ms	_
87-15	15946-15948	in	_
87-16	15949-15957	relation	_
87-17	15958-15960	to	_
87-18	15961-15966	onset	_
87-19	15967-15969	of	_
87-20	15970-15973	the	_
87-21	15974-15985	Preparatory	_
87-22	15986-15992	Period	_
87-23	15992-15993	)	_
87-24	15994-16000	showed	_
87-25	16001-16002	a	_
87-26	16003-16007	main	_
87-27	16008-16014	effect	_
87-28	16015-16017	of	_
87-29	16018-16022	Task	_
87-30	16022-16023	,	_
87-31	16024-16025	F	_
87-32	16025-16026	(	_
87-33	16026-16031	1,151	_
87-34	16031-16032	)	_
87-35	16032-16033	=	_
87-36	16033-16037	5.07	_
87-37	16037-16038	,	_
87-38	16039-16040	p	_
87-39	16040-16041	=	_
87-40	16041-16045	.026	_
87-41	16045-16046	,	_
87-42	16047-16052	being	_
87-43	16053-16060	greater	_
87-44	16061-16067	during	_
87-45	16068-16072	anti	_
87-46	16072-16073	-	_
87-47	16074-16078	than	_
87-48	16079-16090	pro-saccade	_
87-49	16091-16097	blocks	_
87-50	16098-16099	(	_
87-51	16099-16105	Figure	_
87-52	16106-16107	3	_
87-53	16107-16108	)	_
87-54	16108-16109	.	_

#Text=This presumably reflects changed activity levels in the basic saccade circuitry and/or activity in newly recruited neural regions.
88-1	16110-16114	This	_
88-2	16115-16125	presumably	_
88-3	16126-16134	reflects	_
88-4	16135-16142	changed	_
88-5	16143-16151	activity	_
88-6	16152-16158	levels	_
88-7	16159-16161	in	_
88-8	16162-16165	the	_
88-9	16166-16171	basic	_
88-10	16172-16179	saccade	_
88-11	16180-16189	circuitry	_
88-12	16190-16193	and	_
88-13	16193-16194	/	_
88-14	16194-16196	or	_
88-15	16197-16205	activity	_
88-16	16206-16208	in	_
88-17	16209-16214	newly	_
88-18	16215-16224	recruited	_
88-19	16225-16231	neural	_
88-20	16232-16239	regions	_
88-21	16239-16240	.	_

#Text=There was a main effect of Group, F(3,151)=3.94, p=.01, with Biotype-2 greater than all other groups, as proposed by.
89-1	16241-16246	There	_
89-2	16247-16250	was	_
89-3	16251-16252	a	_
89-4	16253-16257	main	_
89-5	16258-16264	effect	_
89-6	16265-16267	of	_
89-7	16268-16273	Group	_
89-8	16273-16274	,	_
89-9	16275-16276	F	_
89-10	16276-16277	(	_
89-11	16277-16282	3,151	_
89-12	16282-16283	)	_
89-13	16283-16284	=	_
89-14	16284-16288	3.94	_
89-15	16288-16289	,	_
89-16	16290-16291	p	_
89-17	16291-16292	=	_
89-18	16292-16295	.01	_
89-19	16295-16296	,	_
89-20	16297-16301	with	_
89-21	16302-16309	Biotype	_
89-22	16309-16310	-	_
89-23	16310-16311	2	_
89-24	16312-16319	greater	_
89-25	16320-16324	than	_
89-26	16325-16328	all	_
89-27	16329-16334	other	_
89-28	16335-16341	groups	_
89-29	16341-16342	,	_
89-30	16343-16345	as	_
89-31	16346-16354	proposed	_
89-32	16355-16357	by	_
89-33	16357-16358	.	_

#Text=There was also a Group × Task interaction, F(3,151)=3.12, p=.028, driven by only HC and Biotype-1 showing greater intrinsic activity during anti- than pro-saccade blocks.
90-1	16359-16364	There	_
90-2	16365-16368	was	_
90-3	16369-16373	also	_
90-4	16374-16375	a	_
90-5	16376-16381	Group	_
90-6	16382-16383	×	_
90-7	16384-16388	Task	_
90-8	16389-16400	interaction	_
90-9	16400-16401	,	_
90-10	16402-16403	F	_
90-11	16403-16404	(	_
90-12	16404-16409	3,151	_
90-13	16409-16410	)	_
90-14	16410-16411	=	_
90-15	16411-16415	3.12	_
90-16	16415-16416	,	_
90-17	16417-16418	p	_
90-18	16418-16419	=	_
90-19	16419-16423	.028	_
90-20	16423-16424	,	_
90-21	16425-16431	driven	_
90-22	16432-16434	by	_
90-23	16435-16439	only	_
90-24	16440-16442	HC	_
90-25	16443-16446	and	_
90-26	16447-16454	Biotype	_
90-27	16454-16455	-	_
90-28	16455-16456	1	_
90-29	16457-16464	showing	_
90-30	16465-16472	greater	_
90-31	16473-16482	intrinsic	_
90-32	16483-16491	activity	_
90-33	16492-16498	during	_
90-34	16499-16503	anti	_
90-35	16503-16504	-	_
90-36	16505-16509	than	_
90-37	16510-16521	pro-saccade	_
90-38	16522-16528	blocks	_
90-39	16528-16529	.	_

#Text=Stimulus-specific (i.e., baseline-subtracted) power showed a main effect of Task, F(1,151)=8.06, p=.005, with greater desynchronization observed during anti- than pro-saccade trials.
91-1	16530-16547	Stimulus-specific	_
91-2	16548-16549	(	_
91-3	16549-16552	i.e	_
91-4	16552-16553	.	_
91-5	16553-16554	,	_
91-6	16555-16574	baseline-subtracted	_
91-7	16574-16575	)	_
91-8	16576-16581	power	_
91-9	16582-16588	showed	_
91-10	16589-16590	a	_
91-11	16591-16595	main	_
91-12	16596-16602	effect	_
91-13	16603-16605	of	_
91-14	16606-16610	Task	_
91-15	16610-16611	,	_
91-16	16612-16613	F	_
91-17	16613-16614	(	_
91-18	16614-16619	1,151	_
91-19	16619-16620	)	_
91-20	16620-16621	=	_
91-21	16621-16625	8.06	_
91-22	16625-16626	,	_
91-23	16627-16628	p	_
91-24	16628-16629	=	_
91-25	16629-16633	.005	_
91-26	16633-16634	,	_
91-27	16635-16639	with	_
91-28	16640-16647	greater	_
91-29	16648-16665	desynchronization	_
91-30	16666-16674	observed	_
91-31	16675-16681	during	_
91-32	16682-16686	anti	_
91-33	16686-16687	-	_
91-34	16688-16692	than	_
91-35	16693-16704	pro-saccade	_
91-36	16705-16711	trials	_
91-37	16711-16712	.	_

#Text=This effect is expected based on nonhuman primate neurophysiology studies indicating that inhibition of reflexive saccades during antisaccade tasks requires suppression of visuocortical investment to peripheral locations.
92-1	16713-16717	This	_
92-2	16718-16724	effect	_
92-3	16725-16727	is	_
92-4	16728-16736	expected	_
92-5	16737-16742	based	_
92-6	16743-16745	on	_
92-7	16746-16754	nonhuman	_
92-8	16755-16762	primate	_
92-9	16763-16778	neurophysiology	_
92-10	16779-16786	studies	_
92-11	16787-16797	indicating	_
92-12	16798-16802	that	_
92-13	16803-16813	inhibition	_
92-14	16814-16816	of	_
92-15	16817-16826	reflexive	_
92-16	16827-16835	saccades	_
92-17	16836-16842	during	_
92-18	16843-16854	antisaccade	_
92-19	16855-16860	tasks	_
92-20	16861-16869	requires	_
92-21	16870-16881	suppression	_
92-22	16882-16884	of	_
92-23	16885-16898	visuocortical	_
92-24	16899-16909	investment	_
92-25	16910-16912	to	_
92-26	16913-16923	peripheral	_
92-27	16924-16933	locations	_
92-28	16933-16934	.	_

#Text=There was also a main effect of Time, F(4,148)=34.76, p=3.9E–26, with desynchronization increasing over time, suggesting that some decrease in peripheral investment may be important for both tasks, at least given the current stimulus paradigm.
93-1	16935-16940	There	_
93-2	16941-16944	was	_
93-3	16945-16949	also	_
93-4	16950-16951	a	_
93-5	16952-16956	main	_
93-6	16957-16963	effect	_
93-7	16964-16966	of	_
93-8	16967-16971	Time	_
93-9	16971-16972	,	_
93-10	16973-16974	F	_
93-11	16974-16975	(	_
93-12	16975-16980	4,148	_
93-13	16980-16981	)	_
93-14	16981-16982	=	_
93-15	16982-16987	34.76	_
93-16	16987-16988	,	_
93-17	16989-16990	p	_
93-18	16990-16991	=	_
93-19	16991-16995	3.9E	_
93-20	16995-16996	–	_
93-21	16996-16998	26	_
93-22	16998-16999	,	_
93-23	17000-17004	with	_
93-24	17005-17022	desynchronization	_
93-25	17023-17033	increasing	_
93-26	17034-17038	over	_
93-27	17039-17043	time	_
93-28	17043-17044	,	_
93-29	17045-17055	suggesting	_
93-30	17056-17060	that	_
93-31	17061-17065	some	_
93-32	17066-17074	decrease	_
93-33	17075-17077	in	_
93-34	17078-17088	peripheral	_
93-35	17089-17099	investment	_
93-36	17100-17103	may	_
93-37	17104-17106	be	_
93-38	17107-17116	important	_
93-39	17117-17120	for	_
93-40	17121-17125	both	_
93-41	17126-17131	tasks	_
93-42	17131-17132	,	_
93-43	17133-17135	at	_
93-44	17136-17141	least	_
93-45	17142-17147	given	_
93-46	17148-17151	the	_
93-47	17152-17159	current	_
93-48	17160-17168	stimulus	_
93-49	17169-17177	paradigm	_
93-50	17177-17178	.	_

#Text=Both of these effects are consistent with previous findings using a similar task in healthy individuals.
#Text=3.4.
94-1	17179-17183	Both	_
94-2	17184-17186	of	_
94-3	17187-17192	these	_
94-4	17193-17200	effects	_
94-5	17201-17204	are	_
94-6	17205-17215	consistent	_
94-7	17216-17220	with	_
94-8	17221-17229	previous	_
94-9	17230-17238	findings	_
94-10	17239-17244	using	_
94-11	17245-17246	a	_
94-12	17247-17254	similar	_
94-13	17255-17259	task	_
94-14	17260-17262	in	_
94-15	17263-17270	healthy	_
94-16	17271-17282	individuals	_
94-17	17282-17283	.	_
94-18	17284-17287	3.4	_
94-19	17287-17288	.	_

#Text=Inter-Trial Phase Coherence
#Text=ITC showed a main effect of Time, F(5,148)=72.31, p=7.3E-62, with all time bins increased over baseline (Figure 4), and a Task × Time interaction, F(5,148)=2.35, p=.04, with greater ITC for anti- than pro-saccades at stimulus onset but the reverse effect later during the Preparatory Period.
95-1	17289-17300	Inter-Trial	_
95-2	17301-17306	Phase	_
95-3	17307-17316	Coherence	_
95-4	17317-17320	ITC	_
95-5	17321-17327	showed	_
95-6	17328-17329	a	_
95-7	17330-17334	main	_
95-8	17335-17341	effect	_
95-9	17342-17344	of	_
95-10	17345-17349	Time	_
95-11	17349-17350	,	_
95-12	17351-17352	F	_
95-13	17352-17353	(	_
95-14	17353-17358	5,148	_
95-15	17358-17359	)	_
95-16	17359-17360	=	_
95-17	17360-17365	72.31	_
95-18	17365-17366	,	_
95-19	17367-17368	p	_
95-20	17368-17369	=	_
95-21	17369-17373	7.3E	_
95-22	17373-17374	-	_
95-23	17374-17376	62	_
95-24	17376-17377	,	_
95-25	17378-17382	with	_
95-26	17383-17386	all	_
95-27	17387-17391	time	_
95-28	17392-17396	bins	_
95-29	17397-17406	increased	_
95-30	17407-17411	over	_
95-31	17412-17420	baseline	_
95-32	17421-17422	(	_
95-33	17422-17428	Figure	_
95-34	17429-17430	4	_
95-35	17430-17431	)	_
95-36	17431-17432	,	_
95-37	17433-17436	and	_
95-38	17437-17438	a	_
95-39	17439-17443	Task	_
95-40	17444-17445	×	_
95-41	17446-17450	Time	_
95-42	17451-17462	interaction	_
95-43	17462-17463	,	_
95-44	17464-17465	F	_
95-45	17465-17466	(	_
95-46	17466-17471	5,148	_
95-47	17471-17472	)	_
95-48	17472-17473	=	_
95-49	17473-17477	2.35	_
95-50	17477-17478	,	_
95-51	17479-17480	p	_
95-52	17480-17481	=	_
95-53	17481-17484	.04	_
95-54	17484-17485	,	_
95-55	17486-17490	with	_
95-56	17491-17498	greater	_
95-57	17499-17502	ITC	_
95-58	17503-17506	for	_
95-59	17507-17511	anti	_
95-60	17511-17512	-	_
95-61	17513-17517	than	_
95-62	17518-17530	pro-saccades	_
95-63	17531-17533	at	_
95-64	17534-17542	stimulus	_
95-65	17543-17548	onset	_
95-66	17549-17552	but	_
95-67	17553-17556	the	_
95-68	17557-17564	reverse	_
95-69	17565-17571	effect	_
95-70	17572-17577	later	_
95-71	17578-17584	during	_
95-72	17585-17588	the	_
95-73	17589-17600	Preparatory	_
95-74	17601-17607	Period	_
95-75	17607-17608	.	_

#Text=This is consistent with and is expected, as the greater complexity of anti- versus pro-saccade tasks can yield greater initial involvement of dorsal visual stream circuitry (e.g.,), which is preferentially activated by peripheral stimuli.
96-1	17609-17613	This	_
96-2	17614-17616	is	_
96-3	17617-17627	consistent	_
96-4	17628-17632	with	_
96-5	17633-17636	and	_
96-6	17637-17639	is	_
96-7	17640-17648	expected	_
96-8	17648-17649	,	_
96-9	17650-17652	as	_
96-10	17653-17656	the	_
96-11	17657-17664	greater	_
96-12	17665-17675	complexity	_
96-13	17676-17678	of	_
96-14	17679-17683	anti	_
96-15	17683-17684	-	_
96-16	17685-17691	versus	_
96-17	17692-17703	pro-saccade	_
96-18	17704-17709	tasks	_
96-19	17710-17713	can	_
96-20	17714-17719	yield	_
96-21	17720-17727	greater	_
96-22	17728-17735	initial	_
96-23	17736-17747	involvement	_
96-24	17748-17750	of	_
96-25	17751-17757	dorsal	_
96-26	17758-17764	visual	_
96-27	17765-17771	stream	_
96-28	17772-17781	circuitry	_
96-29	17782-17783	(	_
96-30	17783-17786	e.g	_
96-31	17786-17787	.	_
96-32	17787-17788	,	_
96-33	17788-17789	)	_
96-34	17789-17790	,	_
96-35	17791-17796	which	_
96-36	17797-17799	is	_
96-37	17800-17814	preferentially	_
96-38	17815-17824	activated	_
96-39	17825-17827	by	_
96-40	17828-17838	peripheral	_
96-41	17839-17846	stimuli	_
96-42	17846-17847	.	_

#Text=A Group × Time interaction, F(15,450)=1.8, p=.03, was driven by HC and Biotype-3 significantly decreasing ITC after stimulus onset, as well as Biotype-1 showing diminished ITC at stimulus onset.
97-1	17848-17849	A	_
97-2	17850-17855	Group	_
97-3	17856-17857	×	_
97-4	17858-17862	Time	_
97-5	17863-17874	interaction	_
97-6	17874-17875	,	_
97-7	17876-17877	F	_
97-8	17877-17878	(	_
97-9	17878-17884	15,450	_
97-10	17884-17885	)	_
97-11	17885-17886	=	_
97-12	17886-17889	1.8	_
97-13	17889-17890	,	_
97-14	17891-17892	p	_
97-15	17892-17893	=	_
97-16	17893-17896	.03	_
97-17	17896-17897	,	_
97-18	17898-17901	was	_
97-19	17902-17908	driven	_
97-20	17909-17911	by	_
97-21	17912-17914	HC	_
97-22	17915-17918	and	_
97-23	17919-17926	Biotype	_
97-24	17926-17927	-	_
97-25	17927-17928	3	_
97-26	17929-17942	significantly	_
97-27	17943-17953	decreasing	_
97-28	17954-17957	ITC	_
97-29	17958-17963	after	_
97-30	17964-17972	stimulus	_
97-31	17973-17978	onset	_
97-32	17978-17979	,	_
97-33	17980-17982	as	_
97-34	17983-17987	well	_
97-35	17988-17990	as	_
97-36	17991-17998	Biotype	_
97-37	17998-17999	-	_
97-38	17999-18000	1	_
97-39	18001-18008	showing	_
97-40	18009-18019	diminished	_
97-41	18020-18023	ITC	_
97-42	18024-18026	at	_
97-43	18027-18035	stimulus	_
97-44	18036-18041	onset	_
97-45	18041-18042	.	_

#Text=This neural synchronization decrease by HC and Biotype-3 may represent “gating” information flow from initially high down to levels more appropriate for successful performance.
#Text=4.
98-1	18043-18047	This	_
98-2	18048-18054	neural	_
98-3	18055-18070	synchronization	_
98-4	18071-18079	decrease	_
98-5	18080-18082	by	_
98-6	18083-18085	HC	_
98-7	18086-18089	and	_
98-8	18090-18097	Biotype	_
98-9	18097-18098	-	_
98-10	18098-18099	3	_
98-11	18100-18103	may	_
98-12	18104-18113	represent	_
98-13	18114-18115	“	_
98-14	18115-18121	gating	_
98-15	18121-18122	”	_
98-16	18123-18134	information	_
98-17	18135-18139	flow	_
98-18	18140-18144	from	_
98-19	18145-18154	initially	_
98-20	18155-18159	high	_
98-21	18160-18164	down	_
98-22	18165-18167	to	_
98-23	18168-18174	levels	_
98-24	18175-18179	more	_
98-25	18180-18191	appropriate	_
98-26	18192-18195	for	_
98-27	18196-18206	successful	_
98-28	18207-18218	performance	_
98-29	18218-18219	.	_
98-30	18220-18221	4	_
98-31	18221-18222	.	_

#Text=Discussion
#Text=Intrinsic neural activity levels differ between psychosis Biotypes, with activity being diminished in Biotype-1 and accentuated in Biotype-2.
99-1	18223-18233	Discussion	_
99-2	18234-18243	Intrinsic	_
99-3	18244-18250	neural	_
99-4	18251-18259	activity	_
99-5	18260-18266	levels	_
99-6	18267-18273	differ	_
99-7	18274-18281	between	_
99-8	18282-18291	psychosis	_
99-9	18292-18300	Biotypes	_
99-10	18300-18301	,	_
99-11	18302-18306	with	_
99-12	18307-18315	activity	_
99-13	18316-18321	being	_
99-14	18322-18332	diminished	_
99-15	18333-18335	in	_
99-16	18336-18343	Biotype	_
99-17	18343-18344	-	_
99-18	18344-18345	1	_
99-19	18346-18349	and	_
99-20	18350-18361	accentuated	_
99-21	18362-18364	in	_
99-22	18365-18372	Biotype	_
99-23	18372-18373	-	_
99-24	18373-18374	2	_
99-25	18374-18375	.	_

#Text=Despite this, examination of stimulus-specific oscillatory activity revealed no differences between groups.
100-1	18376-18383	Despite	_
100-2	18384-18388	this	_
100-3	18388-18389	,	_
100-4	18390-18401	examination	_
100-5	18402-18404	of	_
100-6	18405-18422	stimulus-specific	_
100-7	18423-18434	oscillatory	_
100-8	18435-18443	activity	_
100-9	18444-18452	revealed	_
100-10	18453-18455	no	_
100-11	18456-18467	differences	_
100-12	18468-18475	between	_
100-13	18476-18482	groups	_
100-14	18482-18483	.	_

#Text=While all groups similarly modulated stimulus-specific neural power as a function of increasing cognitive demands, only HC and Biotype-1 modulated intrinsic activity.
101-1	18484-18489	While	_
101-2	18490-18493	all	_
101-3	18494-18500	groups	_
101-4	18501-18510	similarly	_
101-5	18511-18520	modulated	_
101-6	18521-18538	stimulus-specific	_
101-7	18539-18545	neural	_
101-8	18546-18551	power	_
101-9	18552-18554	as	_
101-10	18555-18556	a	_
101-11	18557-18565	function	_
101-12	18566-18568	of	_
101-13	18569-18579	increasing	_
101-14	18580-18589	cognitive	_
101-15	18590-18597	demands	_
101-16	18597-18598	,	_
101-17	18599-18603	only	_
101-18	18604-18606	HC	_
101-19	18607-18610	and	_
101-20	18611-18618	Biotype	_
101-21	18618-18619	-	_
101-22	18619-18620	1	_
101-23	18621-18630	modulated	_
101-24	18631-18640	intrinsic	_
101-25	18641-18649	activity	_
101-26	18649-18650	.	_

#Text=This pattern of results provides key implications for the understanding of cognitive control in psychosis and for the relationship between neurobiology and behavioral outcomes.
102-1	18651-18655	This	_
102-2	18656-18663	pattern	_
102-3	18664-18666	of	_
102-4	18667-18674	results	_
102-5	18675-18683	provides	_
102-6	18684-18687	key	_
102-7	18688-18700	implications	_
102-8	18701-18704	for	_
102-9	18705-18708	the	_
102-10	18709-18722	understanding	_
102-11	18723-18725	of	_
102-12	18726-18735	cognitive	_
102-13	18736-18743	control	_
102-14	18744-18746	in	_
102-15	18747-18756	psychosis	_
102-16	18757-18760	and	_
102-17	18761-18764	for	_
102-18	18765-18768	the	_
102-19	18769-18781	relationship	_
102-20	18782-18789	between	_
102-21	18790-18802	neurobiology	_
102-22	18803-18806	and	_
102-23	18807-18817	behavioral	_
102-24	18818-18826	outcomes	_
102-25	18826-18827	.	_

#Text=Individuals with psychotic disorders are often reported as showing deviant levels of non-specific neural activity (see), correspondingly deviant sensory cortical responses, and low signal-to-noise.
103-1	18828-18839	Individuals	_
103-2	18840-18844	with	_
103-3	18845-18854	psychotic	_
103-4	18855-18864	disorders	_
103-5	18865-18868	are	_
103-6	18869-18874	often	_
103-7	18875-18883	reported	_
103-8	18884-18886	as	_
103-9	18887-18894	showing	_
103-10	18895-18902	deviant	_
103-11	18903-18909	levels	_
103-12	18910-18912	of	_
103-13	18913-18925	non-specific	_
103-14	18926-18932	neural	_
103-15	18933-18941	activity	_
103-16	18942-18943	(	_
103-17	18943-18946	see	_
103-18	18946-18947	)	_
103-19	18947-18948	,	_
103-20	18949-18964	correspondingly	_
103-21	18965-18972	deviant	_
103-22	18973-18980	sensory	_
103-23	18981-18989	cortical	_
103-24	18990-18999	responses	_
103-25	18999-19000	,	_
103-26	19001-19004	and	_
103-27	19005-19008	low	_
103-28	19009-19024	signal-to-noise	_
103-29	19024-19025	.	_

#Text=The current study found diametrically opposed abnormalities in intrinsic neural activity levels between psychosis subgroups, with Biotype-1 showing hypoactivity, Biotype-2 showing hyperactivity, and Biotype-3 the closest to HC, consistent with expectations based on.
104-1	19026-19029	The	_
104-2	19030-19037	current	_
104-3	19038-19043	study	_
104-4	19044-19049	found	_
104-5	19050-19063	diametrically	_
104-6	19064-19071	opposed	_
104-7	19072-19085	abnormalities	_
104-8	19086-19088	in	_
104-9	19089-19098	intrinsic	_
104-10	19099-19105	neural	_
104-11	19106-19114	activity	_
104-12	19115-19121	levels	_
104-13	19122-19129	between	_
104-14	19130-19139	psychosis	_
104-15	19140-19149	subgroups	_
104-16	19149-19150	,	_
104-17	19151-19155	with	_
104-18	19156-19163	Biotype	_
104-19	19163-19164	-	_
104-20	19164-19165	1	_
104-21	19166-19173	showing	_
104-22	19174-19186	hypoactivity	_
104-23	19186-19187	,	_
104-24	19188-19195	Biotype	_
104-25	19195-19196	-	_
104-26	19196-19197	2	_
104-27	19198-19205	showing	_
104-28	19206-19219	hyperactivity	_
104-29	19219-19220	,	_
104-30	19221-19224	and	_
104-31	19225-19232	Biotype	_
104-32	19232-19233	-	_
104-33	19233-19234	3	_
104-34	19235-19238	the	_
104-35	19239-19246	closest	_
104-36	19247-19249	to	_
104-37	19250-19252	HC	_
104-38	19252-19253	,	_
104-39	19254-19264	consistent	_
104-40	19265-19269	with	_
104-41	19270-19282	expectations	_
104-42	19283-19288	based	_
104-43	19289-19291	on	_
104-44	19291-19292	.	_

#Text=It may be that both Biotype-1 and Biotype-2 have “attractor state” (one of multiple, more-or-less stable firing patterns to which a given neural network can be attracted by internal or external cues) problems, although for different reasons.
105-1	19293-19295	It	_
105-2	19296-19299	may	_
105-3	19300-19302	be	_
105-4	19303-19307	that	_
105-5	19308-19312	both	_
105-6	19313-19320	Biotype	_
105-7	19320-19321	-	_
105-8	19321-19322	1	_
105-9	19323-19326	and	_
105-10	19327-19334	Biotype	_
105-11	19334-19335	-	_
105-12	19335-19336	2	_
105-13	19337-19341	have	_
105-14	19342-19343	“	_
105-15	19343-19352	attractor	_
105-16	19353-19358	state	_
105-17	19358-19359	”	_
105-18	19360-19361	(	_
105-19	19361-19364	one	_
105-20	19365-19367	of	_
105-21	19368-19376	multiple	_
105-22	19376-19377	,	_
105-23	19378-19390	more-or-less	_
105-24	19391-19397	stable	_
105-25	19398-19404	firing	_
105-26	19405-19413	patterns	_
105-27	19414-19416	to	_
105-28	19417-19422	which	_
105-29	19423-19424	a	_
105-30	19425-19430	given	_
105-31	19431-19437	neural	_
105-32	19438-19445	network	_
105-33	19446-19449	can	_
105-34	19450-19452	be	_
105-35	19453-19462	attracted	_
105-36	19463-19465	by	_
105-37	19466-19474	internal	_
105-38	19475-19477	or	_
105-39	19478-19486	external	_
105-40	19487-19491	cues	_
105-41	19491-19492	)	_
105-42	19493-19501	problems	_
105-43	19501-19502	,	_
105-44	19503-19511	although	_
105-45	19512-19515	for	_
105-46	19516-19525	different	_
105-47	19526-19533	reasons	_
105-48	19533-19534	.	_

#Text=Neuronal hyperexcitation, as in Biotype-2, would decrease the stability of cortical networks selected to support current behavioral requirements.
106-1	19535-19543	Neuronal	_
106-2	19544-19559	hyperexcitation	_
106-3	19559-19560	,	_
106-4	19561-19563	as	_
106-5	19564-19566	in	_
106-6	19567-19574	Biotype	_
106-7	19574-19575	-	_
106-8	19575-19576	2	_
106-9	19576-19577	,	_
106-10	19578-19583	would	_
106-11	19584-19592	decrease	_
106-12	19593-19596	the	_
106-13	19597-19606	stability	_
106-14	19607-19609	of	_
106-15	19610-19618	cortical	_
106-16	19619-19627	networks	_
106-17	19628-19636	selected	_
106-18	19637-19639	to	_
106-19	19640-19647	support	_
106-20	19648-19655	current	_
106-21	19656-19666	behavioral	_
106-22	19667-19679	requirements	_
106-23	19679-19680	.	_

#Text=Competing cortical networks could periodically attain higher signal strength, leading to behavioral indications of “distraction.”
107-1	19681-19690	Competing	_
107-2	19691-19699	cortical	_
107-3	19700-19708	networks	_
107-4	19709-19714	could	_
107-5	19715-19727	periodically	_
107-6	19728-19734	attain	_
107-7	19735-19741	higher	_
107-8	19742-19748	signal	_
107-9	19749-19757	strength	_
107-10	19757-19758	,	_
107-11	19759-19766	leading	_
107-12	19767-19769	to	_
107-13	19770-19780	behavioral	_
107-14	19781-19792	indications	_
107-15	19793-19795	of	_
107-16	19796-19797	“	_
107-17	19797-19808	distraction	_
107-18	19808-19809	.	_
107-19	19809-19810	”	_

#Text=Neuronal hypoexcitation, as in Biotype-1, could result in difficulty initiating switches between cortical network states, which could also lead to many of the cognitive symptoms found in psychosis, including reduced behavioral flexibility.
108-1	19811-19819	Neuronal	_
108-2	19820-19834	hypoexcitation	_
108-3	19834-19835	,	_
108-4	19836-19838	as	_
108-5	19839-19841	in	_
108-6	19842-19849	Biotype	_
108-7	19849-19850	-	_
108-8	19850-19851	1	_
108-9	19851-19852	,	_
108-10	19853-19858	could	_
108-11	19859-19865	result	_
108-12	19866-19868	in	_
108-13	19869-19879	difficulty	_
108-14	19880-19890	initiating	_
108-15	19891-19899	switches	_
108-16	19900-19907	between	_
108-17	19908-19916	cortical	_
108-18	19917-19924	network	_
108-19	19925-19931	states	_
108-20	19931-19932	,	_
108-21	19933-19938	which	_
108-22	19939-19944	could	_
108-23	19945-19949	also	_
108-24	19950-19954	lead	_
108-25	19955-19957	to	_
108-26	19958-19962	many	_
108-27	19963-19965	of	_
108-28	19966-19969	the	_
108-29	19970-19979	cognitive	_
108-30	19980-19988	symptoms	_
108-31	19989-19994	found	_
108-32	19995-19997	in	_
108-33	19998-20007	psychosis	_
108-34	20007-20008	,	_
108-35	20009-20018	including	_
108-36	20019-20026	reduced	_
108-37	20027-20037	behavioral	_
108-38	20038-20049	flexibility	_
108-39	20049-20050	.	_

#Text=The hypoexcitation of Biotype-1 and hyperexcitation of Biotype-2 may be consistent with models of psychosis that invoke NMDA-receptor dysfunction on inhibitory interneurons or models of psychosis with the NMDA-receptor dysfunction on pyramidal neurons themselves, but association with these potential mechanistic underpinnings remains to be established.
109-1	20051-20054	The	_
109-2	20055-20069	hypoexcitation	_
109-3	20070-20072	of	_
109-4	20073-20080	Biotype	_
109-5	20080-20081	-	_
109-6	20081-20082	1	_
109-7	20083-20086	and	_
109-8	20087-20102	hyperexcitation	_
109-9	20103-20105	of	_
109-10	20106-20113	Biotype	_
109-11	20113-20114	-	_
109-12	20114-20115	2	_
109-13	20116-20119	may	_
109-14	20120-20122	be	_
109-15	20123-20133	consistent	_
109-16	20134-20138	with	_
109-17	20139-20145	models	_
109-18	20146-20148	of	_
109-19	20149-20158	psychosis	_
109-20	20159-20163	that	_
109-21	20164-20170	invoke	_
109-22	20171-20184	NMDA-receptor	_
109-23	20185-20196	dysfunction	_
109-24	20197-20199	on	_
109-25	20200-20210	inhibitory	_
109-26	20211-20223	interneurons	_
109-27	20224-20226	or	_
109-28	20227-20233	models	_
109-29	20234-20236	of	_
109-30	20237-20246	psychosis	_
109-31	20247-20251	with	_
109-32	20252-20255	the	_
109-33	20256-20269	NMDA-receptor	_
109-34	20270-20281	dysfunction	_
109-35	20282-20284	on	_
109-36	20285-20294	pyramidal	_
109-37	20295-20302	neurons	_
109-38	20303-20313	themselves	_
109-39	20313-20314	,	_
109-40	20315-20318	but	_
109-41	20319-20330	association	_
109-42	20331-20335	with	_
109-43	20336-20341	these	_
109-44	20342-20351	potential	_
109-45	20352-20363	mechanistic	_
109-46	20364-20377	underpinnings	_
109-47	20378-20385	remains	_
109-48	20386-20388	to	_
109-49	20389-20391	be	_
109-50	20392-20403	established	_
109-51	20403-20404	.	_

#Text=The current findings support a proposal by that exploration into potassium and/or calcium channel alterations and channel-based therapies which may correct neuronal hypo- or hyperexcitability might be fruitful for both subgroups.
110-1	20405-20408	The	_
110-2	20409-20416	current	_
110-3	20417-20425	findings	_
110-4	20426-20433	support	_
110-5	20434-20435	a	_
110-6	20436-20444	proposal	_
110-7	20445-20447	by	_
110-8	20448-20452	that	_
110-9	20453-20464	exploration	_
110-10	20465-20469	into	_
110-11	20470-20479	potassium	_
110-12	20480-20483	and	_
110-13	20483-20484	/	_
110-14	20484-20486	or	_
110-15	20487-20494	calcium	_
110-16	20495-20502	channel	_
110-17	20503-20514	alterations	_
110-18	20515-20518	and	_
110-19	20519-20532	channel-based	_
110-20	20533-20542	therapies	_
110-21	20543-20548	which	_
110-22	20549-20552	may	_
110-23	20553-20560	correct	_
110-24	20561-20569	neuronal	_
110-25	20570-20574	hypo	_
110-26	20574-20575	-	_
110-27	20576-20578	or	_
110-28	20579-20596	hyperexcitability	_
110-29	20597-20602	might	_
110-30	20603-20605	be	_
110-31	20606-20614	fruitful	_
110-32	20615-20618	for	_
110-33	20619-20623	both	_
110-34	20624-20633	subgroups	_
110-35	20633-20634	.	_

#Text=As either abnormally high or low NMDA-related current flow could decrease cortical network stability, it is noteworthy that HC and Biotype-3 showed greater and more dynamic changes in neural synchrony than Biotype-1 or Biotype-2, suggesting an inability in the latter groups to properly modulate synchronous activity.
111-1	20635-20637	As	_
111-2	20638-20644	either	_
111-3	20645-20655	abnormally	_
111-4	20656-20660	high	_
111-5	20661-20663	or	_
111-6	20664-20667	low	_
111-7	20668-20680	NMDA-related	_
111-8	20681-20688	current	_
111-9	20689-20693	flow	_
111-10	20694-20699	could	_
111-11	20700-20708	decrease	_
111-12	20709-20717	cortical	_
111-13	20718-20725	network	_
111-14	20726-20735	stability	_
111-15	20735-20736	,	_
111-16	20737-20739	it	_
111-17	20740-20742	is	_
111-18	20743-20753	noteworthy	_
111-19	20754-20758	that	_
111-20	20759-20761	HC	_
111-21	20762-20765	and	_
111-22	20766-20773	Biotype	_
111-23	20773-20774	-	_
111-24	20774-20775	3	_
111-25	20776-20782	showed	_
111-26	20783-20790	greater	_
111-27	20791-20794	and	_
111-28	20795-20799	more	_
111-29	20800-20807	dynamic	_
111-30	20808-20815	changes	_
111-31	20816-20818	in	_
111-32	20819-20825	neural	_
111-33	20826-20835	synchrony	_
111-34	20836-20840	than	_
111-35	20841-20848	Biotype	_
111-36	20848-20849	-	_
111-37	20849-20850	1	_
111-38	20851-20853	or	_
111-39	20854-20861	Biotype	_
111-40	20861-20862	-	_
111-41	20862-20863	2	_
111-42	20863-20864	,	_
111-43	20865-20875	suggesting	_
111-44	20876-20878	an	_
111-45	20879-20888	inability	_
111-46	20889-20891	in	_
111-47	20892-20895	the	_
111-48	20896-20902	latter	_
111-49	20903-20909	groups	_
111-50	20910-20912	to	_
111-51	20913-20921	properly	_
111-52	20922-20930	modulate	_
111-53	20931-20942	synchronous	_
111-54	20943-20951	activity	_
111-55	20951-20952	.	_

#Text=It is unclear why ITC deviations in Biotypes-1 and -2 were found only after trial onset in the current study and only before trial onset in.
112-1	20953-20955	It	_
112-2	20956-20958	is	_
112-3	20959-20966	unclear	_
112-4	20967-20970	why	_
112-5	20971-20974	ITC	_
112-6	20975-20985	deviations	_
112-7	20986-20988	in	_
112-8	20989-20997	Biotypes	_
112-9	20997-20998	-	_
112-10	20998-20999	1	_
112-11	21000-21003	and	_
112-12	21004-21005	-	_
112-13	21005-21006	2	_
112-14	21007-21011	were	_
112-15	21012-21017	found	_
112-16	21018-21022	only	_
112-17	21023-21028	after	_
112-18	21029-21034	trial	_
112-19	21035-21040	onset	_
112-20	21041-21043	in	_
112-21	21044-21047	the	_
112-22	21048-21055	current	_
112-23	21056-21061	study	_
112-24	21062-21065	and	_
112-25	21066-21070	only	_
112-26	21071-21077	before	_
112-27	21078-21083	trial	_
112-28	21084-21089	onset	_
112-29	21090-21092	in	_
112-30	21092-21093	.	_

#Text=One possibility may be differential processing of the central versus peripheral steady-state stimuli, which could also provide insight into why Biotype-2 exhibited better antisaccade performance in the current study than in.
113-1	21094-21097	One	_
113-2	21098-21109	possibility	_
113-3	21110-21113	may	_
113-4	21114-21116	be	_
113-5	21117-21129	differential	_
113-6	21130-21140	processing	_
113-7	21141-21143	of	_
113-8	21144-21147	the	_
113-9	21148-21155	central	_
113-10	21156-21162	versus	_
113-11	21163-21173	peripheral	_
113-12	21174-21186	steady-state	_
113-13	21187-21194	stimuli	_
113-14	21194-21195	,	_
113-15	21196-21201	which	_
113-16	21202-21207	could	_
113-17	21208-21212	also	_
113-18	21213-21220	provide	_
113-19	21221-21228	insight	_
113-20	21229-21233	into	_
113-21	21234-21237	why	_
113-22	21238-21245	Biotype	_
113-23	21245-21246	-	_
113-24	21246-21247	2	_
113-25	21248-21257	exhibited	_
113-26	21258-21264	better	_
113-27	21265-21276	antisaccade	_
113-28	21277-21288	performance	_
113-29	21289-21291	in	_
113-30	21292-21295	the	_
113-31	21296-21303	current	_
113-32	21304-21309	study	_
113-33	21310-21314	than	_
113-34	21315-21317	in	_
113-35	21317-21318	.	_

#Text=Further study will be needed on the heterogeneity among psychosis subgroups of central versus peripheral visual processing pathways and susceptibility to distraction under varying stimulus and task conditions.
114-1	21319-21326	Further	_
114-2	21327-21332	study	_
114-3	21333-21337	will	_
114-4	21338-21340	be	_
114-5	21341-21347	needed	_
114-6	21348-21350	on	_
114-7	21351-21354	the	_
114-8	21355-21368	heterogeneity	_
114-9	21369-21374	among	_
114-10	21375-21384	psychosis	_
114-11	21385-21394	subgroups	_
114-12	21395-21397	of	_
114-13	21398-21405	central	_
114-14	21406-21412	versus	_
114-15	21413-21423	peripheral	_
114-16	21424-21430	visual	_
114-17	21431-21441	processing	_
114-18	21442-21450	pathways	_
114-19	21451-21454	and	_
114-20	21455-21469	susceptibility	_
114-21	21470-21472	to	_
114-22	21473-21484	distraction	_
114-23	21485-21490	under	_
114-24	21491-21498	varying	_
114-25	21499-21507	stimulus	_
114-26	21508-21511	and	_
114-27	21512-21516	task	_
114-28	21517-21527	conditions	_
114-29	21527-21528	.	_

#Text=Findings from studies on nonhuman primates and HC indicate that successful antisaccade performance requires sustained anticipatory modulation of neural activity in specific regions of saccade motor circuitry, presumably via top-down control by prefrontal cortex.
115-1	21529-21537	Findings	_
115-2	21538-21542	from	_
115-3	21543-21550	studies	_
115-4	21551-21553	on	_
115-5	21554-21562	nonhuman	_
115-6	21563-21571	primates	_
115-7	21572-21575	and	_
115-8	21576-21578	HC	_
115-9	21579-21587	indicate	_
115-10	21588-21592	that	_
115-11	21593-21603	successful	_
115-12	21604-21615	antisaccade	_
115-13	21616-21627	performance	_
115-14	21628-21636	requires	_
115-15	21637-21646	sustained	_
115-16	21647-21659	anticipatory	_
115-17	21660-21670	modulation	_
115-18	21671-21673	of	_
115-19	21674-21680	neural	_
115-20	21681-21689	activity	_
115-21	21690-21692	in	_
115-22	21693-21701	specific	_
115-23	21702-21709	regions	_
115-24	21710-21712	of	_
115-25	21713-21720	saccade	_
115-26	21721-21726	motor	_
115-27	21727-21736	circuitry	_
115-28	21736-21737	,	_
115-29	21738-21748	presumably	_
115-30	21749-21752	via	_
115-31	21753-21761	top-down	_
115-32	21762-21769	control	_
115-33	21770-21772	by	_
115-34	21773-21783	prefrontal	_
115-35	21784-21790	cortex	_
115-36	21790-21791	.	_

#Text=Together with findings from, the current results provide direct evidence in the same sample of HC for the complementary processes of increasing visuocortical investment to central stimuli and decreasing investment to peripheral stimuli prior to anti- relative to pro-saccades.
116-1	21792-21800	Together	_
116-2	21801-21805	with	_
116-3	21806-21814	findings	_
116-4	21815-21819	from	_
116-5	21819-21820	,	_
116-6	21821-21824	the	_
116-7	21825-21832	current	_
116-8	21833-21840	results	_
116-9	21841-21848	provide	_
116-10	21849-21855	direct	_
116-11	21856-21864	evidence	_
116-12	21865-21867	in	_
116-13	21868-21871	the	_
116-14	21872-21876	same	_
116-15	21877-21883	sample	_
116-16	21884-21886	of	_
116-17	21887-21889	HC	_
116-18	21890-21893	for	_
116-19	21894-21897	the	_
116-20	21898-21911	complementary	_
116-21	21912-21921	processes	_
116-22	21922-21924	of	_
116-23	21925-21935	increasing	_
116-24	21936-21949	visuocortical	_
116-25	21950-21960	investment	_
116-26	21961-21963	to	_
116-27	21964-21971	central	_
116-28	21972-21979	stimuli	_
116-29	21980-21983	and	_
116-30	21984-21994	decreasing	_
116-31	21995-22005	investment	_
116-32	22006-22008	to	_
116-33	22009-22019	peripheral	_
116-34	22020-22027	stimuli	_
116-35	22028-22033	prior	_
116-36	22034-22036	to	_
116-37	22037-22041	anti	_
116-38	22041-22042	-	_
116-39	22043-22051	relative	_
116-40	22052-22054	to	_
116-41	22055-22067	pro-saccades	_
116-42	22067-22068	.	_

#Text=Interestingly, both of these preparatory neural modulation processes were found to be preserved in psychosis Biotypes, despite diminished behavioral performance.
117-1	22069-22082	Interestingly	_
117-2	22082-22083	,	_
117-3	22084-22088	both	_
117-4	22089-22091	of	_
117-5	22092-22097	these	_
117-6	22098-22109	preparatory	_
117-7	22110-22116	neural	_
117-8	22117-22127	modulation	_
117-9	22128-22137	processes	_
117-10	22138-22142	were	_
117-11	22143-22148	found	_
117-12	22149-22151	to	_
117-13	22152-22154	be	_
117-14	22155-22164	preserved	_
117-15	22165-22167	in	_
117-16	22168-22177	psychosis	_
117-17	22178-22186	Biotypes	_
117-18	22186-22187	,	_
117-19	22188-22195	despite	_
117-20	22196-22206	diminished	_
117-21	22207-22217	behavioral	_
117-22	22218-22229	performance	_
117-23	22229-22230	.	_

#Text=This finding indicates that preparatory modulation alone is not sufficient for successful antisaccade performance.
118-1	22231-22235	This	_
118-2	22236-22243	finding	_
118-3	22244-22253	indicates	_
118-4	22254-22258	that	_
118-5	22259-22270	preparatory	_
118-6	22271-22281	modulation	_
118-7	22282-22287	alone	_
118-8	22288-22290	is	_
118-9	22291-22294	not	_
118-10	22295-22305	sufficient	_
118-11	22306-22309	for	_
118-12	22310-22320	successful	_
118-13	22321-22332	antisaccade	_
118-14	22333-22344	performance	_
118-15	22344-22345	.	_

#Text=While all groups similarly modulated stimulus-specific neural power as a function of increasing cognitive demands, only HC and Biotype-1 modulated intrinsic activity.
119-1	22346-22351	While	_
119-2	22352-22355	all	_
119-3	22356-22362	groups	_
119-4	22363-22372	similarly	_
119-5	22373-22382	modulated	_
119-6	22383-22400	stimulus-specific	_
119-7	22401-22407	neural	_
119-8	22408-22413	power	_
119-9	22414-22416	as	_
119-10	22417-22418	a	_
119-11	22419-22427	function	_
119-12	22428-22430	of	_
119-13	22431-22441	increasing	_
119-14	22442-22451	cognitive	_
119-15	22452-22459	demands	_
119-16	22459-22460	,	_
119-17	22461-22465	only	_
119-18	22466-22468	HC	_
119-19	22469-22472	and	_
119-20	22473-22480	Biotype	_
119-21	22480-22481	-	_
119-22	22481-22482	1	_
119-23	22483-22492	modulated	_
119-24	22493-22502	intrinsic	_
119-25	22503-22511	activity	_
119-26	22511-22512	.	_

#Text=That Biotype-2 and Biotype-3, both with slightly impaired behavioral performance, failed to modulate intrinsic activity levels as a function of cognitive demands suggests differences in the cognitive strategies employed by each group.
120-1	22513-22517	That	_
120-2	22518-22525	Biotype	_
120-3	22525-22526	-	_
120-4	22526-22527	2	_
120-5	22528-22531	and	_
120-6	22532-22539	Biotype	_
120-7	22539-22540	-	_
120-8	22540-22541	3	_
120-9	22541-22542	,	_
120-10	22543-22547	both	_
120-11	22548-22552	with	_
120-12	22553-22561	slightly	_
120-13	22562-22570	impaired	_
120-14	22571-22581	behavioral	_
120-15	22582-22593	performance	_
120-16	22593-22594	,	_
120-17	22595-22601	failed	_
120-18	22602-22604	to	_
120-19	22605-22613	modulate	_
120-20	22614-22623	intrinsic	_
120-21	22624-22632	activity	_
120-22	22633-22639	levels	_
120-23	22640-22642	as	_
120-24	22643-22644	a	_
120-25	22645-22653	function	_
120-26	22654-22656	of	_
120-27	22657-22666	cognitive	_
120-28	22667-22674	demands	_
120-29	22675-22683	suggests	_
120-30	22684-22695	differences	_
120-31	22696-22698	in	_
120-32	22699-22702	the	_
120-33	22703-22712	cognitive	_
120-34	22713-22723	strategies	_
120-35	22724-22732	employed	_
120-36	22733-22735	by	_
120-37	22736-22740	each	_
120-38	22741-22746	group	_
120-39	22746-22747	.	_

#Text=For Biotype-1, however, increases in task-specific neural activity appear to require large increases in non-specific activity.
121-1	22748-22751	For	_
121-2	22752-22759	Biotype	_
121-3	22759-22760	-	_
121-4	22760-22761	1	_
121-5	22761-22762	,	_
121-6	22763-22770	however	_
121-7	22770-22771	,	_
121-8	22772-22781	increases	_
121-9	22782-22784	in	_
121-10	22785-22798	task-specific	_
121-11	22799-22805	neural	_
121-12	22806-22814	activity	_
121-13	22815-22821	appear	_
121-14	22822-22824	to	_
121-15	22825-22832	require	_
121-16	22833-22838	large	_
121-17	22839-22848	increases	_
121-18	22849-22851	in	_
121-19	22852-22864	non-specific	_
121-20	22865-22873	activity	_
121-21	22873-22874	.	_

#Text=This may indicate an attempt to compensate for overall hypoactivity and/or a propensity to become overwhelmed as cognitive demands increase.
122-1	22875-22879	This	_
122-2	22880-22883	may	_
122-3	22884-22892	indicate	_
122-4	22893-22895	an	_
122-5	22896-22903	attempt	_
122-6	22904-22906	to	_
122-7	22907-22917	compensate	_
122-8	22918-22921	for	_
122-9	22922-22929	overall	_
122-10	22930-22942	hypoactivity	_
122-11	22943-22946	and	_
122-12	22946-22947	/	_
122-13	22947-22949	or	_
122-14	22950-22951	a	_
122-15	22952-22962	propensity	_
122-16	22963-22965	to	_
122-17	22966-22972	become	_
122-18	22973-22984	overwhelmed	_
122-19	22985-22987	as	_
122-20	22988-22997	cognitive	_
122-21	22998-23005	demands	_
122-22	23006-23014	increase	_
122-23	23014-23015	.	_

#Text=Distinct subgroups of psychosis cases show diametrically opposed deviations in nonspecific neural oscillatory activity.
123-1	23016-23024	Distinct	_
123-2	23025-23034	subgroups	_
123-3	23035-23037	of	_
123-4	23038-23047	psychosis	_
123-5	23048-23053	cases	_
123-6	23054-23058	show	_
123-7	23059-23072	diametrically	_
123-8	23073-23080	opposed	_
123-9	23081-23091	deviations	_
123-10	23092-23094	in	_
123-11	23095-23106	nonspecific	_
123-12	23107-23113	neural	_
123-13	23114-23125	oscillatory	_
123-14	23126-23134	activity	_
123-15	23134-23135	.	_

#Text=This pattern of differences between groups in absolute activity levels is also reflected in evoked potentials at stimulus onset (see Figure 2A).
124-1	23136-23140	This	_
124-2	23141-23148	pattern	_
124-3	23149-23151	of	_
124-4	23152-23163	differences	_
124-5	23164-23171	between	_
124-6	23172-23178	groups	_
124-7	23179-23181	in	_
124-8	23182-23190	absolute	_
124-9	23191-23199	activity	_
124-10	23200-23206	levels	_
124-11	23207-23209	is	_
124-12	23210-23214	also	_
124-13	23215-23224	reflected	_
124-14	23225-23227	in	_
124-15	23228-23234	evoked	_
124-16	23235-23245	potentials	_
124-17	23246-23248	at	_
124-18	23249-23257	stimulus	_
124-19	23258-23263	onset	_
124-20	23264-23265	(	_
124-21	23265-23268	see	_
124-22	23269-23275	Figure	_
124-23	23276-23278	2A	_
124-24	23278-23279	)	_
124-25	23279-23280	.	_

#Text=It is unlikely that these differences are the result of medication effects, as Biotypes were similarly medicated (see Table 1).
125-1	23281-23283	It	_
125-2	23284-23286	is	_
125-3	23287-23295	unlikely	_
125-4	23296-23300	that	_
125-5	23301-23306	these	_
125-6	23307-23318	differences	_
125-7	23319-23322	are	_
125-8	23323-23326	the	_
125-9	23327-23333	result	_
125-10	23334-23336	of	_
125-11	23337-23347	medication	_
125-12	23348-23355	effects	_
125-13	23355-23356	,	_
125-14	23357-23359	as	_
125-15	23360-23368	Biotypes	_
125-16	23369-23373	were	_
125-17	23374-23383	similarly	_
125-18	23384-23393	medicated	_
125-19	23394-23395	(	_
125-20	23395-23398	see	_
125-21	23399-23404	Table	_
125-22	23405-23406	1	_
125-23	23406-23407	)	_
125-24	23407-23408	.	_

#Text=While the results of the current study advance the notion that differences in intrinsic neural activity levels play a key role in cognitive performance in psychosis, they also indicate that intrinsic activity levels cannot fully explain the differences between psychosis subgroups or vs.
126-1	23409-23414	While	_
126-2	23415-23418	the	_
126-3	23419-23426	results	_
126-4	23427-23429	of	_
126-5	23430-23433	the	_
126-6	23434-23441	current	_
126-7	23442-23447	study	_
126-8	23448-23455	advance	_
126-9	23456-23459	the	_
126-10	23460-23466	notion	_
126-11	23467-23471	that	_
126-12	23472-23483	differences	_
126-13	23484-23486	in	_
126-14	23487-23496	intrinsic	_
126-15	23497-23503	neural	_
126-16	23504-23512	activity	_
126-17	23513-23519	levels	_
126-18	23520-23524	play	_
126-19	23525-23526	a	_
126-20	23527-23530	key	_
126-21	23531-23535	role	_
126-22	23536-23538	in	_
126-23	23539-23548	cognitive	_
126-24	23549-23560	performance	_
126-25	23561-23563	in	_
126-26	23564-23573	psychosis	_
126-27	23573-23574	,	_
126-28	23575-23579	they	_
126-29	23580-23584	also	_
126-30	23585-23593	indicate	_
126-31	23594-23598	that	_
126-32	23599-23608	intrinsic	_
126-33	23609-23617	activity	_
126-34	23618-23624	levels	_
126-35	23625-23631	cannot	_
126-36	23632-23637	fully	_
126-37	23638-23645	explain	_
126-38	23646-23649	the	_
126-39	23650-23661	differences	_
126-40	23662-23669	between	_
126-41	23670-23679	psychosis	_
126-42	23680-23689	subgroups	_
126-43	23690-23692	or	_
126-44	23693-23695	vs	_
126-45	23695-23696	.	_

#Text=HC.
127-1	23697-23699	HC	_
127-2	23699-23700	.	_

#Text=For example, Biotype-3 did not deviate significantly from HC on any brain measure, despite slightly impaired behavioral performance.
128-1	23701-23704	For	_
128-2	23705-23712	example	_
128-3	23712-23713	,	_
128-4	23714-23721	Biotype	_
128-5	23721-23722	-	_
128-6	23722-23723	3	_
128-7	23724-23727	did	_
128-8	23728-23731	not	_
128-9	23732-23739	deviate	_
128-10	23740-23753	significantly	_
128-11	23754-23758	from	_
128-12	23759-23761	HC	_
128-13	23762-23764	on	_
128-14	23765-23768	any	_
128-15	23769-23774	brain	_
128-16	23775-23782	measure	_
128-17	23782-23783	,	_
128-18	23784-23791	despite	_
128-19	23792-23800	slightly	_
128-20	23801-23809	impaired	_
128-21	23810-23820	behavioral	_
128-22	23821-23832	performance	_
128-23	23832-23833	.	_

#Text=Finally, replication of all analyses subgrouping psychosis cases based on either DSM diagnosis or a continuum of psychotic symptomology revealed fewer and less consistent differences, including no intrinsic activity differences between any clinical subgroup and healthy individuals (see Supplemental Results).
129-1	23834-23841	Finally	_
129-2	23841-23842	,	_
129-3	23843-23854	replication	_
129-4	23855-23857	of	_
129-5	23858-23861	all	_
129-6	23862-23870	analyses	_
129-7	23871-23882	subgrouping	_
129-8	23883-23892	psychosis	_
129-9	23893-23898	cases	_
129-10	23899-23904	based	_
129-11	23905-23907	on	_
129-12	23908-23914	either	_
129-13	23915-23918	DSM	_
129-14	23919-23928	diagnosis	_
129-15	23929-23931	or	_
129-16	23932-23933	a	_
129-17	23934-23943	continuum	_
129-18	23944-23946	of	_
129-19	23947-23956	psychotic	_
129-20	23957-23969	symptomology	_
129-21	23970-23978	revealed	_
129-22	23979-23984	fewer	_
129-23	23985-23988	and	_
129-24	23989-23993	less	_
129-25	23994-24004	consistent	_
129-26	24005-24016	differences	_
129-27	24016-24017	,	_
129-28	24018-24027	including	_
129-29	24028-24030	no	_
129-30	24031-24040	intrinsic	_
129-31	24041-24049	activity	_
129-32	24050-24061	differences	_
129-33	24062-24069	between	_
129-34	24070-24073	any	_
129-35	24074-24082	clinical	_
129-36	24083-24091	subgroup	_
129-37	24092-24095	and	_
129-38	24096-24103	healthy	_
129-39	24104-24115	individuals	_
129-40	24116-24117	(	_
129-41	24117-24120	see	_
129-42	24121-24133	Supplemental	_
129-43	24134-24141	Results	_
129-44	24141-24142	)	_
129-45	24142-24143	.	_

#Text=While not the principle interest of the current investigation, it is nonetheless important to highlight this finding.
130-1	24144-24149	While	_
130-2	24150-24153	not	_
130-3	24154-24157	the	_
130-4	24158-24167	principle	_
130-5	24168-24176	interest	_
130-6	24177-24179	of	_
130-7	24180-24183	the	_
130-8	24184-24191	current	_
130-9	24192-24205	investigation	_
130-10	24205-24206	,	_
130-11	24207-24209	it	_
130-12	24210-24212	is	_
130-13	24213-24224	nonetheless	_
130-14	24225-24234	important	_
130-15	24235-24237	to	_
130-16	24238-24247	highlight	_
130-17	24248-24252	this	_
130-18	24253-24260	finding	_
130-19	24260-24261	.	_

#Text=The reproducibility and longitudinal stability of the Biotype constructs developed in are being addressed in independent samples in our ongoing work, but it is clear that there exist meaningful differences between distinct psychosis subgroups that are not adequately accounted for by clinical symptomatology.
131-1	24262-24265	The	_
131-2	24266-24281	reproducibility	_
131-3	24282-24285	and	_
131-4	24286-24298	longitudinal	_
131-5	24299-24308	stability	_
131-6	24309-24311	of	_
131-7	24312-24315	the	_
131-8	24316-24323	Biotype	_
131-9	24324-24334	constructs	_
131-10	24335-24344	developed	_
131-11	24345-24347	in	_
131-12	24348-24351	are	_
131-13	24352-24357	being	_
131-14	24358-24367	addressed	_
131-15	24368-24370	in	_
131-16	24371-24382	independent	_
131-17	24383-24390	samples	_
131-18	24391-24393	in	_
131-19	24394-24397	our	_
131-20	24398-24405	ongoing	_
131-21	24406-24410	work	_
131-22	24410-24411	,	_
131-23	24412-24415	but	_
131-24	24416-24418	it	_
131-25	24419-24421	is	_
131-26	24422-24427	clear	_
131-27	24428-24432	that	_
131-28	24433-24438	there	_
131-29	24439-24444	exist	_
131-30	24445-24455	meaningful	_
131-31	24456-24467	differences	_
131-32	24468-24475	between	_
131-33	24476-24484	distinct	_
131-34	24485-24494	psychosis	_
131-35	24495-24504	subgroups	_
131-36	24505-24509	that	_
131-37	24510-24513	are	_
131-38	24514-24517	not	_
131-39	24518-24528	adequately	_
131-40	24529-24538	accounted	_
131-41	24539-24542	for	_
131-42	24543-24545	by	_
131-43	24546-24554	clinical	_
131-44	24555-24569	symptomatology	_
131-45	24569-24570	.	_

#Text=Above all, these findings indicate that grouping patients based on multidimensional classification using neurobiological data has demonstrable advantages for resolving heterogeneity and clarifying illness mechanisms relative to traditional psychiatric diagnoses and emphasize the need for studies of psychosis to consider the possibility of complex interactions between behavioral and brain measures.
132-1	24571-24576	Above	_
132-2	24577-24580	all	_
132-3	24580-24581	,	_
132-4	24582-24587	these	_
132-5	24588-24596	findings	_
132-6	24597-24605	indicate	_
132-7	24606-24610	that	_
132-8	24611-24619	grouping	_
132-9	24620-24628	patients	_
132-10	24629-24634	based	_
132-11	24635-24637	on	_
132-12	24638-24654	multidimensional	_
132-13	24655-24669	classification	_
132-14	24670-24675	using	_
132-15	24676-24691	neurobiological	_
132-16	24692-24696	data	_
132-17	24697-24700	has	_
132-18	24701-24713	demonstrable	_
132-19	24714-24724	advantages	_
132-20	24725-24728	for	_
132-21	24729-24738	resolving	_
132-22	24739-24752	heterogeneity	_
132-23	24753-24756	and	_
132-24	24757-24767	clarifying	_
132-25	24768-24775	illness	_
132-26	24776-24786	mechanisms	_
132-27	24787-24795	relative	_
132-28	24796-24798	to	_
132-29	24799-24810	traditional	_
132-30	24811-24822	psychiatric	_
132-31	24823-24832	diagnoses	_
132-32	24833-24836	and	_
132-33	24837-24846	emphasize	_
132-34	24847-24850	the	_
132-35	24851-24855	need	_
132-36	24856-24859	for	_
132-37	24860-24867	studies	_
132-38	24868-24870	of	_
132-39	24871-24880	psychosis	_
132-40	24881-24883	to	_
132-41	24884-24892	consider	_
132-42	24893-24896	the	_
132-43	24897-24908	possibility	_
132-44	24909-24911	of	_
132-45	24912-24919	complex	_
132-46	24920-24932	interactions	_
132-47	24933-24940	between	_
132-48	24941-24951	behavioral	_
132-49	24952-24955	and	_
132-50	24956-24961	brain	_
132-51	24962-24970	measures	_
132-52	24970-24971	.	_

#Text=Supplementary Material
#Text=Contributors
#Text=BAC and JAS designed the study and wrote the protocol.
133-1	24972-24985	Supplementary	_
133-2	24986-24994	Material	_
133-3	24995-25007	Contributors	_
133-4	25008-25011	BAC	_
133-5	25012-25015	and	_
133-6	25016-25019	JAS	_
133-7	25020-25028	designed	_
133-8	25029-25032	the	_
133-9	25033-25038	study	_
133-10	25039-25042	and	_
133-11	25043-25048	wrote	_
133-12	25049-25052	the	_
133-13	25053-25061	protocol	_
133-14	25061-25062	.	_

#Text=SKK collected the data.
134-1	25063-25066	SKK	_
134-2	25067-25076	collected	_
134-3	25077-25080	the	_
134-4	25081-25085	data	_
134-5	25085-25086	.	_

#Text=LEE performed preliminary analyses.
135-1	25087-25090	LEE	_
135-2	25091-25100	performed	_
135-3	25101-25112	preliminary	_
135-4	25113-25121	analyses	_
135-5	25121-25122	.	_

#Text=MEH performed all final analyses.
136-1	25123-25126	MEH	_
136-2	25127-25136	performed	_
136-3	25137-25140	all	_
136-4	25141-25146	final	_
136-5	25147-25155	analyses	_
136-6	25155-25156	.	_

#Text=MEH and BAC wrote the manuscript.
137-1	25157-25160	MEH	_
137-2	25161-25164	and	_
137-3	25165-25168	BAC	_
137-4	25169-25174	wrote	_
137-5	25175-25178	the	_
137-6	25179-25189	manuscript	_
137-7	25189-25190	.	_

#Text=All authors edited the manuscript and have seen and approved the final version.
138-1	25191-25194	All	_
138-2	25195-25202	authors	_
138-3	25203-25209	edited	_
138-4	25210-25213	the	_
138-5	25214-25224	manuscript	_
138-6	25225-25228	and	_
138-7	25229-25233	have	_
138-8	25234-25238	seen	_
138-9	25239-25242	and	_
138-10	25243-25251	approved	_
138-11	25252-25255	the	_
138-12	25256-25261	final	_
138-13	25262-25269	version	_
138-14	25269-25270	.	_

#Text=Financial Disclosures
#Text=Author JAS has served as a consultant for Takeda, Inc.
139-1	25271-25280	Financial	_
139-2	25281-25292	Disclosures	_
139-3	25293-25299	Author	_
139-4	25300-25303	JAS	_
139-5	25304-25307	has	_
139-6	25308-25314	served	_
139-7	25315-25317	as	_
139-8	25318-25319	a	_
139-9	25320-25330	consultant	_
139-10	25331-25334	for	_
139-11	25335-25341	Takeda	_
139-12	25341-25342	,	_
139-13	25343-25346	Inc	_
139-14	25346-25347	.	_

#Text=The remaining authors report no biomedical financial interests or potential conflicts of interest.
140-1	25348-25351	The	_
140-2	25352-25361	remaining	_
140-3	25362-25369	authors	_
140-4	25370-25376	report	_
140-5	25377-25379	no	_
140-6	25380-25390	biomedical	_
140-7	25391-25400	financial	_
140-8	25401-25410	interests	_
140-9	25411-25413	or	_
140-10	25414-25423	potential	_
140-11	25424-25433	conflicts	_
140-12	25434-25436	of	_
140-13	25437-25445	interest	_
140-14	25445-25446	.	_

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
141-1	25447-25451	This	_
141-2	25452-25454	is	_
141-3	25455-25456	a	_
141-4	25457-25460	PDF	_
141-5	25461-25465	file	_
141-6	25466-25468	of	_
141-7	25469-25471	an	_
141-8	25472-25480	unedited	_
141-9	25481-25491	manuscript	_
141-10	25492-25496	that	_
141-11	25497-25500	has	_
141-12	25501-25505	been	_
141-13	25506-25514	accepted	_
141-14	25515-25518	for	_
141-15	25519-25530	publication	_
141-16	25530-25531	.	_

#Text=As a service to our customers we are providing this early version of the manuscript.
142-1	25532-25534	As	_
142-2	25535-25536	a	_
142-3	25537-25544	service	_
142-4	25545-25547	to	_
142-5	25548-25551	our	_
142-6	25552-25561	customers	_
142-7	25562-25564	we	_
142-8	25565-25568	are	_
142-9	25569-25578	providing	_
142-10	25579-25583	this	_
142-11	25584-25589	early	_
142-12	25590-25597	version	_
142-13	25598-25600	of	_
142-14	25601-25604	the	_
142-15	25605-25615	manuscript	_
142-16	25615-25616	.	_

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
143-1	25617-25620	The	_
143-2	25621-25631	manuscript	_
143-3	25632-25636	will	_
143-4	25637-25644	undergo	_
143-5	25645-25656	copyediting	_
143-6	25656-25657	,	_
143-7	25658-25669	typesetting	_
143-8	25669-25670	,	_
143-9	25671-25674	and	_
143-10	25675-25681	review	_
143-11	25682-25684	of	_
143-12	25685-25688	the	_
143-13	25689-25698	resulting	_
143-14	25699-25704	proof	_
143-15	25705-25711	before	_
143-16	25712-25714	it	_
143-17	25715-25717	is	_
143-18	25718-25727	published	_
143-19	25728-25730	in	_
143-20	25731-25734	its	_
143-21	25735-25740	final	_
143-22	25741-25748	citable	_
143-23	25749-25753	form	_
143-24	25753-25754	.	_

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
144-1	25755-25761	Please	_
144-2	25762-25766	note	_
144-3	25767-25771	that	_
144-4	25772-25778	during	_
144-5	25779-25782	the	_
144-6	25783-25793	production	_
144-7	25794-25801	process	_
144-8	25802-25808	errors	_
144-9	25809-25812	may	_
144-10	25813-25815	be	_
144-11	25816-25826	discovered	_
144-12	25827-25832	which	_
144-13	25833-25838	could	_
144-14	25839-25845	affect	_
144-15	25846-25849	the	_
144-16	25850-25857	content	_
144-17	25857-25858	,	_
144-18	25859-25862	and	_
144-19	25863-25866	all	_
144-20	25867-25872	legal	_
144-21	25873-25884	disclaimers	_
144-22	25885-25889	that	_
144-23	25890-25895	apply	_
144-24	25896-25898	to	_
144-25	25899-25902	the	_
144-26	25903-25910	journal	_
144-27	25911-25918	pertain	_
144-28	25918-25919	.	_

#Text=Contributions of spectral frequency analyses to the study of P50 ERP amplitude and suppression in bipolar disorder with or without a history of psychosis
#Text=Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia
#Text=When does the brain inform the eyes whether and where to move?
145-1	25920-25933	Contributions	_
145-2	25934-25936	of	_
145-3	25937-25945	spectral	_
145-4	25946-25955	frequency	_
145-5	25956-25964	analyses	_
145-6	25965-25967	to	_
145-7	25968-25971	the	_
145-8	25972-25977	study	_
145-9	25978-25980	of	_
145-10	25981-25984	P50	_
145-11	25985-25988	ERP	_
145-12	25989-25998	amplitude	_
145-13	25999-26002	and	_
145-14	26003-26014	suppression	_
145-15	26015-26017	in	_
145-16	26018-26025	bipolar	_
145-17	26026-26034	disorder	_
145-18	26035-26039	with	_
145-19	26040-26042	or	_
145-20	26043-26050	without	_
145-21	26051-26052	a	_
145-22	26053-26060	history	_
145-23	26061-26063	of	_
145-24	26064-26073	psychosis	_
145-25	26074-26086	Multichannel	_
145-26	26087-26110	electroencephalographic	_
145-27	26111-26121	assessment	_
145-28	26122-26124	of	_
145-29	26125-26133	auditory	_
145-30	26134-26140	evoked	_
145-31	26141-26149	response	_
145-32	26150-26161	suppression	_
145-33	26162-26164	in	_
145-34	26165-26178	schizophrenia	_
145-35	26179-26183	When	_
145-36	26184-26188	does	_
145-37	26189-26192	the	_
145-38	26193-26198	brain	_
145-39	26199-26205	inform	_
145-40	26206-26209	the	_
145-41	26210-26214	eyes	_
145-42	26215-26222	whether	_
145-43	26223-26226	and	_
145-44	26227-26232	where	_
145-45	26233-26235	to	_
145-46	26236-26240	move	_
145-47	26240-26241	?	_

#Text=An EEG study in humans
#Text=Top-down control of visual sensory processing during an ocular motor response inhibition task
#Text=Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives
#Text=Identification of distinct psychosis biotypes using brain-based biomarkers
#Text=Normal electrocortical facilitation but abnormal target identification during visual sustained attention in schizophrenia
#Text=Neural correlates of fast stimulus discrimination and response selection in top-level fencers
#Text=Applying Principal Components Analysis to Event-Related Potentials: A Tutorial
#Text=An effect of context on saccade-related behavior and brain activity
#Text=Event-Related Potential and Time-Frequency Endophenotypes for Schizophrenia and Psychotic Bipolar Disorder
#Text=Sustained versus transient brain responses in schizophrenia: the role of intrinsic neural activity
#Text=Behavioral response inhibition in psychotic disorders: Diagnostic specificity, familiality and relation to generalized cognitive deficit
#Text=
#Text=Neural Processes Associated With Antisaccade Task Performance Investigated With Event-Related fMRI
#Text=Primary and secondary saccades to goals defined by instructions
#Text=Diagnostic specificity and familiality of early versus late evoked potentials to auditory paired stimuli across the schizophrenia-bipolar psychosis spectrum
#Text=Intrinsic neural activity differences among psychotic illnesses
#Text=Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate Receptors, and Dopamine–Glutamate Interactions
#Text=Neural Activity in Monkey Prefrontal Cortex Is Modulated by Task Context and Behavioral Instruction during Delayed-match-to-sample and Conditional Prosaccade—Antisaccade Tasks
#Text=Reimagining psychoses: An agnostic approach to diagnosis
#Text=A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: The Schizo-Bipolar Scale
#Text=Steady state visual evoked potential abnormalities in schizophrenia
#Text=Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia
#Text=Significance Test for Sphericity of a Normal n-Variate Distribution
#Text=Neurophysiology and neuroanatomy of reflexive and volitional saccades: Evidence from studies of humans
#Text=Electroencephalography/magnetoencephalography study of cortical activities preceding prosaccades and antisaccades
#Text=Measuring liability for schizophrenia using optimized antisaccade stimulus parameters
#Text=Neural mechanisms of evoked oscillations: stability and interaction with transient events
#Text=Look away: the anti-saccade task and the voluntary control of eye movement
#Text=Human Cerebral Activation during Steady-State Visual-Evoked Responses
#Text=Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories
#Text=Computational models of schizophrenia and dopamine modulation in the prefrontal cortex
#Text=A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities
#Text=Neural synchrony indexes disordered perception and cognition in schizophrenia
#Text=Attention modulates synchronized neuronal firing in primate somatosensory cortex
#Text=Central versus peripheral visual field stimulation results in timing differences in dorsal stream sources as measured with MEG
#Text=Positron emission tomography study of voluntary saccadic eye movements and spatial working memory
#Text=Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)
#Text=Projections to the superior temporal sulcus from the central and peripheral field representations of V1 and V2
#Text=Diminished parietal cortex activity associated with poor motion direction discrimination performance in schizophrenia
#Text=The neural correlates of feature-based selective attention when viewing spatially and temporally overlapping images
#Text=Prefrontal Broadband Noise, Working Memory, and Genetic Risk for Schizophrenia
#Text=Instability of prefrontal signal processing in schizophrenia
#Text=Genes, dopamine and cortical signal-to-noise ratio in schizophrenia
#Text=Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing
#Text=Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs
#Text=Example Prosaccade Trial.
146-1	26242-26244	An	_
146-2	26245-26248	EEG	_
146-3	26249-26254	study	_
146-4	26255-26257	in	_
146-5	26258-26264	humans	_
146-6	26265-26273	Top-down	_
146-7	26274-26281	control	_
146-8	26282-26284	of	_
146-9	26285-26291	visual	_
146-10	26292-26299	sensory	_
146-11	26300-26310	processing	_
146-12	26311-26317	during	_
146-13	26318-26320	an	_
146-14	26321-26327	ocular	_
146-15	26328-26333	motor	_
146-16	26334-26342	response	_
146-17	26343-26353	inhibition	_
146-18	26354-26358	task	_
146-19	26359-26366	Resting	_
146-20	26367-26370	EEG	_
146-21	26371-26373	in	_
146-22	26374-26387	first-episode	_
146-23	26388-26401	schizophrenia	_
146-24	26402-26410	patients	_
146-25	26410-26411	,	_
146-26	26412-26419	bipolar	_
146-27	26420-26429	psychosis	_
146-28	26430-26438	patients	_
146-29	26438-26439	,	_
146-30	26440-26443	and	_
146-31	26444-26449	their	_
146-32	26450-26462	first-degree	_
146-33	26463-26472	relatives	_
146-34	26473-26487	Identification	_
146-35	26488-26490	of	_
146-36	26491-26499	distinct	_
146-37	26500-26509	psychosis	_
146-38	26510-26518	biotypes	_
146-39	26519-26524	using	_
146-40	26525-26536	brain-based	_
146-41	26537-26547	biomarkers	_
146-42	26548-26554	Normal	_
146-43	26555-26570	electrocortical	_
146-44	26571-26583	facilitation	_
146-45	26584-26587	but	_
146-46	26588-26596	abnormal	_
146-47	26597-26603	target	_
146-48	26604-26618	identification	_
146-49	26619-26625	during	_
146-50	26626-26632	visual	_
146-51	26633-26642	sustained	_
146-52	26643-26652	attention	_
146-53	26653-26655	in	_
146-54	26656-26669	schizophrenia	_
146-55	26670-26676	Neural	_
146-56	26677-26687	correlates	_
146-57	26688-26690	of	_
146-58	26691-26695	fast	_
146-59	26696-26704	stimulus	_
146-60	26705-26719	discrimination	_
146-61	26720-26723	and	_
146-62	26724-26732	response	_
146-63	26733-26742	selection	_
146-64	26743-26745	in	_
146-65	26746-26755	top-level	_
146-66	26756-26763	fencers	_
146-67	26764-26772	Applying	_
146-68	26773-26782	Principal	_
146-69	26783-26793	Components	_
146-70	26794-26802	Analysis	_
146-71	26803-26805	to	_
146-72	26806-26819	Event-Related	_
146-73	26820-26830	Potentials	_
146-74	26830-26831	:	_
146-75	26832-26833	A	_
146-76	26834-26842	Tutorial	_
146-77	26843-26845	An	_
146-78	26846-26852	effect	_
146-79	26853-26855	of	_
146-80	26856-26863	context	_
146-81	26864-26866	on	_
146-82	26867-26882	saccade-related	_
146-83	26883-26891	behavior	_
146-84	26892-26895	and	_
146-85	26896-26901	brain	_
146-86	26902-26910	activity	_
146-87	26911-26924	Event-Related	_
146-88	26925-26934	Potential	_
146-89	26935-26938	and	_
146-90	26939-26953	Time-Frequency	_
146-91	26954-26968	Endophenotypes	_
146-92	26969-26972	for	_
146-93	26973-26986	Schizophrenia	_
146-94	26987-26990	and	_
146-95	26991-27000	Psychotic	_
146-96	27001-27008	Bipolar	_
146-97	27009-27017	Disorder	_
146-98	27018-27027	Sustained	_
146-99	27028-27034	versus	_
146-100	27035-27044	transient	_
146-101	27045-27050	brain	_
146-102	27051-27060	responses	_
146-103	27061-27063	in	_
146-104	27064-27077	schizophrenia	_
146-105	27077-27078	:	_
146-106	27079-27082	the	_
146-107	27083-27087	role	_
146-108	27088-27090	of	_
146-109	27091-27100	intrinsic	_
146-110	27101-27107	neural	_
146-111	27108-27116	activity	_
146-112	27117-27127	Behavioral	_
146-113	27128-27136	response	_
146-114	27137-27147	inhibition	_
146-115	27148-27150	in	_
146-116	27151-27160	psychotic	_
146-117	27161-27170	disorders	_
146-118	27170-27171	:	_
146-119	27172-27182	Diagnostic	_
146-120	27183-27194	specificity	_
146-121	27194-27195	,	_
146-122	27196-27207	familiality	_
146-123	27208-27211	and	_
146-124	27212-27220	relation	_
146-125	27221-27223	to	_
146-126	27224-27235	generalized	_
146-127	27236-27245	cognitive	_
146-128	27246-27253	deficit	_
146-129	27255-27261	Neural	_
146-130	27262-27271	Processes	_
146-131	27272-27282	Associated	_
146-132	27283-27287	With	_
146-133	27288-27299	Antisaccade	_
146-134	27300-27304	Task	_
146-135	27305-27316	Performance	_
146-136	27317-27329	Investigated	_
146-137	27330-27334	With	_
146-138	27335-27348	Event-Related	_
146-139	27349-27353	fMRI	_
146-140	27354-27361	Primary	_
146-141	27362-27365	and	_
146-142	27366-27375	secondary	_
146-143	27376-27384	saccades	_
146-144	27385-27387	to	_
146-145	27388-27393	goals	_
146-146	27394-27401	defined	_
146-147	27402-27404	by	_
146-148	27405-27417	instructions	_
146-149	27418-27428	Diagnostic	_
146-150	27429-27440	specificity	_
146-151	27441-27444	and	_
146-152	27445-27456	familiality	_
146-153	27457-27459	of	_
146-154	27460-27465	early	_
146-155	27466-27472	versus	_
146-156	27473-27477	late	_
146-157	27478-27484	evoked	_
146-158	27485-27495	potentials	_
146-159	27496-27498	to	_
146-160	27499-27507	auditory	_
146-161	27508-27514	paired	_
146-162	27515-27522	stimuli	_
146-163	27523-27529	across	_
146-164	27530-27533	the	_
146-165	27534-27555	schizophrenia-bipolar	_
146-166	27556-27565	psychosis	_
146-167	27566-27574	spectrum	_
146-168	27575-27584	Intrinsic	_
146-169	27585-27591	neural	_
146-170	27592-27600	activity	_
146-171	27601-27612	differences	_
146-172	27613-27618	among	_
146-173	27619-27628	psychotic	_
146-174	27629-27638	illnesses	_
146-175	27639-27648	Glutamate	_
146-176	27649-27652	and	_
146-177	27653-27666	Schizophrenia	_
146-178	27666-27667	:	_
146-179	27668-27681	Phencyclidine	_
146-180	27681-27682	,	_
146-181	27683-27703	N-Methyl-d-Aspartate	_
146-182	27704-27713	Receptors	_
146-183	27713-27714	,	_
146-184	27715-27718	and	_
146-185	27719-27737	Dopamine–Glutamate	_
146-186	27738-27750	Interactions	_
146-187	27751-27757	Neural	_
146-188	27758-27766	Activity	_
146-189	27767-27769	in	_
146-190	27770-27776	Monkey	_
146-191	27777-27787	Prefrontal	_
146-192	27788-27794	Cortex	_
146-193	27795-27797	Is	_
146-194	27798-27807	Modulated	_
146-195	27808-27810	by	_
146-196	27811-27815	Task	_
146-197	27816-27823	Context	_
146-198	27824-27827	and	_
146-199	27828-27838	Behavioral	_
146-200	27839-27850	Instruction	_
146-201	27851-27857	during	_
146-202	27858-27881	Delayed-match-to-sample	_
146-203	27882-27885	and	_
146-204	27886-27897	Conditional	_
146-205	27898-27920	Prosaccade—Antisaccade	_
146-206	27921-27926	Tasks	_
146-207	27927-27938	Reimagining	_
146-208	27939-27948	psychoses	_
146-209	27948-27949	:	_
146-210	27950-27952	An	_
146-211	27953-27961	agnostic	_
146-212	27962-27970	approach	_
146-213	27971-27973	to	_
146-214	27974-27983	diagnosis	_
146-215	27984-27985	A	_
146-216	27986-27997	dimensional	_
146-217	27998-28006	approach	_
146-218	28007-28009	to	_
146-219	28010-28013	the	_
146-220	28014-28023	psychosis	_
146-221	28024-28032	spectrum	_
146-222	28033-28040	between	_
146-223	28041-28048	bipolar	_
146-224	28049-28057	disorder	_
146-225	28058-28061	and	_
146-226	28062-28075	schizophrenia	_
146-227	28075-28076	:	_
146-228	28077-28080	The	_
146-229	28081-28095	Schizo-Bipolar	_
146-230	28096-28101	Scale	_
146-231	28102-28108	Steady	_
146-232	28109-28114	state	_
146-233	28115-28121	visual	_
146-234	28122-28128	evoked	_
146-235	28129-28138	potential	_
146-236	28139-28152	abnormalities	_
146-237	28153-28155	in	_
146-238	28156-28169	schizophrenia	_
146-239	28170-28178	Synaptic	_
146-240	28179-28187	proteins	_
146-241	28188-28190	in	_
146-242	28191-28194	the	_
146-243	28195-28206	hippocampus	_
146-244	28207-28217	indicative	_
146-245	28218-28220	of	_
146-246	28221-28230	increased	_
146-247	28231-28239	neuronal	_
146-248	28240-28248	activity	_
146-249	28249-28251	in	_
146-250	28252-28255	CA3	_
146-251	28256-28258	in	_
146-252	28259-28272	schizophrenia	_
146-253	28273-28285	Significance	_
146-254	28286-28290	Test	_
146-255	28291-28294	for	_
146-256	28295-28305	Sphericity	_
146-257	28306-28308	of	_
146-258	28309-28310	a	_
146-259	28311-28317	Normal	_
146-260	28318-28327	n-Variate	_
146-261	28328-28340	Distribution	_
146-262	28341-28356	Neurophysiology	_
146-263	28357-28360	and	_
146-264	28361-28373	neuroanatomy	_
146-265	28374-28376	of	_
146-266	28377-28386	reflexive	_
146-267	28387-28390	and	_
146-268	28391-28401	volitional	_
146-269	28402-28410	saccades	_
146-270	28410-28411	:	_
146-271	28412-28420	Evidence	_
146-272	28421-28425	from	_
146-273	28426-28433	studies	_
146-274	28434-28436	of	_
146-275	28437-28443	humans	_
146-276	28444-28466	Electroencephalography	_
146-277	28466-28467	/	_
146-278	28467-28489	magnetoencephalography	_
146-279	28490-28495	study	_
146-280	28496-28498	of	_
146-281	28499-28507	cortical	_
146-282	28508-28518	activities	_
146-283	28519-28528	preceding	_
146-284	28529-28540	prosaccades	_
146-285	28541-28544	and	_
146-286	28545-28557	antisaccades	_
146-287	28558-28567	Measuring	_
146-288	28568-28577	liability	_
146-289	28578-28581	for	_
146-290	28582-28595	schizophrenia	_
146-291	28596-28601	using	_
146-292	28602-28611	optimized	_
146-293	28612-28623	antisaccade	_
146-294	28624-28632	stimulus	_
146-295	28633-28643	parameters	_
146-296	28644-28650	Neural	_
146-297	28651-28661	mechanisms	_
146-298	28662-28664	of	_
146-299	28665-28671	evoked	_
146-300	28672-28684	oscillations	_
146-301	28684-28685	:	_
146-302	28686-28695	stability	_
146-303	28696-28699	and	_
146-304	28700-28711	interaction	_
146-305	28712-28716	with	_
146-306	28717-28726	transient	_
146-307	28727-28733	events	_
146-308	28734-28738	Look	_
146-309	28739-28743	away	_
146-310	28743-28744	:	_
146-311	28745-28748	the	_
146-312	28749-28761	anti-saccade	_
146-313	28762-28766	task	_
146-314	28767-28770	and	_
146-315	28771-28774	the	_
146-316	28775-28784	voluntary	_
146-317	28785-28792	control	_
146-318	28793-28795	of	_
146-319	28796-28799	eye	_
146-320	28800-28808	movement	_
146-321	28809-28814	Human	_
146-322	28815-28823	Cerebral	_
146-323	28824-28834	Activation	_
146-324	28835-28841	during	_
146-325	28842-28854	Steady-State	_
146-326	28855-28868	Visual-Evoked	_
146-327	28869-28878	Responses	_
146-328	28879-28887	Elevated	_
146-329	28888-28899	antisaccade	_
146-330	28900-28905	error	_
146-331	28906-28910	rate	_
146-332	28911-28913	as	_
146-333	28914-28916	an	_
146-334	28917-28929	intermediate	_
146-335	28930-28939	phenotype	_
146-336	28940-28943	for	_
146-337	28944-28953	psychosis	_
146-338	28954-28960	across	_
146-339	28961-28971	diagnostic	_
146-340	28972-28982	categories	_
146-341	28983-28996	Computational	_
146-342	28997-29003	models	_
146-343	29004-29006	of	_
146-344	29007-29020	schizophrenia	_
146-345	29021-29024	and	_
146-346	29025-29033	dopamine	_
146-347	29034-29044	modulation	_
146-348	29045-29047	in	_
146-349	29048-29051	the	_
146-350	29052-29062	prefrontal	_
146-351	29063-29069	cortex	_
146-352	29070-29071	A	_
146-353	29072-29087	Pharmacological	_
146-354	29088-29093	Model	_
146-355	29094-29097	for	_
146-356	29098-29107	Psychosis	_
146-357	29108-29113	Based	_
146-358	29114-29116	on	_
146-359	29117-29137	N-methyl-D-aspartate	_
146-360	29138-29146	Receptor	_
146-361	29147-29159	Hypofunction	_
146-362	29159-29160	:	_
146-363	29161-29170	Molecular	_
146-364	29170-29171	,	_
146-365	29172-29180	Cellular	_
146-366	29180-29181	,	_
146-367	29182-29192	Functional	_
146-368	29193-29196	and	_
146-369	29197-29207	Behavioral	_
146-370	29208-29221	Abnormalities	_
146-371	29222-29228	Neural	_
146-372	29229-29238	synchrony	_
146-373	29239-29246	indexes	_
146-374	29247-29257	disordered	_
146-375	29258-29268	perception	_
146-376	29269-29272	and	_
146-377	29273-29282	cognition	_
146-378	29283-29285	in	_
146-379	29286-29299	schizophrenia	_
146-380	29300-29309	Attention	_
146-381	29310-29319	modulates	_
146-382	29320-29332	synchronized	_
146-383	29333-29341	neuronal	_
146-384	29342-29348	firing	_
146-385	29349-29351	in	_
146-386	29352-29359	primate	_
146-387	29360-29373	somatosensory	_
146-388	29374-29380	cortex	_
146-389	29381-29388	Central	_
146-390	29389-29395	versus	_
146-391	29396-29406	peripheral	_
146-392	29407-29413	visual	_
146-393	29414-29419	field	_
146-394	29420-29431	stimulation	_
146-395	29432-29439	results	_
146-396	29440-29442	in	_
146-397	29443-29449	timing	_
146-398	29450-29461	differences	_
146-399	29462-29464	in	_
146-400	29465-29471	dorsal	_
146-401	29472-29478	stream	_
146-402	29479-29486	sources	_
146-403	29487-29489	as	_
146-404	29490-29498	measured	_
146-405	29499-29503	with	_
146-406	29504-29507	MEG	_
146-407	29508-29516	Positron	_
146-408	29517-29525	emission	_
146-409	29526-29536	tomography	_
146-410	29537-29542	study	_
146-411	29543-29545	of	_
146-412	29546-29555	voluntary	_
146-413	29556-29564	saccadic	_
146-414	29565-29568	eye	_
146-415	29569-29578	movements	_
146-416	29579-29582	and	_
146-417	29583-29590	spatial	_
146-418	29591-29598	working	_
146-419	29599-29605	memory	_
146-420	29606-29614	Clinical	_
146-421	29615-29625	phenotypes	_
146-422	29626-29628	of	_
146-423	29629-29638	psychosis	_
146-424	29639-29641	in	_
146-425	29642-29645	the	_
146-426	29646-29667	Bipolar-Schizophrenia	_
146-427	29668-29675	Network	_
146-428	29676-29678	on	_
146-429	29679-29691	Intermediate	_
146-430	29692-29702	Phenotypes	_
146-431	29703-29704	(	_
146-432	29704-29710	B-SNIP	_
146-433	29710-29711	)	_
146-434	29712-29723	Projections	_
146-435	29724-29726	to	_
146-436	29727-29730	the	_
146-437	29731-29739	superior	_
146-438	29740-29748	temporal	_
146-439	29749-29755	sulcus	_
146-440	29756-29760	from	_
146-441	29761-29764	the	_
146-442	29765-29772	central	_
146-443	29773-29776	and	_
146-444	29777-29787	peripheral	_
146-445	29788-29793	field	_
146-446	29794-29809	representations	_
146-447	29810-29812	of	_
146-448	29813-29815	V1	_
146-449	29816-29819	and	_
146-450	29820-29822	V2	_
146-451	29823-29833	Diminished	_
146-452	29834-29842	parietal	_
146-453	29843-29849	cortex	_
146-454	29850-29858	activity	_
146-455	29859-29869	associated	_
146-456	29870-29874	with	_
146-457	29875-29879	poor	_
146-458	29880-29886	motion	_
146-459	29887-29896	direction	_
146-460	29897-29911	discrimination	_
146-461	29912-29923	performance	_
146-462	29924-29926	in	_
146-463	29927-29940	schizophrenia	_
146-464	29941-29944	The	_
146-465	29945-29951	neural	_
146-466	29952-29962	correlates	_
146-467	29963-29965	of	_
146-468	29966-29979	feature-based	_
146-469	29980-29989	selective	_
146-470	29990-29999	attention	_
146-471	30000-30004	when	_
146-472	30005-30012	viewing	_
146-473	30013-30022	spatially	_
146-474	30023-30026	and	_
146-475	30027-30037	temporally	_
146-476	30038-30049	overlapping	_
146-477	30050-30056	images	_
146-478	30057-30067	Prefrontal	_
146-479	30068-30077	Broadband	_
146-480	30078-30083	Noise	_
146-481	30083-30084	,	_
146-482	30085-30092	Working	_
146-483	30093-30099	Memory	_
146-484	30099-30100	,	_
146-485	30101-30104	and	_
146-486	30105-30112	Genetic	_
146-487	30113-30117	Risk	_
146-488	30118-30121	for	_
146-489	30122-30135	Schizophrenia	_
146-490	30136-30147	Instability	_
146-491	30148-30150	of	_
146-492	30151-30161	prefrontal	_
146-493	30162-30168	signal	_
146-494	30169-30179	processing	_
146-495	30180-30182	in	_
146-496	30183-30196	schizophrenia	_
146-497	30197-30202	Genes	_
146-498	30202-30203	,	_
146-499	30204-30212	dopamine	_
146-500	30213-30216	and	_
146-501	30217-30225	cortical	_
146-502	30226-30241	signal-to-noise	_
146-503	30242-30247	ratio	_
146-504	30248-30250	in	_
146-505	30251-30264	schizophrenia	_
146-506	30265-30278	Schizophrenia	_
146-507	30278-30279	:	_
146-508	30280-30287	reduced	_
146-509	30288-30303	signal-to-noise	_
146-510	30304-30309	ratio	_
146-511	30310-30313	and	_
146-512	30314-30322	impaired	_
146-513	30323-30336	phase-locking	_
146-514	30337-30343	during	_
146-515	30344-30355	information	_
146-516	30356-30366	processing	_
146-517	30367-30372	Kv3.1	_
146-518	30372-30373	-	_
146-519	30373-30383	containing	_
146-520	30384-30385	K	_
146-521	30385-30386	(	_
146-522	30386-30387	+	_
146-523	30387-30388	)	_
146-524	30389-30397	channels	_
146-525	30398-30401	are	_
146-526	30402-30409	reduced	_
146-527	30410-30412	in	_
146-528	30413-30422	untreated	_
146-529	30423-30436	schizophrenia	_
146-530	30437-30440	and	_
146-531	30441-30451	normalized	_
146-532	30452-30456	with	_
146-533	30457-30470	antipsychotic	_
146-534	30471-30476	drugs	_
146-535	30477-30484	Example	_
146-536	30485-30495	Prosaccade	_
146-537	30496-30501	Trial	_
146-538	30501-30502	.	_

#Text=During the antisaccade block, stimuli would be red rather than green.
147-1	30503-30509	During	_
147-2	30510-30513	the	_
147-3	30514-30525	antisaccade	_
147-4	30526-30531	block	_
147-5	30531-30532	,	_
147-6	30533-30540	stimuli	_
147-7	30541-30546	would	_
147-8	30547-30549	be	_
147-9	30550-30553	red	_
147-10	30554-30560	rather	_
147-11	30561-30565	than	_
147-12	30566-30571	green	_
147-13	30571-30572	.	_

#Text=Peripheral checkerboards flickered at 12 Hz (left) and 15 Hz (right), with the central checkerboard not flickering.
148-1	30573-30583	Peripheral	_
148-2	30584-30597	checkerboards	_
148-3	30598-30607	flickered	_
148-4	30608-30610	at	_
148-5	30611-30613	12	_
148-6	30614-30616	Hz	_
148-7	30617-30618	(	_
148-8	30618-30622	left	_
148-9	30622-30623	)	_
148-10	30624-30627	and	_
148-11	30628-30630	15	_
148-12	30631-30633	Hz	_
148-13	30634-30635	(	_
148-14	30635-30640	right	_
148-15	30640-30641	)	_
148-16	30641-30642	,	_
148-17	30643-30647	with	_
148-18	30648-30651	the	_
148-19	30652-30659	central	_
148-20	30660-30672	checkerboard	_
148-21	30673-30676	not	_
148-22	30677-30687	flickering	_
148-23	30687-30688	.	_

#Text=The frequency labels (white) are for visualization and were not present during the task.
149-1	30689-30692	The	_
149-2	30693-30702	frequency	_
149-3	30703-30709	labels	_
149-4	30710-30711	(	_
149-5	30711-30716	white	_
149-6	30716-30717	)	_
149-7	30718-30721	are	_
149-8	30722-30725	for	_
149-9	30726-30739	visualization	_
149-10	30740-30743	and	_
149-11	30744-30748	were	_
149-12	30749-30752	not	_
149-13	30753-30760	present	_
149-14	30761-30767	during	_
149-15	30768-30771	the	_
149-16	30772-30776	task	_
149-17	30776-30777	.	_

#Text=At each quarter of the Fixation Period (1500 ms), the central fixation square decreased in size by ¼ in order to provide a “countdown” to the next trial.
150-1	30778-30780	At	_
150-2	30781-30785	each	_
150-3	30786-30793	quarter	_
150-4	30794-30796	of	_
150-5	30797-30800	the	_
150-6	30801-30809	Fixation	_
150-7	30810-30816	Period	_
150-8	30817-30818	(	_
150-9	30818-30822	1500	_
150-10	30823-30825	ms	_
150-11	30825-30826	)	_
150-12	30826-30827	,	_
150-13	30828-30831	the	_
150-14	30832-30839	central	_
150-15	30840-30848	fixation	_
150-16	30849-30855	square	_
150-17	30856-30865	decreased	_
150-18	30866-30868	in	_
150-19	30869-30873	size	_
150-20	30874-30876	by	_
150-21	30877-30878	¼	_
150-22	30879-30881	in	_
150-23	30882-30887	order	_
150-24	30888-30890	to	_
150-25	30891-30898	provide	_
150-26	30899-30900	a	_
150-27	30901-30902	“	_
150-28	30902-30911	countdown	_
150-29	30911-30912	”	_
150-30	30913-30915	to	_
150-31	30916-30919	the	_
150-32	30920-30924	next	_
150-33	30925-30930	trial	_
150-34	30930-30931	.	_

#Text=Similarly, at 1000 ms intervals during the Preparatory Period, the central square of the central checkerboard decreased in size by ¼ in order to provide the participants information about the impending response requirement.
151-1	30932-30941	Similarly	_
151-2	30941-30942	,	_
151-3	30943-30945	at	_
151-4	30946-30950	1000	_
151-5	30951-30953	ms	_
151-6	30954-30963	intervals	_
151-7	30964-30970	during	_
151-8	30971-30974	the	_
151-9	30975-30986	Preparatory	_
151-10	30987-30993	Period	_
151-11	30993-30994	,	_
151-12	30995-30998	the	_
151-13	30999-31006	central	_
151-14	31007-31013	square	_
151-15	31014-31016	of	_
151-16	31017-31020	the	_
151-17	31021-31028	central	_
151-18	31029-31041	checkerboard	_
151-19	31042-31051	decreased	_
151-20	31052-31054	in	_
151-21	31055-31059	size	_
151-22	31060-31062	by	_
151-23	31063-31064	¼	_
151-24	31065-31067	in	_
151-25	31068-31073	order	_
151-26	31074-31076	to	_
151-27	31077-31084	provide	_
151-28	31085-31088	the	_
151-29	31089-31101	participants	_
151-30	31102-31113	information	_
151-31	31114-31119	about	_
151-32	31120-31123	the	_
151-33	31124-31133	impending	_
151-34	31134-31142	response	_
151-35	31143-31154	requirement	_
151-36	31154-31155	.	_

#Text=After the 5 sec Preparatory Period, one of the peripheral checkerboards (pseudo-randomly determined) increased in luminance for 1.25 sec (the saccadic response period), while both peripheral checkerboards continued flickering.
152-1	31156-31161	After	_
152-2	31162-31165	the	_
152-3	31166-31167	5	_
152-4	31168-31171	sec	_
152-5	31172-31183	Preparatory	_
152-6	31184-31190	Period	_
152-7	31190-31191	,	_
152-8	31192-31195	one	_
152-9	31196-31198	of	_
152-10	31199-31202	the	_
152-11	31203-31213	peripheral	_
152-12	31214-31227	checkerboards	_
152-13	31228-31229	(	_
152-14	31229-31244	pseudo-randomly	_
152-15	31245-31255	determined	_
152-16	31255-31256	)	_
152-17	31257-31266	increased	_
152-18	31267-31269	in	_
152-19	31270-31279	luminance	_
152-20	31280-31283	for	_
152-21	31284-31288	1.25	_
152-22	31289-31292	sec	_
152-23	31293-31294	(	_
152-24	31294-31297	the	_
152-25	31298-31306	saccadic	_
152-26	31307-31315	response	_
152-27	31316-31322	period	_
152-28	31322-31323	)	_
152-29	31323-31324	,	_
152-30	31325-31330	while	_
152-31	31331-31335	both	_
152-32	31336-31346	peripheral	_
152-33	31347-31360	checkerboards	_
152-34	31361-31370	continued	_
152-35	31371-31381	flickering	_
152-36	31381-31382	.	_

#Text=On prosaccade trials, participants were to look as quickly and accurately as possible toward this target; on antisaccade trials, participants were instructed to look as quickly and accurately as possible to the mirror image location (opposite peripheral checkerboard).
153-1	31383-31385	On	_
153-2	31386-31396	prosaccade	_
153-3	31397-31403	trials	_
153-4	31403-31404	,	_
153-5	31405-31417	participants	_
153-6	31418-31422	were	_
153-7	31423-31425	to	_
153-8	31426-31430	look	_
153-9	31431-31433	as	_
153-10	31434-31441	quickly	_
153-11	31442-31445	and	_
153-12	31446-31456	accurately	_
153-13	31457-31459	as	_
153-14	31460-31468	possible	_
153-15	31469-31475	toward	_
153-16	31476-31480	this	_
153-17	31481-31487	target	_
153-18	31487-31488	;	_
153-19	31489-31491	on	_
153-20	31492-31503	antisaccade	_
153-21	31504-31510	trials	_
153-22	31510-31511	,	_
153-23	31512-31524	participants	_
153-24	31525-31529	were	_
153-25	31530-31540	instructed	_
153-26	31541-31543	to	_
153-27	31544-31548	look	_
153-28	31549-31551	as	_
153-29	31552-31559	quickly	_
153-30	31560-31563	and	_
153-31	31564-31574	accurately	_
153-32	31575-31577	as	_
153-33	31578-31586	possible	_
153-34	31587-31589	to	_
153-35	31590-31593	the	_
153-36	31594-31600	mirror	_
153-37	31601-31606	image	_
153-38	31607-31615	location	_
153-39	31616-31617	(	_
153-40	31617-31625	opposite	_
153-41	31626-31636	peripheral	_
153-42	31637-31649	checkerboard	_
153-43	31649-31650	)	_
153-44	31650-31651	.	_

#Text=All analyses are time-locked to the onset of the Preparatory Period.
154-1	31652-31655	All	_
154-2	31656-31664	analyses	_
154-3	31665-31668	are	_
154-4	31669-31680	time-locked	_
154-5	31681-31683	to	_
154-6	31684-31687	the	_
154-7	31688-31693	onset	_
154-8	31694-31696	of	_
154-9	31697-31700	the	_
154-10	31701-31712	Preparatory	_
154-11	31713-31719	Period	_
154-12	31719-31720	.	_

#Text=The Response Period was used solely to assess behavior; no brain data from this period are included in the analyses.
155-1	31721-31724	The	_
155-2	31725-31733	Response	_
155-3	31734-31740	Period	_
155-4	31741-31744	was	_
155-5	31745-31749	used	_
155-6	31750-31756	solely	_
155-7	31757-31759	to	_
155-8	31760-31766	assess	_
155-9	31767-31775	behavior	_
155-10	31775-31776	;	_
155-11	31777-31779	no	_
155-12	31780-31785	brain	_
155-13	31786-31790	data	_
155-14	31791-31795	from	_
155-15	31796-31800	this	_
155-16	31801-31807	period	_
155-17	31808-31811	are	_
155-18	31812-31820	included	_
155-19	31821-31823	in	_
155-20	31824-31827	the	_
155-21	31828-31836	analyses	_
155-22	31836-31837	.	_

#Text=Evoked Potentials to the Onset of the Preparatory Period.
156-1	31838-31844	Evoked	_
156-2	31845-31855	Potentials	_
156-3	31856-31858	to	_
156-4	31859-31862	the	_
156-5	31863-31868	Onset	_
156-6	31869-31871	of	_
156-7	31872-31875	the	_
156-8	31876-31887	Preparatory	_
156-9	31888-31894	Period	_
156-10	31894-31895	.	_

#Text=For each participant, EEG data from 250ms before to 500 ms after the onset of the Preparatory Period were averaged across trials and baseline-subtracted using the average of −250:0 ms.
157-1	31896-31899	For	_
157-2	31900-31904	each	_
157-3	31905-31916	participant	_
157-4	31916-31917	,	_
157-5	31918-31921	EEG	_
157-6	31922-31926	data	_
157-7	31927-31931	from	_
157-8	31932-31937	250ms	_
157-9	31938-31944	before	_
157-10	31945-31947	to	_
157-11	31948-31951	500	_
157-12	31952-31954	ms	_
157-13	31955-31960	after	_
157-14	31961-31964	the	_
157-15	31965-31970	onset	_
157-16	31971-31973	of	_
157-17	31974-31977	the	_
157-18	31978-31989	Preparatory	_
157-19	31990-31996	Period	_
157-20	31997-32001	were	_
157-21	32002-32010	averaged	_
157-22	32011-32017	across	_
157-23	32018-32024	trials	_
157-24	32025-32028	and	_
157-25	32029-32048	baseline-subtracted	_
157-26	32049-32054	using	_
157-27	32055-32058	the	_
157-28	32059-32066	average	_
157-29	32067-32069	of	_
157-30	32070-32071	−	_
157-31	32071-32074	250	_
157-32	32074-32075	:	_
157-33	32075-32076	0	_
157-34	32077-32079	ms	_
157-35	32079-32080	.	_

#Text=Global field power (GFP; the root mean square of voltage over all sensors at each time point) was calculated for each participant and task.
158-1	32081-32087	Global	_
158-2	32088-32093	field	_
158-3	32094-32099	power	_
158-4	32100-32101	(	_
158-5	32101-32104	GFP	_
158-6	32104-32105	;	_
158-7	32106-32109	the	_
158-8	32110-32114	root	_
158-9	32115-32119	mean	_
158-10	32120-32126	square	_
158-11	32127-32129	of	_
158-12	32130-32137	voltage	_
158-13	32138-32142	over	_
158-14	32143-32146	all	_
158-15	32147-32154	sensors	_
158-16	32155-32157	at	_
158-17	32158-32162	each	_
158-18	32163-32167	time	_
158-19	32168-32173	point	_
158-20	32173-32174	)	_
158-21	32175-32178	was	_
158-22	32179-32189	calculated	_
158-23	32190-32193	for	_
158-24	32194-32198	each	_
158-25	32199-32210	participant	_
158-26	32211-32214	and	_
158-27	32215-32219	task	_
158-28	32219-32220	.	_

#Text=Waveforms were averaged into 10 ms bins and analyzed using a 2-way ANOVA (Group × Saccade Type) at each time bin.
159-1	32221-32230	Waveforms	_
159-2	32231-32235	were	_
159-3	32236-32244	averaged	_
159-4	32245-32249	into	_
159-5	32250-32252	10	_
159-6	32253-32255	ms	_
159-7	32256-32260	bins	_
159-8	32261-32264	and	_
159-9	32265-32273	analyzed	_
159-10	32274-32279	using	_
159-11	32280-32281	a	_
159-12	32282-32283	2	_
159-13	32283-32284	-	_
159-14	32284-32287	way	_
159-15	32288-32293	ANOVA	_
159-16	32294-32295	(	_
159-17	32295-32300	Group	_
159-18	32301-32302	×	_
159-19	32303-32310	Saccade	_
159-20	32311-32315	Type	_
159-21	32315-32316	)	_
159-22	32317-32319	at	_
159-23	32320-32324	each	_
159-24	32325-32329	time	_
159-25	32330-32333	bin	_
159-26	32333-32334	.	_

#Text=To control for increased family-wise error rate due to multiple comparisons, a clustering method (Forman et al., 1995) was used to take account of the non-independence of data from adjacent time bins (for examples, see Hamm et al. 2012; Hudgens-Haney et al., 2013; and Monte Carlo simulations, Cox, 1996).
160-1	32335-32337	To	_
160-2	32338-32345	control	_
160-3	32346-32349	for	_
160-4	32350-32359	increased	_
160-5	32360-32371	family-wise	_
160-6	32372-32377	error	_
160-7	32378-32382	rate	_
160-8	32383-32386	due	_
160-9	32387-32389	to	_
160-10	32390-32398	multiple	_
160-11	32399-32410	comparisons	_
160-12	32410-32411	,	_
160-13	32412-32413	a	_
160-14	32414-32424	clustering	_
160-15	32425-32431	method	_
160-16	32432-32433	(	_
160-17	32433-32439	Forman	_
160-18	32440-32442	et	_
160-19	32443-32445	al	_
160-20	32445-32446	.	_
160-21	32446-32447	,	_
160-22	32448-32452	1995	_
160-23	32452-32453	)	_
160-24	32454-32457	was	_
160-25	32458-32462	used	_
160-26	32463-32465	to	_
160-27	32466-32470	take	_
160-28	32471-32478	account	_
160-29	32479-32481	of	_
160-30	32482-32485	the	_
160-31	32486-32502	non-independence	_
160-32	32503-32505	of	_
160-33	32506-32510	data	_
160-34	32511-32515	from	_
160-35	32516-32524	adjacent	_
160-36	32525-32529	time	_
160-37	32530-32534	bins	_
160-38	32535-32536	(	_
160-39	32536-32539	for	_
160-40	32540-32548	examples	_
160-41	32548-32549	,	_
160-42	32550-32553	see	_
160-43	32554-32558	Hamm	_
160-44	32559-32561	et	_
160-45	32562-32564	al	_
160-46	32564-32565	.	_
160-47	32566-32570	2012	_
160-48	32570-32571	;	_
160-49	32572-32585	Hudgens-Haney	_
160-50	32586-32588	et	_
160-51	32589-32591	al	_
160-52	32591-32592	.	_
160-53	32592-32593	,	_
160-54	32594-32598	2013	_
160-55	32598-32599	;	_
160-56	32600-32603	and	_
160-57	32604-32609	Monte	_
160-58	32610-32615	Carlo	_
160-59	32616-32627	simulations	_
160-60	32627-32628	,	_
160-61	32629-32632	Cox	_
160-62	32632-32633	,	_
160-63	32634-32638	1996	_
160-64	32638-32639	)	_
160-65	32639-32640	.	_

#Text=Time bin “clusters” were considered significant at overall family-wise α < .01 if at least three adjacent time bins were significant at p < .05.
161-1	32641-32645	Time	_
161-2	32646-32649	bin	_
161-3	32650-32651	“	_
161-4	32651-32659	clusters	_
161-5	32659-32660	”	_
161-6	32661-32665	were	_
161-7	32666-32676	considered	_
161-8	32677-32688	significant	_
161-9	32689-32691	at	_
161-10	32692-32699	overall	_
161-11	32700-32711	family-wise	_
161-12	32712-32713	α	_
161-13	32714-32715	<	_
161-14	32716-32719	.01	_
161-15	32720-32722	if	_
161-16	32723-32725	at	_
161-17	32726-32731	least	_
161-18	32732-32737	three	_
161-19	32738-32746	adjacent	_
161-20	32747-32751	time	_
161-21	32752-32756	bins	_
161-22	32757-32761	were	_
161-23	32762-32773	significant	_
161-24	32774-32776	at	_
161-25	32777-32778	p	_
161-26	32779-32780	<	_
161-27	32781-32784	.05	_
161-28	32784-32785	.	_

#Text=Surviving time bin clusters were subjected to planned post hoc t-tests.
162-1	32786-32795	Surviving	_
162-2	32796-32800	time	_
162-3	32801-32804	bin	_
162-4	32805-32813	clusters	_
162-5	32814-32818	were	_
162-6	32819-32828	subjected	_
162-7	32829-32831	to	_
162-8	32832-32839	planned	_
162-9	32840-32844	post	_
162-10	32845-32848	hoc	_
162-11	32849-32856	t-tests	_
162-12	32856-32857	.	_

#Text=(A) The colored top-down topographies are grand average voltage maps (μV) from the three time bin clusters at which a significant Main Effect of Group was found.
163-1	32858-32859	(	_
163-2	32859-32860	A	_
163-3	32860-32861	)	_
163-4	32862-32865	The	_
163-5	32866-32873	colored	_
163-6	32874-32882	top-down	_
163-7	32883-32895	topographies	_
163-8	32896-32899	are	_
163-9	32900-32905	grand	_
163-10	32906-32913	average	_
163-11	32914-32921	voltage	_
163-12	32922-32926	maps	_
163-13	32927-32928	(	_
163-14	32928-32930	μV	_
163-15	32930-32931	)	_
163-16	32932-32936	from	_
163-17	32937-32940	the	_
163-18	32941-32946	three	_
163-19	32947-32951	time	_
163-20	32952-32955	bin	_
163-21	32956-32964	clusters	_
163-22	32965-32967	at	_
163-23	32968-32973	which	_
163-24	32974-32975	a	_
163-25	32976-32987	significant	_
163-26	32988-32992	Main	_
163-27	32993-32999	Effect	_
163-28	33000-33002	of	_
163-29	33003-33008	Group	_
163-30	33009-33012	was	_
163-31	33013-33018	found	_
163-32	33018-33019	.	_

#Text=(B) The topographies are voltage maps for Biotype-2 from pro- and anti-saccade trials during the time bin cluster at which a significant Group × Task Interaction was found.
164-1	33020-33021	(	_
164-2	33021-33022	B	_
164-3	33022-33023	)	_
164-4	33024-33027	The	_
164-5	33028-33040	topographies	_
164-6	33041-33044	are	_
164-7	33045-33052	voltage	_
164-8	33053-33057	maps	_
164-9	33058-33061	for	_
164-10	33062-33069	Biotype	_
164-11	33069-33070	-	_
164-12	33070-33071	2	_
164-13	33072-33076	from	_
164-14	33077-33080	pro	_
164-15	33080-33081	-	_
164-16	33082-33085	and	_
164-17	33086-33098	anti-saccade	_
164-18	33099-33105	trials	_
164-19	33106-33112	during	_
164-20	33113-33116	the	_
164-21	33117-33121	time	_
164-22	33122-33125	bin	_
164-23	33126-33133	cluster	_
164-24	33134-33136	at	_
164-25	33137-33142	which	_
164-26	33143-33144	a	_
164-27	33145-33156	significant	_
164-28	33157-33162	Group	_
164-29	33163-33164	×	_
164-30	33165-33169	Task	_
164-31	33170-33181	Interaction	_
164-32	33182-33185	was	_
164-33	33186-33191	found	_
164-34	33191-33192	.	_

#Text=*p<.05
#Text=Single-Trial Oscillatory Power.
165-1	33193-33194	*	_
165-2	33194-33195	p	_
165-3	33195-33196	<	_
165-4	33196-33199	.05	_
165-5	33200-33212	Single-Trial	_
165-6	33213-33224	Oscillatory	_
165-7	33225-33230	Power	_
165-8	33230-33231	.	_

#Text=Top-down topographies of oscillatory power averaged over the steady-state driving frequencies (12 & 15Hz) for intrinsic activity (power averaged from −500ms to 5000ms in relation to stimulus onset; left) and stimulus-specific (i.e., baseline-subtracted) power (right).
166-1	33232-33240	Top-down	_
166-2	33241-33253	topographies	_
166-3	33254-33256	of	_
166-4	33257-33268	oscillatory	_
166-5	33269-33274	power	_
166-6	33275-33283	averaged	_
166-7	33284-33288	over	_
166-8	33289-33292	the	_
166-9	33293-33305	steady-state	_
166-10	33306-33313	driving	_
166-11	33314-33325	frequencies	_
166-12	33326-33327	(	_
166-13	33327-33329	12	_
166-14	33330-33331	&	_
166-15	33332-33336	15Hz	_
166-16	33336-33337	)	_
166-17	33338-33341	for	_
166-18	33342-33351	intrinsic	_
166-19	33352-33360	activity	_
166-20	33361-33362	(	_
166-21	33362-33367	power	_
166-22	33368-33376	averaged	_
166-23	33377-33381	from	_
166-24	33382-33383	−	_
166-25	33383-33388	500ms	_
166-26	33389-33391	to	_
166-27	33392-33398	5000ms	_
166-28	33399-33401	in	_
166-29	33402-33410	relation	_
166-30	33411-33413	to	_
166-31	33414-33422	stimulus	_
166-32	33423-33428	onset	_
166-33	33428-33429	;	_
166-34	33430-33434	left	_
166-35	33434-33435	)	_
166-36	33436-33439	and	_
166-37	33440-33457	stimulus-specific	_
166-38	33458-33459	(	_
166-39	33459-33462	i.e	_
166-40	33462-33463	.	_
166-41	33463-33464	,	_
166-42	33465-33484	baseline-subtracted	_
166-43	33484-33485	)	_
166-44	33486-33491	power	_
166-45	33492-33493	(	_
166-46	33493-33498	right	_
166-47	33498-33499	)	_
166-48	33499-33500	.	_

#Text=Bar plots represent PCA-weighted power (see Supplemental Figure 2).
167-1	33501-33504	Bar	_
167-2	33505-33510	plots	_
167-3	33511-33520	represent	_
167-4	33521-33533	PCA-weighted	_
167-5	33534-33539	power	_
167-6	33540-33541	(	_
167-7	33541-33544	see	_
167-8	33545-33557	Supplemental	_
167-9	33558-33564	Figure	_
167-10	33565-33566	2	_
167-11	33566-33567	)	_
167-12	33567-33568	.	_

#Text=Error bars indicate standard error of the mean.
168-1	33569-33574	Error	_
168-2	33575-33579	bars	_
168-3	33580-33588	indicate	_
168-4	33589-33597	standard	_
168-5	33598-33603	error	_
168-6	33604-33606	of	_
168-7	33607-33610	the	_
168-8	33611-33615	mean	_
168-9	33615-33616	.	_

#Text=For intrinsic activity (PCA-weighted power averaged from −500:5000 ms) on the left, a 2-way ANOVA (Group × Saccade Type) was calculated, with post hoc Tukey honestly significant difference tests on the estimated marginal means.
169-1	33617-33620	For	_
169-2	33621-33630	intrinsic	_
169-3	33631-33639	activity	_
169-4	33640-33641	(	_
169-5	33641-33653	PCA-weighted	_
169-6	33654-33659	power	_
169-7	33660-33668	averaged	_
169-8	33669-33673	from	_
169-9	33674-33675	−	_
169-10	33675-33678	500	_
169-11	33678-33679	:	_
169-12	33679-33683	5000	_
169-13	33684-33686	ms	_
169-14	33686-33687	)	_
169-15	33688-33690	on	_
169-16	33691-33694	the	_
169-17	33695-33699	left	_
169-18	33699-33700	,	_
169-19	33701-33702	a	_
169-20	33703-33704	2	_
169-21	33704-33705	-	_
169-22	33705-33708	way	_
169-23	33709-33714	ANOVA	_
169-24	33715-33716	(	_
169-25	33716-33721	Group	_
169-26	33722-33723	×	_
169-27	33724-33731	Saccade	_
169-28	33732-33736	Type	_
169-29	33736-33737	)	_
169-30	33738-33741	was	_
169-31	33742-33752	calculated	_
169-32	33752-33753	,	_
169-33	33754-33758	with	_
169-34	33759-33763	post	_
169-35	33764-33767	hoc	_
169-36	33768-33773	Tukey	_
169-37	33774-33782	honestly	_
169-38	33783-33794	significant	_
169-39	33795-33805	difference	_
169-40	33806-33811	tests	_
169-41	33812-33814	on	_
169-42	33815-33818	the	_
169-43	33819-33828	estimated	_
169-44	33829-33837	marginal	_
169-45	33838-33843	means	_
169-46	33843-33844	.	_

#Text=For task-specific desynchronization (i.e., baseline-corrected PCA-weighted power) on the right, a mixed effects 3-way MANOVA (Group × Saccade Type × Time Bin) was calculated, with post hoc Tukey honestly significant difference tests on the estimated marginal means.
170-1	33845-33848	For	_
170-2	33849-33862	task-specific	_
170-3	33863-33880	desynchronization	_
170-4	33881-33882	(	_
170-5	33882-33885	i.e	_
170-6	33885-33886	.	_
170-7	33886-33887	,	_
170-8	33888-33906	baseline-corrected	_
170-9	33907-33919	PCA-weighted	_
170-10	33920-33925	power	_
170-11	33925-33926	)	_
170-12	33927-33929	on	_
170-13	33930-33933	the	_
170-14	33934-33939	right	_
170-15	33939-33940	,	_
170-16	33941-33942	a	_
170-17	33943-33948	mixed	_
170-18	33949-33956	effects	_
170-19	33957-33958	3	_
170-20	33958-33959	-	_
170-21	33959-33962	way	_
170-22	33963-33969	MANOVA	_
170-23	33970-33971	(	_
170-24	33971-33976	Group	_
170-25	33977-33978	×	_
170-26	33979-33986	Saccade	_
170-27	33987-33991	Type	_
170-28	33992-33993	×	_
170-29	33994-33998	Time	_
170-30	33999-34002	Bin	_
170-31	34002-34003	)	_
170-32	34004-34007	was	_
170-33	34008-34018	calculated	_
170-34	34018-34019	,	_
170-35	34020-34024	with	_
170-36	34025-34029	post	_
170-37	34030-34033	hoc	_
170-38	34034-34039	Tukey	_
170-39	34040-34048	honestly	_
170-40	34049-34060	significant	_
170-41	34061-34071	difference	_
170-42	34072-34077	tests	_
170-43	34078-34080	on	_
170-44	34081-34084	the	_
170-45	34085-34094	estimated	_
170-46	34095-34103	marginal	_
170-47	34104-34109	means	_
170-48	34109-34110	.	_

#Text=*p<.05, **p<.01
#Text=Inter-Trial Phase Coherence.
171-1	34111-34112	*	_
171-2	34112-34113	p	_
171-3	34113-34114	<	_
171-4	34114-34117	.05	_
171-5	34117-34118	,	_
171-6	34119-34120	*	_
171-7	34120-34121	*	_
171-8	34121-34122	p	_
171-9	34122-34123	<	_
171-10	34123-34126	.01	_
171-11	34127-34138	Inter-Trial	_
171-12	34139-34144	Phase	_
171-13	34145-34154	Coherence	_
171-14	34154-34155	.	_

#Text=Inter-Trial Phase Coherence (ITC) averaged over the steady-state driving frequencies (12 and 15Hz).
172-1	34156-34167	Inter-Trial	_
172-2	34168-34173	Phase	_
172-3	34174-34183	Coherence	_
172-4	34184-34185	(	_
172-5	34185-34188	ITC	_
172-6	34188-34189	)	_
172-7	34190-34198	averaged	_
172-8	34199-34203	over	_
172-9	34204-34207	the	_
172-10	34208-34220	steady-state	_
172-11	34221-34228	driving	_
172-12	34229-34240	frequencies	_
172-13	34241-34242	(	_
172-14	34242-34244	12	_
172-15	34245-34248	and	_
172-16	34249-34253	15Hz	_
172-17	34253-34254	)	_
172-18	34254-34255	.	_

#Text=Bar plots represent ITC over visual cortex.
173-1	34256-34259	Bar	_
173-2	34260-34265	plots	_
173-3	34266-34275	represent	_
173-4	34276-34279	ITC	_
173-5	34280-34284	over	_
173-6	34285-34291	visual	_
173-7	34292-34298	cortex	_
173-8	34298-34299	.	_

#Text=For all groups, baseline ITC is significantly lower than all later time bins, though this is not indicated in the figure.
174-1	34300-34303	For	_
174-2	34304-34307	all	_
174-3	34308-34314	groups	_
174-4	34314-34315	,	_
174-5	34316-34324	baseline	_
174-6	34325-34328	ITC	_
174-7	34329-34331	is	_
174-8	34332-34345	significantly	_
174-9	34346-34351	lower	_
174-10	34352-34356	than	_
174-11	34357-34360	all	_
174-12	34361-34366	later	_
174-13	34367-34371	time	_
174-14	34372-34376	bins	_
174-15	34376-34377	,	_
174-16	34378-34384	though	_
174-17	34385-34389	this	_
174-18	34390-34392	is	_
174-19	34393-34396	not	_
174-20	34397-34406	indicated	_
174-21	34407-34409	in	_
174-22	34410-34413	the	_
174-23	34414-34420	figure	_
174-24	34420-34421	.	_

#Text=Error bars indicate standard error of the mean.
175-1	34422-34427	Error	_
175-2	34428-34432	bars	_
175-3	34433-34441	indicate	_
175-4	34442-34450	standard	_
175-5	34451-34456	error	_
175-6	34457-34459	of	_
175-7	34460-34463	the	_
175-8	34464-34468	mean	_
175-9	34468-34469	.	_

#Text=A mixed effects 3-way MANOVA (Group × Saccade Type × Time Bin) was calculated, with post hoc Tukey honestly significant difference tests on the estimated marginal means.
176-1	34470-34471	A	_
176-2	34472-34477	mixed	_
176-3	34478-34485	effects	_
176-4	34486-34487	3	_
176-5	34487-34488	-	_
176-6	34488-34491	way	_
176-7	34492-34498	MANOVA	_
176-8	34499-34500	(	_
176-9	34500-34505	Group	_
176-10	34506-34507	×	_
176-11	34508-34515	Saccade	_
176-12	34516-34520	Type	_
176-13	34521-34522	×	_
176-14	34523-34527	Time	_
176-15	34528-34531	Bin	_
176-16	34531-34532	)	_
176-17	34533-34536	was	_
176-18	34537-34547	calculated	_
176-19	34547-34548	,	_
176-20	34549-34553	with	_
176-21	34554-34558	post	_
176-22	34559-34562	hoc	_
176-23	34563-34568	Tukey	_
176-24	34569-34577	honestly	_
176-25	34578-34589	significant	_
176-26	34590-34600	difference	_
176-27	34601-34606	tests	_
176-28	34607-34609	on	_
176-29	34610-34613	the	_
176-30	34614-34623	estimated	_
176-31	34624-34632	marginal	_
176-32	34633-34638	means	_
176-33	34638-34639	.	_

#Text=*p<.05, **p<.01, ***p<.005
#Text=Demographic and Clinical Characteristics of Healthy Comparison Subjects and Probands as a Function of Biotype
#Text=Percent Female\tHealthy (N=50)\tBiotype-1 (N=20)\tBiotype-2 (N=30)\tBiotype-3 (N=55)\tSignificance Test\t \t56\t70\t53\t44\tχ2(3)=4.44, p=.22\t \tMean\tSD\tMean\tSD\tMean\tSD\tMean\tSD\t\t \t Age\t37.9\t12.2\t31.8\t13.9\t32.3\t12.2\t35.5\t13.4\tF(3,151)=1.75, p=.16\t \t\t \t Trials accepted\t \tProsaccades\t47.6\t4.4\t48.2\t2.7\t48.1\t2.8\t47.3\t3.5\tF(3,151)=0.43, p=.73\t \tAntisaccades\t48.0\t3.4\t48.2\t2.5\t48.1\t2.7\t47.1\t5.5\tF(3,151)=0.74, p=.53\t \t\t \t Percent Correct\t \t  Prosaccades\t97.2\t3.2\t94.1\t6.0\t94.6\t6.1\t95.8\t4.5\tF(3,151)=3.0, p=.03\t \t  Antisaccades\t90.7\t6.3\t77.4\t12.2\t86.1\t11.7\t83.6\t11.1\tF(3,151)=9.30, p=.00001\t \t\t \t Response Latency (ms)a\t \t  Correct Prosaccades\t376.7\t55.0\t379.8\t85.4\t365.3\t76.9\t366.3\t70.8\tF(3,151)=0.37, p=.78\t \t  Correct Antisaccades\t415.1\t73.5\t455.7\t103.5\t437.4\t91.2\t428.6\t84.0\tF(3,151)=1.20, p=.31\t \t  Incorrect Antisaccades\t352.2\t102.9\t331.3\t75.0\t350.4\t132.1\t361.2\t89.0\tF(3,145)=0.42, p=.74\t \t\t \t GAFb\t84.56\t5.4\t43.6\t8.2\t49.5\t11.3\t53.7\t13.7\tF(2,102)=5.26, p=.007\t \t\t \t BACS\t−0.05\t1.2\t−2.6\t0.7\t−1.8\t1.0\t−0.3\t0.8\tF(2,99)=65.3, p=8E-19\t \t\t \t Birchwood Social Functioning Scale\t163.0\t18.9\t126.6\t23.8\t130.1\t18.8\t133.7\t23.2\tF(2,77)=0.59, p=.56\t \t\t \t PANSS-positive\t–\t–\t19.0\t7.8\t15.6\t4.8\t15.7\t5.0\tF(2,101)=2.84, p=.06\t \t\t \t PANSS-negative\t–\t–\t20.3\t7.8\t15.3\t5.3\t15.7\t6.0\tF(2,101)=4.53, p=.01\t \t\t \t PANSS-general\t–\t–\t38.3\t10.4\t33.4\t7.8\t34.3\t8.0\tF(2,101)=2.19, p=.12\t \t\t \t MADRS\t–\t–\t14.8\t9.4\t10.4\t8.6\t10.1\t8.5\tF(2,101)=2.25, p=.11\t \t\t \t Young Mania Scale\t–\t–\t7.3\t6.5\t5.9\t5.2\t6.3\t6.6\tF(2,102)=0.28, p=.75\t \t\t \t Medication Class\t \t  Antipsychotic first generation\t0.0%\t15.0%\t10.0%\t5.5%\tχ2(2)=1.82, p=.40\t \t  Antipsychotic second generation\t0.0%\t75.0%\t73.3%\t61.8%\tχ2(2)=1.79, p=.41\t \t  Mood stabilizer\t0.0%\t50.0%\t46.7%\t47.3%\tχ2(2)=0.06, p=.97\t \t  Lithium\t0.0%\t5.0%\t20.0%\t16.4%\tχ2(2)=2.20, p=.33\t \t  Antidepressant\t2.0%\t45.0%\t40.0%\t43.6%\tχ2(2)=0.15, p=.93\t \t  Sedative/anxiolytic\t2.0%\t30.0%\t23.3%\t25.5%\tχ2(2)=0.28, p=.87\t \t  Stimulant\t0.0%\t5.0%\t3.3%\t14.5%\tχ2(2)=3.42, p=.18\t \t  Anticholinergic\t0.0%\t10.0%\t6.7%\t7.3%\tχ2(2)=0.21, p=.90\t \t
#Text=GAF, Global Assessment of Functioning; PANSS, Positive and Negative Symptom Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; BACS, Brief Assessment of Cognition in Schizophrenia.
177-1	34640-34641	*	_
177-2	34641-34642	p	_
177-3	34642-34643	<	_
177-4	34643-34646	.05	_
177-5	34646-34647	,	_
177-6	34648-34649	*	_
177-7	34649-34650	*	_
177-8	34650-34651	p	_
177-9	34651-34652	<	_
177-10	34652-34655	.01	_
177-11	34655-34656	,	_
177-12	34657-34658	*	_
177-13	34658-34659	*	_
177-14	34659-34660	*	_
177-15	34660-34661	p	_
177-16	34661-34662	<	_
177-17	34662-34666	.005	_
177-18	34667-34678	Demographic	_
177-19	34679-34682	and	_
177-20	34683-34691	Clinical	_
177-21	34692-34707	Characteristics	_
177-22	34708-34710	of	_
177-23	34711-34718	Healthy	_
177-24	34719-34729	Comparison	_
177-25	34730-34738	Subjects	_
177-26	34739-34742	and	_
177-27	34743-34751	Probands	_
177-28	34752-34754	as	_
177-29	34755-34756	a	_
177-30	34757-34765	Function	_
177-31	34766-34768	of	_
177-32	34769-34776	Biotype	_
177-33	34777-34784	Percent	_
177-34	34785-34791	Female	_
177-35	34792-34799	Healthy	_
177-36	34800-34801	(	_
177-37	34801-34802	N	_
177-38	34802-34803	=	_
177-39	34803-34805	50	_
177-40	34805-34806	)	_
177-41	34807-34814	Biotype	_
177-42	34814-34815	-	_
177-43	34815-34816	1	_
177-44	34817-34818	(	_
177-45	34818-34819	N	_
177-46	34819-34820	=	_
177-47	34820-34822	20	_
177-48	34822-34823	)	_
177-49	34824-34831	Biotype	_
177-50	34831-34832	-	_
177-51	34832-34833	2	_
177-52	34834-34835	(	_
177-53	34835-34836	N	_
177-54	34836-34837	=	_
177-55	34837-34839	30	_
177-56	34839-34840	)	_
177-57	34841-34848	Biotype	_
177-58	34848-34849	-	_
177-59	34849-34850	3	_
177-60	34851-34852	(	_
177-61	34852-34853	N	_
177-62	34853-34854	=	_
177-63	34854-34856	55	_
177-64	34856-34857	)	_
177-65	34858-34870	Significance	_
177-66	34871-34875	Test	_
177-67	34878-34880	56	_
177-68	34881-34883	70	_
177-69	34884-34886	53	_
177-70	34887-34889	44	_
177-71	34890-34892	χ2	_
177-72	34892-34893	(	_
177-73	34893-34894	3	_
177-74	34894-34895	)	_
177-75	34895-34896	=	_
177-76	34896-34900	4.44	_
177-77	34900-34901	,	_
177-78	34902-34903	p	_
177-79	34903-34904	=	_
177-80	34904-34907	.22	_
177-81	34910-34914	Mean	_
177-82	34915-34917	SD	_
177-83	34918-34922	Mean	_
177-84	34923-34925	SD	_
177-85	34926-34930	Mean	_
177-86	34931-34933	SD	_
177-87	34934-34938	Mean	_
177-88	34939-34941	SD	_
177-89	34946-34949	Age	_
177-90	34950-34954	37.9	_
177-91	34955-34959	12.2	_
177-92	34960-34964	31.8	_
177-93	34965-34969	13.9	_
177-94	34970-34974	32.3	_
177-95	34975-34979	12.2	_
177-96	34980-34984	35.5	_
177-97	34985-34989	13.4	_
177-98	34990-34991	F	_
177-99	34991-34992	(	_
177-100	34992-34997	3,151	_
177-101	34997-34998	)	_
177-102	34998-34999	=	_
177-103	34999-35003	1.75	_
177-104	35003-35004	,	_
177-105	35005-35006	p	_
177-106	35006-35007	=	_
177-107	35007-35010	.16	_
177-108	35017-35023	Trials	_
177-109	35024-35032	accepted	_
177-110	35035-35046	Prosaccades	_
177-111	35047-35051	47.6	_
177-112	35052-35055	4.4	_
177-113	35056-35060	48.2	_
177-114	35061-35064	2.7	_
177-115	35065-35069	48.1	_
177-116	35070-35073	2.8	_
177-117	35074-35078	47.3	_
177-118	35079-35082	3.5	_
177-119	35083-35084	F	_
177-120	35084-35085	(	_
177-121	35085-35090	3,151	_
177-122	35090-35091	)	_
177-123	35091-35092	=	_
177-124	35092-35096	0.43	_
177-125	35096-35097	,	_
177-126	35098-35099	p	_
177-127	35099-35100	=	_
177-128	35100-35103	.73	_
177-129	35106-35118	Antisaccades	_
177-130	35119-35123	48.0	_
177-131	35124-35127	3.4	_
177-132	35128-35132	48.2	_
177-133	35133-35136	2.5	_
177-134	35137-35141	48.1	_
177-135	35142-35145	2.7	_
177-136	35146-35150	47.1	_
177-137	35151-35154	5.5	_
177-138	35155-35156	F	_
177-139	35156-35157	(	_
177-140	35157-35162	3,151	_
177-141	35162-35163	)	_
177-142	35163-35164	=	_
177-143	35164-35168	0.74	_
177-144	35168-35169	,	_
177-145	35170-35171	p	_
177-146	35171-35172	=	_
177-147	35172-35175	.53	_
177-148	35182-35189	Percent	_
177-149	35190-35197	Correct	_
177-150	35202-35213	Prosaccades	_
177-151	35214-35218	97.2	_
177-152	35219-35222	3.2	_
177-153	35223-35227	94.1	_
177-154	35228-35231	6.0	_
177-155	35232-35236	94.6	_
177-156	35237-35240	6.1	_
177-157	35241-35245	95.8	_
177-158	35246-35249	4.5	_
177-159	35250-35251	F	_
177-160	35251-35252	(	_
177-161	35252-35257	3,151	_
177-162	35257-35258	)	_
177-163	35258-35259	=	_
177-164	35259-35262	3.0	_
177-165	35262-35263	,	_
177-166	35264-35265	p	_
177-167	35265-35266	=	_
177-168	35266-35269	.03	_
177-169	35274-35286	Antisaccades	_
177-170	35287-35291	90.7	_
177-171	35292-35295	6.3	_
177-172	35296-35300	77.4	_
177-173	35301-35305	12.2	_
177-174	35306-35310	86.1	_
177-175	35311-35315	11.7	_
177-176	35316-35320	83.6	_
177-177	35321-35325	11.1	_
177-178	35326-35327	F	_
177-179	35327-35328	(	_
177-180	35328-35333	3,151	_
177-181	35333-35334	)	_
177-182	35334-35335	=	_
177-183	35335-35339	9.30	_
177-184	35339-35340	,	_
177-185	35341-35342	p	_
177-186	35342-35343	=	_
177-187	35343-35349	.00001	_
177-188	35356-35364	Response	_
177-189	35365-35372	Latency	_
177-190	35373-35374	(	_
177-191	35374-35376	ms	_
177-192	35376-35377	)	_
177-193	35377-35378	a	_
177-194	35383-35390	Correct	_
177-195	35391-35402	Prosaccades	_
177-196	35403-35408	376.7	_
177-197	35409-35413	55.0	_
177-198	35414-35419	379.8	_
177-199	35420-35424	85.4	_
177-200	35425-35430	365.3	_
177-201	35431-35435	76.9	_
177-202	35436-35441	366.3	_
177-203	35442-35446	70.8	_
177-204	35447-35448	F	_
177-205	35448-35449	(	_
177-206	35449-35454	3,151	_
177-207	35454-35455	)	_
177-208	35455-35456	=	_
177-209	35456-35460	0.37	_
177-210	35460-35461	,	_
177-211	35462-35463	p	_
177-212	35463-35464	=	_
177-213	35464-35467	.78	_
177-214	35472-35479	Correct	_
177-215	35480-35492	Antisaccades	_
177-216	35493-35498	415.1	_
177-217	35499-35503	73.5	_
177-218	35504-35509	455.7	_
177-219	35510-35515	103.5	_
177-220	35516-35521	437.4	_
177-221	35522-35526	91.2	_
177-222	35527-35532	428.6	_
177-223	35533-35537	84.0	_
177-224	35538-35539	F	_
177-225	35539-35540	(	_
177-226	35540-35545	3,151	_
177-227	35545-35546	)	_
177-228	35546-35547	=	_
177-229	35547-35551	1.20	_
177-230	35551-35552	,	_
177-231	35553-35554	p	_
177-232	35554-35555	=	_
177-233	35555-35558	.31	_
177-234	35563-35572	Incorrect	_
177-235	35573-35585	Antisaccades	_
177-236	35586-35591	352.2	_
177-237	35592-35597	102.9	_
177-238	35598-35603	331.3	_
177-239	35604-35608	75.0	_
177-240	35609-35614	350.4	_
177-241	35615-35620	132.1	_
177-242	35621-35626	361.2	_
177-243	35627-35631	89.0	_
177-244	35632-35633	F	_
177-245	35633-35634	(	_
177-246	35634-35639	3,145	_
177-247	35639-35640	)	_
177-248	35640-35641	=	_
177-249	35641-35645	0.42	_
177-250	35645-35646	,	_
177-251	35647-35648	p	_
177-252	35648-35649	=	_
177-253	35649-35652	.74	_
177-254	35659-35663	GAFb	_
177-255	35664-35669	84.56	_
177-256	35670-35673	5.4	_
177-257	35674-35678	43.6	_
177-258	35679-35682	8.2	_
177-259	35683-35687	49.5	_
177-260	35688-35692	11.3	_
177-261	35693-35697	53.7	_
177-262	35698-35702	13.7	_
177-263	35703-35704	F	_
177-264	35704-35705	(	_
177-265	35705-35710	2,102	_
177-266	35710-35711	)	_
177-267	35711-35712	=	_
177-268	35712-35716	5.26	_
177-269	35716-35717	,	_
177-270	35718-35719	p	_
177-271	35719-35720	=	_
177-272	35720-35724	.007	_
177-273	35731-35735	BACS	_
177-274	35736-35737	−	_
177-275	35737-35741	0.05	_
177-276	35742-35745	1.2	_
177-277	35746-35747	−	_
177-278	35747-35750	2.6	_
177-279	35751-35754	0.7	_
177-280	35755-35756	−	_
177-281	35756-35759	1.8	_
177-282	35760-35763	1.0	_
177-283	35764-35765	−	_
177-284	35765-35768	0.3	_
177-285	35769-35772	0.8	_
177-286	35773-35774	F	_
177-287	35774-35775	(	_
177-288	35775-35779	2,99	_
177-289	35779-35780	)	_
177-290	35780-35781	=	_
177-291	35781-35785	65.3	_
177-292	35785-35786	,	_
177-293	35787-35788	p	_
177-294	35788-35789	=	_
177-295	35789-35791	8E	_
177-296	35791-35792	-	_
177-297	35792-35794	19	_
177-298	35801-35810	Birchwood	_
177-299	35811-35817	Social	_
177-300	35818-35829	Functioning	_
177-301	35830-35835	Scale	_
177-302	35836-35841	163.0	_
177-303	35842-35846	18.9	_
177-304	35847-35852	126.6	_
177-305	35853-35857	23.8	_
177-306	35858-35863	130.1	_
177-307	35864-35868	18.8	_
177-308	35869-35874	133.7	_
177-309	35875-35879	23.2	_
177-310	35880-35881	F	_
177-311	35881-35882	(	_
177-312	35882-35886	2,77	_
177-313	35886-35887	)	_
177-314	35887-35888	=	_
177-315	35888-35892	0.59	_
177-316	35892-35893	,	_
177-317	35894-35895	p	_
177-318	35895-35896	=	_
177-319	35896-35899	.56	_
177-320	35906-35920	PANSS-positive	_
177-321	35921-35922	–	_
177-322	35923-35924	–	_
177-323	35925-35929	19.0	_
177-324	35930-35933	7.8	_
177-325	35934-35938	15.6	_
177-326	35939-35942	4.8	_
177-327	35943-35947	15.7	_
177-328	35948-35951	5.0	_
177-329	35952-35953	F	_
177-330	35953-35954	(	_
177-331	35954-35959	2,101	_
177-332	35959-35960	)	_
177-333	35960-35961	=	_
177-334	35961-35965	2.84	_
177-335	35965-35966	,	_
177-336	35967-35968	p	_
177-337	35968-35969	=	_
177-338	35969-35972	.06	_
177-339	35979-35993	PANSS-negative	_
177-340	35994-35995	–	_
177-341	35996-35997	–	_
177-342	35998-36002	20.3	_
177-343	36003-36006	7.8	_
177-344	36007-36011	15.3	_
177-345	36012-36015	5.3	_
177-346	36016-36020	15.7	_
177-347	36021-36024	6.0	_
177-348	36025-36026	F	_
177-349	36026-36027	(	_
177-350	36027-36032	2,101	_
177-351	36032-36033	)	_
177-352	36033-36034	=	_
177-353	36034-36038	4.53	_
177-354	36038-36039	,	_
177-355	36040-36041	p	_
177-356	36041-36042	=	_
177-357	36042-36045	.01	_
177-358	36052-36065	PANSS-general	_
177-359	36066-36067	–	_
177-360	36068-36069	–	_
177-361	36070-36074	38.3	_
177-362	36075-36079	10.4	_
177-363	36080-36084	33.4	_
177-364	36085-36088	7.8	_
177-365	36089-36093	34.3	_
177-366	36094-36097	8.0	_
177-367	36098-36099	F	_
177-368	36099-36100	(	_
177-369	36100-36105	2,101	_
177-370	36105-36106	)	_
177-371	36106-36107	=	_
177-372	36107-36111	2.19	_
177-373	36111-36112	,	_
177-374	36113-36114	p	_
177-375	36114-36115	=	_
177-376	36115-36118	.12	_
177-377	36125-36130	MADRS	_
177-378	36131-36132	–	_
177-379	36133-36134	–	_
177-380	36135-36139	14.8	_
177-381	36140-36143	9.4	_
177-382	36144-36148	10.4	_
177-383	36149-36152	8.6	_
177-384	36153-36157	10.1	_
177-385	36158-36161	8.5	_
177-386	36162-36163	F	_
177-387	36163-36164	(	_
177-388	36164-36169	2,101	_
177-389	36169-36170	)	_
177-390	36170-36171	=	_
177-391	36171-36175	2.25	_
177-392	36175-36176	,	_
177-393	36177-36178	p	_
177-394	36178-36179	=	_
177-395	36179-36182	.11	_
177-396	36189-36194	Young	_
177-397	36195-36200	Mania	_
177-398	36201-36206	Scale	_
177-399	36207-36208	–	_
177-400	36209-36210	–	_
177-401	36211-36214	7.3	_
177-402	36215-36218	6.5	_
177-403	36219-36222	5.9	_
177-404	36223-36226	5.2	_
177-405	36227-36230	6.3	_
177-406	36231-36234	6.6	_
177-407	36235-36236	F	_
177-408	36236-36237	(	_
177-409	36237-36242	2,102	_
177-410	36242-36243	)	_
177-411	36243-36244	=	_
177-412	36244-36248	0.28	_
177-413	36248-36249	,	_
177-414	36250-36251	p	_
177-415	36251-36252	=	_
177-416	36252-36255	.75	_
177-417	36262-36272	Medication	_
177-418	36273-36278	Class	_
177-419	36283-36296	Antipsychotic	_
177-420	36297-36302	first	_
177-421	36303-36313	generation	_
177-422	36314-36318	0.0%	_
177-423	36319-36324	15.0%	_
177-424	36325-36330	10.0%	_
177-425	36331-36335	5.5%	_
177-426	36336-36338	χ2	_
177-427	36338-36339	(	_
177-428	36339-36340	2	_
177-429	36340-36341	)	_
177-430	36341-36342	=	_
177-431	36342-36346	1.82	_
177-432	36346-36347	,	_
177-433	36348-36349	p	_
177-434	36349-36350	=	_
177-435	36350-36353	.40	_
177-436	36358-36371	Antipsychotic	_
177-437	36372-36378	second	_
177-438	36379-36389	generation	_
177-439	36390-36394	0.0%	_
177-440	36395-36400	75.0%	_
177-441	36401-36406	73.3%	_
177-442	36407-36412	61.8%	_
177-443	36413-36415	χ2	_
177-444	36415-36416	(	_
177-445	36416-36417	2	_
177-446	36417-36418	)	_
177-447	36418-36419	=	_
177-448	36419-36423	1.79	_
177-449	36423-36424	,	_
177-450	36425-36426	p	_
177-451	36426-36427	=	_
177-452	36427-36430	.41	_
177-453	36435-36439	Mood	_
177-454	36440-36450	stabilizer	_
177-455	36451-36455	0.0%	_
177-456	36456-36461	50.0%	_
177-457	36462-36467	46.7%	_
177-458	36468-36473	47.3%	_
177-459	36474-36476	χ2	_
177-460	36476-36477	(	_
177-461	36477-36478	2	_
177-462	36478-36479	)	_
177-463	36479-36480	=	_
177-464	36480-36484	0.06	_
177-465	36484-36485	,	_
177-466	36486-36487	p	_
177-467	36487-36488	=	_
177-468	36488-36491	.97	_
177-469	36496-36503	Lithium	_
177-470	36504-36508	0.0%	_
177-471	36509-36513	5.0%	_
177-472	36514-36519	20.0%	_
177-473	36520-36525	16.4%	_
177-474	36526-36528	χ2	_
177-475	36528-36529	(	_
177-476	36529-36530	2	_
177-477	36530-36531	)	_
177-478	36531-36532	=	_
177-479	36532-36536	2.20	_
177-480	36536-36537	,	_
177-481	36538-36539	p	_
177-482	36539-36540	=	_
177-483	36540-36543	.33	_
177-484	36548-36562	Antidepressant	_
177-485	36563-36567	2.0%	_
177-486	36568-36573	45.0%	_
177-487	36574-36579	40.0%	_
177-488	36580-36585	43.6%	_
177-489	36586-36588	χ2	_
177-490	36588-36589	(	_
177-491	36589-36590	2	_
177-492	36590-36591	)	_
177-493	36591-36592	=	_
177-494	36592-36596	0.15	_
177-495	36596-36597	,	_
177-496	36598-36599	p	_
177-497	36599-36600	=	_
177-498	36600-36603	.93	_
177-499	36608-36616	Sedative	_
177-500	36616-36617	/	_
177-501	36617-36627	anxiolytic	_
177-502	36628-36632	2.0%	_
177-503	36633-36638	30.0%	_
177-504	36639-36644	23.3%	_
177-505	36645-36650	25.5%	_
177-506	36651-36653	χ2	_
177-507	36653-36654	(	_
177-508	36654-36655	2	_
177-509	36655-36656	)	_
177-510	36656-36657	=	_
177-511	36657-36661	0.28	_
177-512	36661-36662	,	_
177-513	36663-36664	p	_
177-514	36664-36665	=	_
177-515	36665-36668	.87	_
177-516	36673-36682	Stimulant	_
177-517	36683-36687	0.0%	_
177-518	36688-36692	5.0%	_
177-519	36693-36697	3.3%	_
177-520	36698-36703	14.5%	_
177-521	36704-36706	χ2	_
177-522	36706-36707	(	_
177-523	36707-36708	2	_
177-524	36708-36709	)	_
177-525	36709-36710	=	_
177-526	36710-36714	3.42	_
177-527	36714-36715	,	_
177-528	36716-36717	p	_
177-529	36717-36718	=	_
177-530	36718-36721	.18	_
177-531	36726-36741	Anticholinergic	_
177-532	36742-36746	0.0%	_
177-533	36747-36752	10.0%	_
177-534	36753-36757	6.7%	_
177-535	36758-36762	7.3%	_
177-536	36763-36765	χ2	_
177-537	36765-36766	(	_
177-538	36766-36767	2	_
177-539	36767-36768	)	_
177-540	36768-36769	=	_
177-541	36769-36773	0.21	_
177-542	36773-36774	,	_
177-543	36775-36776	p	_
177-544	36776-36777	=	_
177-545	36777-36780	.90	_
177-546	36784-36787	GAF	_
177-547	36787-36788	,	_
177-548	36789-36795	Global	_
177-549	36796-36806	Assessment	_
177-550	36807-36809	of	_
177-551	36810-36821	Functioning	_
177-552	36821-36822	;	_
177-553	36823-36828	PANSS	_
177-554	36828-36829	,	_
177-555	36830-36838	Positive	_
177-556	36839-36842	and	_
177-557	36843-36851	Negative	_
177-558	36852-36859	Symptom	_
177-559	36860-36865	Scale	_
177-560	36865-36866	;	_
177-561	36867-36872	MADRS	_
177-562	36872-36873	,	_
177-563	36874-36891	Montgomery–Åsberg	_
177-564	36892-36902	Depression	_
177-565	36903-36909	Rating	_
177-566	36910-36915	Scale	_
177-567	36915-36916	;	_
177-568	36917-36921	BACS	_
177-569	36921-36922	,	_
177-570	36923-36928	Brief	_
177-571	36929-36939	Assessment	_
177-572	36940-36942	of	_
177-573	36943-36952	Cognition	_
177-574	36953-36955	in	_
177-575	36956-36969	Schizophrenia	_
177-576	36969-36970	.	_

#Text=Only 40% of participants made any incorrect responses during prosaccade trials.
178-1	36971-36975	Only	_
178-2	36976-36979	40%	_
178-3	36980-36982	of	_
178-4	36983-36995	participants	_
178-5	36996-37000	made	_
178-6	37001-37004	any	_
178-7	37005-37014	incorrect	_
178-8	37015-37024	responses	_
178-9	37025-37031	during	_
178-10	37032-37042	prosaccade	_
178-11	37043-37049	trials	_
178-12	37049-37050	.	_

#Text=Healthy subjects were excluded from comparisons of clinical characteristics and medication status.
179-1	37051-37058	Healthy	_
179-2	37059-37067	subjects	_
179-3	37068-37072	were	_
179-4	37073-37081	excluded	_
179-5	37082-37086	from	_
179-6	37087-37098	comparisons	_
179-7	37099-37101	of	_
179-8	37102-37110	clinical	_
179-9	37111-37126	characteristics	_
179-10	37127-37130	and	_
179-11	37131-37141	medication	_
179-12	37142-37148	status	_
179-13	37148-37149	.	_
